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ABSTRACT 
 
Muscle injuries are associated with changes in skeletal muscle as well as the immune 
system.  All studies investigating possible treatment modalities have found both positive and 
negative effects on muscle recovery.  Since no universally accepted treatment modality 
exists, this thesis aims to determine whether a plant-derived antioxidant, proanthocyanidolic 
oligomer (PCO), might prove beneficial as treatment for sports injuries in order for athletes to 
return to the sports field quicker.  The difference in recovery of muscle following both chronic 
(supplementation started 14 days prior to injury and continued thereafter) and acute 
supplementation (supplementation started two hours after injury) were also investigated. 
Both chronic and acute PCO supplementation in a rat hindlimb contusion injury model 
resulted in earlier muscle recovery, verified by an earlier satellite cell response compared to 
the placebo group.  This effect was most prominent already at the four hour time point 
following injury, compared to day seven and three after chronic and acute placebo treatment 
respectively.  PCO supplementation also resulted in quicker foetal myosin heavy chain 
(MHCf) expression compared to placebo treatment.  Chronic supplementation specifically 
resulted in a blunted circulatory pro-inflammatory cytokine response, whilst allowing for a 
significant increase in IL-10, an anti-inflammatory cytokine, on day three (in the PCO group 
only).  At tissue level, the response of the muscle pro-inflammatory cytokines, TNF-α and IL-
6, coincided with the satellite cell response.  Macrophage infiltration into the injured muscle 
also followed a similar pattern to that seen for the pro-inflammatory cytokines.  Macrophages 
invaded the injured area quicker when supplemented with PCO chronically, however, 
macrophage infiltration could not explain the cytokine response seen with acute 
supplementation.  Both chronic and acute supplementation with PCO was responsible for a 
severely blunted neutrophil response, a novel finding of this particular antioxidant.   
The main findings of the in vivo rodent study were that PCO was able to blunt the neutrophil 
response, whilst allowing for earlier macrophage infiltration. To establish possible 
mechanisms by which PCO might exert these beneficial effects, further analysis included 
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determining macrophage phenotypes and neutrophil numbers in circulation.  An in vitro 
neutrophil migration assay was also employed to further elucidate PCO’s ability to blunt 
neutrophil infiltration into the injured area.  For this study, conditioned plasma were harvested 
from experimental animals and added together with neutrophils from control rats and 
granulocyte colony stimulating factor (G-CSF) to the insert of the migration chamber.  A 
chemotactic factor, N-formyl methionine-leucine-phenylalanine (fMLP), was added to the 
bottom well and neutrophils were allowed to migrate for two hours.  Results from this study 
indicated that neutrophil migration was attenuated in vitro in the presence of conditioned 
plasma from PCO supplemented rats only. 
The studies in this thesis on the effect of PCO on parameters of muscle and the immune 
system led to the following main conclusions:  a) PCO supplementation resulted in earlier 
muscle recovery as a result of earlier satellite cell activation and MHCf synthesis; b) PCO 
favours an anti-inflammatory cytokine reaction, whilst blunting the pro-inflammatory cytokine 
response; and c) PCO blunted the neutrophil response whilst facilitating earlier macrophage 
infiltration into the injured area.  The specific mechanism of action of PCO to blunt the 
neutrophil response specifically, possibly includes the ability to suppress adhesion molecule 
expression on the neutrophils themselves.  However, this warrants further investigation.  
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OPSOMMING 
 
Spier beserings word geassosiëer met veranderinge in skeletspier sowel as die 
immuunstelsel.  Meeste studies wat moontlike behandelingsopsies ondersoek, het beide 
positiewe en negatiewe spierherstel gerapporteer.  Omrede daar geen universele 
behandelingsmoontlikheid bestaan nie, is die doel van hierdie tesis om die effek van ‘n 
plantgebaseerde anti-oksidant, pro-antosianiedoliese oligomeer (PSO), as ‘n voordelige 
behandelingstrategie vir sportbeserings te toets.  Die verskil in spierherstel na beide kroniese 
(supplementering wat 14 dae voor besering begin is, en volgehou is daarna) en akute 
supplementering (supplementering het twee uur na besering begin), is ook ondersoek. 
Beide kroniese en akute PSO supplementering, in ‘n rot agterbeen-kneusbeseringmodel, het 
gelei tot vroeë spierherstel.  Die bevindinge is geverifiëer deur ‘n vroeë satelietselrespons in 
vergelyking met die plasebo groep.  Hierdie effek was reeds opvallend vier uur na besering, 
in vergelyking met die dag sewe en dag drie tydpunt tydens kroniese en acute plasebo 
behandeling onderskeidelik.  In vergelyking met die kontrole groep, het PSO 
supplementering ook gelei to vininger uitdrukking van miosienswaarketting (MHCf).  Kroniese 
supplementering het spesifiek gelei to ‘n onderdrukte sirkulatoriese pro-inflammatoriese 
sitokien response, terwyl ‘n betekenisvolle toename in IL-10 op dag drie (in die PSO groep 
alleenlik) waargeneem is.  
Op weefselvlak, het die pro-inflammatoriese sitokiene, IL-6 en TNF-α, dieselfde patron 
gevolg as die van satelietselle.  Makrofaaginfiltrasie binne die beseerde spier het ook ‘n 
soorgelyke patroon gevolg.  Makrofage het die beseerde area vinniger geïnfiltreer in die 
kronies PSO-gesupplementeerde groep, maar kon nie die sitokienrespons, wat waargeneem 
is met akute supplementasie, verklaar nie.  Beide kroniese en akute PSO supplementering 
was verantwoordelik vir ‘n onderdrukte neutrofiel respons, wat ‘n nuwe bevinding is vir 
hierdie spesifieke anti-oksidant.   
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Die hoof bevindinge in die in vivo rotstudies, is dat PSO instaat is om die neutrofielrespons te 
onderdruk, en sodoende vroeë makrofaaginfiltrasie teweeg te bring.  Om meganismes 
waarby PSO hierdie voordelige effekte veroorsaak te ondersoek, is verdere analises gedoen 
om makrofaagfenotipe en neutrofielgetalle in die sirkulasie te bepaal.  ‘n In vitro 
neutrofielmigrasie studie is ook aangewend om PSO se vermoë om neutrofielinfiltrasie in die 
beseerde area te onderdruk, te ondersoek.  Neutrofiele van kontrole rotte, tesame met 
gekondisioneerde plasma van eksperimentele diere en granulosiet-kolonie stimulerende 
faktor (G-KSF), is toegelaat om vir twee ure in die teenwoordigheid van ‘n chemotaktiese 
faktor, N-formiel metionien-leusien-fenielalanien (fMLP) te migreer.  Resultate van hierdie 
studie het aangetoon dat neutrofielmigrasie, in vitro, alleenlik onderdruk word in die 
teenwoordigheid van gekondisioneerde plasma van PSO-gesupplementeerde rotte.   
Die studies in hierdie tesis oor die effek van PSO op parameters van spier en die 
immuunsisteem, het tot die volgende hoofgevolgtrekkings gelei:  a) PSO supplementering 
het vroeë spierherstel, as gevolge van vroeë satelietselaktivering en MHCf sintese, teweeg 
gebring; b) PSO verkies ‘n anti-inflammatoriese sitokien reaksie, terwyl dit die pro-
inflammatoriese sitokienrespons onderdruk; en c) PSO onderdruk die neutrofielrespons, 
terwyl vroeë makrofaaginfiltrasie in die beseerde area gefasiliteer word.  Die spesifieke 
meganisme van aksie van PSO, om die neutrofielrespons te onderdruk, kan moontlik die 
vermoë van neutrofiele om adhesie molekule uit te druk, insluit.  Hierdie aanname moet egter 
verder ondersoek word.  
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CHAPTER 1 
 
Background 
 
1.1  General introduction 
In sports, contusion injuries - defined as an impact by a blunt non-penetrating object - occur 
both during practice and in competition (Kibler 1993).  Muscle groups most commonly 
affected by these types of injuries, which result in mechanical damage to muscle fibres, 
capillary rupturing, infiltrative bleeding, oedema and inflammation, are those in the arms, 
legs, hands, feet and buttocks (Kearns et al., 2004).  The trauma can produce significant 
disability because of inflammation-related pain and impaired muscle function, often resulting 
in a loss of flexibility and strength, placing the player at increased risk of re-injury (Gates and 
Huard 2005) if returning to the sports field before full muscle recovery.     
Satellite cells (SCs), precursor/stem cells specific to skeletal muscle, are located on the 
surface of muscle fibres (myofibres), beneath the basement membrane (Bischoff 1997; 
Grounds 1999; Grounds et al., 2002; McComas 1996).  SCs function to replace or repair 
damaged muscle fibres.  Upon muscle damage, SCs become activated and start to 
proliferate, differentiate and fuse either with other myoblasts, or with damaged muscle fibres 
in order to repair muscle fibre ultrastructure (Cornelison and Wold 1997; Scime and Rudnicki 
2006).  It is also well known that the entire process of muscle regeneration is regulated by 
the myogenic regulatory factors (MRFs – discussed in section 1.2.3) (Florini et al., 1991a; 
Grounds 1999).    
The interaction between the immune system and skeletal muscle is regarded as an important 
regulatory process, modulating the events during repair and remodelling.  Upon muscle 
injury, muscle fibres and capillaries located around the muscle fibres rupture at or adjacent to 
the impact area, the latter resulting in exposed collagen.  Platelets adhere to the exposed 
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collagen, become activated as a result and release pro-inflammatory mediators such as 5-
hydroxy tryptamine (serotonin), histamine and thromboxane A2 (TxA2).  Mast cells in the 
tissue also release histamine, which increases the blood flow to the injury site, allowing 
blood-borne inflammatory cells to gain direct access to the injury area (Pedersen et al., 1998; 
Jarvinen et al., 2005).  Neutrophils are the most abundant immune cells at the injury site 
during the first couple of hours and days after injury, whilst macrophages (M1 followed by 
M2) appear a couple of days later (Li et al., 2001).  For a chronological illustration of immune 
cell involvement after injury, see Figure 1.1.  As part of the phagocytic process, these 
immune cells release substantial amounts of reactive species to aid in the degeneration of 
necrotic areas, but this process can involve surrounding healthy tissue, thereby contributing 
to secondary damage (Fialkow et al., 2007).  In addition, both neutrophils and macrophages 
also differentially secrete cytokines to attract more immune cells to the injured area for fast 
and effective regeneration (see Table 1.3 on pg 27). 
 
Figure 1.1:  An illustrative time course of inflammatory immune cells after injury.  A 
100 % cell presence indicates a specific point in time where the specific immune cell had a 
peak response after injury.  The duration of this inflammatory response depends on the type 
and severity of the injury.  Reproduced from Smith et al. (2008). 
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To date, interactions between the immune system and skeletal muscle after trauma have not 
been studied as extensively as the histological assessment of muscle inflammation, following  
acute muscle injury or diagnosis of inflammatory myopathies (Authier et al., 1997; Liprandi et 
al., 1999; Confalonieri et al., 2000).  Nevertheless, the scientific literature suggests that 
immune cells may play a greater role in the regulation of muscle development, repair and 
regeneration than only the removal of debris.  The purpose of this thesis is therefore to 
further elucidate the relationship between these two systems (specifically inflammatory 
immune cells and satellite cells) during the response to a contusion injury, focussing on the 
various role players involved in the inflammatory process.   
In this chapter, I will give a basic overview of satellite cell and immune cell physiology and 
how they interact with one another.  I will also provide an overview of the available literature 
on the reaction of these cells to a muscle contusion injury.  In Chapter 2, I will discuss the 
different treatment regimens for muscle injury in general, and then focus on grape seed-
derived proanthocyanidin (PCO, Oxiprovin™), a natural supplement with potential to aid 
muscle recovery.  Chapter 3-5 will focus on experiments investigating both mechanism of 
action and in vivo efficacy of treating muscle contusion injury with proanthocyanidin using 
two different treatment regimens.  A synthesis of results and conclusions are presented in 
Chapter 6. 
 
1.2  Satellite cells 
Skeletal muscle regeneration after muscle injury involves the degeneration of damaged 
muscle fibres, removal of debris and the formation of new myofibres through myogenesis.  
As mentioned in the introduction, activation of satellite cells usually results in the formation of 
reactive species (Scime and Rudnicki 2006), which will be discussed in more detail below 
(refer to section 1.2.4).  The involvement of these satellite cells in muscle regeneration is 
also characterised by the expression of different myogenic regulatory factors (MRFs) (see 
section 1.2.3).   
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In order to understand the literature on satellite cell function in muscle recovery, it is 
necessary to first consider different labelling systems used to identify and/or quantify these 
cells in their different stages of activation, proliferation and differentiation. 
 
1.2.1 Choosing the appropriate satellite cell marker(s) 
Satellite cells can be characterized by their expression of conserved molecules such as M-
cadherin (M-cad) (Irintchev et al., 1994), CD34 (Beauchamp et al., 2000), CD56 (Kadi and 
Thornell 2000), Msx1, cMet (Cornelison and Wold 1997), MNF or Foxk1 (Garry et al., 2000) 
and Pax-7 (Cornelison and Wold 1997; Beauchamp et al., 2000; Cornelison et al., 2000; 
Seale and Rudnicki 2000), as well as by their typical morphological appearance.  However, 
although all of these markers can be used to identify satellite cells, SCs do not represent a 
unique cell type but a rather heterogeneous population of muscle precursor cells in various 
stages of activation, proliferation and differentiation (see Table 1.1 on p 5).  Furthermore, 
although some satellite cell markers, such as Pax-7, CD56, or CD34 are expressed at 
various stages during injury, the expression pattern differs, with expression being high during 
quiescence, followed by decreasing expression during activation and proliferation.  Also, not 
all the molecular markers are unique to SCs, e.g. CD56 is also present on a number of other 
cell types.  Although a comprehensive list of SC markers are presented in Table 1.1, only SC 
markers used in the experimental sections of this study will be discussed in detail below. 
CD34 has been widely used as a marker of quiescent satellite cells (Beauchamp et al., 
2000).  However, it became apparent that CD34 is not only expressed by satellite cells in 
their quiescent state, but also by haematopoietic stem/progenitor cells (Krause et al., 1996), 
as well as by small-vessel endothelial tissue (Baumhueter et al., 1994).  Although 
researchers have commonly used CD34 as a marker of quiescence, CD34 expression has 
also been present during activation and progression towards self-renewal or differentiation 
(Sato et al., 1999b).  Therefore, CD34 may not be such a good singular marker for 
distinguishing only one population of satellite cells. 
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Table 1.1:  Expression patterns of satellite cell markers in adult skeletal muscle after 
injury.  Compiled from Charge and Rudnicki (2004), Hawke and Garry (2001) and Zammit et 
al. (2006). 
Molecular Marker Quiescent 
SCs 
Activated 
SCs 
Proliferating 
SCs 
Myoblasts Adult 
myofibres 
MNF High Low Low   
Pax-7    High Low Low   
c-Met                 High Low Low   
CD56/NCAM High Low Low   
CD34 High Low Low   
VCAM-1   High Low Low   
M-cadherin                 Low High Low   
myf5     High Low   
Pax-3  Low High, Low Low  
BrdU (uptake)    High, Low   
PCNA      High, Low   
[3H]thymidine (uptake)    High, Low   
MyoD     Low High Low Low 
Desmin  Low Low High High 
Myogenin   Low Low High 
MRF4    Low High 
        
High indicates that the level of the expression of the various markers is at its highest, whereas low 
indicates where the expression is at its lowest.  High, followed by low as is the case with Pax-3, BrdU, 
PCNA and [3H]thymidine, indicates that expression is high early on in proliferation, and low later in the 
proliferation cycle.  Abbreviations:  MNF, myocyte nuclear factor; NCAM, neural cell adhesion 
molecule; VCAM, vascular cell adhesion molecule; BrdU, bromodeoxyuridine; PCNA, proliferating cell 
nuclear antigen; MRF, myogenic regulatory factor.   
 
CD56/NCAM recognizes the neural cell adhesion molecule (NCAM), which is expressed 
during developmental myogenesis and in adult muscle satellite cells (Schubert et al., 1989).  
However, CD56 is also expressed in nerves, natural killer (NK) cells, neuromuscular 
junctions and even occasionally in the cytoplasm of myofibres (Kaufmann et al., 1999; Kadi 
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and Thornell 2000).  According to various researchers, satellite cells are closely attached to 
the plasma membrane of the adjacent muscle fibre and express CD56 in the quiescent state 
(Bornemann and Schmalbruch 1994; Irintchev et al., 1994; Schultz and McCormick 1994), as 
well as in the activated state (Malm et al., 2000), indicating once again the non-specificity of 
singular markers.  Due to this non-specificity of the satellite cell markers, analysis to 
distinguish satellite cells from other cells, often requires not only the satellite cell marker but 
also co-immunostaining to identify the basal lamina, with for example an antibody that 
recognises laminin.   
Pax-7 has been described as a member of the paired homeobox gene family, which is 
expressed during somite development (Jostes et al., 1991).  In a study on Pax-7 knockout 
(KO) mice, it was revealed that Pax-7 is an essential transcription factor for satellite cell 
formation (Seale et al., 2000).  In this study, wild-type or Pax-7-/- KO mice exhibited severe 
muscle deficiencies at birth and premature mortality, and were completely devoid of satellite 
cells.  More recently, Pax-7 was suggested to be a better marker due to its specificity in adult 
muscle for satellite cells (SCs) and the availability of effective antibodies against Pax-7 
(Zammit et al., 2006; Day et al., 2007).  Pax-7 is expressed in the nucleus of the majority of, 
if not all, satellite cells [quiescent, active, and proliferating SCs, but not myonuclei] (Seale 
and Rudnicki 2000; Collins et al., 2005; Relaix et al., 2005; Shefer et al., 2006).  In a study by 
Halevy et al. (2004), Pax-7+ cells were present in the intact muscle underneath the myofiber 
basement membrane, and usually associated with the SC nucleus.  Pax-7 expression also 
declined as the cells moved into the myogenin-expression state, while the expression of 
MyoD was still sustained.  Since some cells within the Pax-7+ cell population were positive 
for both Pax-7 and other markers, while some were only positive for Pax-7, it was thought 
that the latter population of cells might represent “reserve” myogenic progenitors (Halevy et 
al., 2004).  It was also postulated that Pax-7 is a major regulator of SC renewal.  This 
function of Pax-7 was suggested because a proportion of activated satellite cells that 
remained undifferentiated, still retained their Pax-7 expression and was therefore thought to 
reconstitute the satellite cell pool (Olguin and Olwin 2004; Oustanina et al., 2004; Zammit et 
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al., 2004).  Pax-7 expression may be influenced by age and muscle fibre type, and is also 
species specific (Hawke and Garry 2001), indicating that if injury was sustained in a slow-
twitch fibre type-specific muscle, Pax-7 expression would differ compared to the expression 
in a fast-twitch muscle.  After reviewing the literature on satellite cell markers, Pax-7 is 
considered the most suitable marker and should be used in combination with a basal lamina 
component such as laminin to enable more accuracy.   
 
1.2.2 Satellite cell response after injury 
Skeletal muscle regeneration is regulated through mechanisms involving cell-cell and cell-
matrix interactions as well as extracellularly secreted factors (Charge and Rudnicki 2004).  In 
mature muscle, satellite cells are quiescent but can re-enter the cell cycle in response to a 
variety of stimuli, which promote their activation and proliferation to form myoblasts, which 
differentiate and fuse to each other or to damaged myofibers (Hawke and Garry 2001).  
Satellite cell activation may be restricted to the damaged area.  However, if the connective 
tissue between muscle fibres is also damaged, satellite cells may also be recruited from 
adjacent fibres (Schultz et al., 1985; Schultz et al., 1986).     
Perhaps the most extensive and reproducible model for severe muscle injury is the delivery 
of cardiotoxin (purified from the venom of the Naja nigricollis snake) into the hindlimb skeletal 
muscle of the mouse (Doroshow et al., 1985; Nicolas et al., 1996; Garry et al., 2000).  The 
intramuscular injection of 100 µl of 10 µM cardiotoxin into the gastrocnemius muscle results 
in 80–90% muscle degeneration.  After cardiotoxin-induced injury, satellite cells become 
activated within 6 hr of injury (Garry et al., 2000).  In response to locally released growth 
factors from injured myotubes and macrophages, the satellite cells proliferate extensively 
within 2–3 days of injury (Garry et al., 1997; Garry et al., 2000).  Approximately 5 days after 
injury, the satellite cells withdraw from the cell cycle and either self-renew or form 
differentiated myotubes containing a central nucleus (Garry et al., 1997; Garry et al., 2000).  
8 
 
In this cardiotoxin-induced injury model, the architecture of the injured muscle is largely 
restored within 10 days after injection. 
In a study by Oustanina et al. (2004) on freeze-crush or cardiotoxin-induced skeletal muscle 
damage, both the number and the staining intensity of Pax-7-lacZ (allele for β-galactosidase 
activity) -positive cells increased, reflecting an expansion of satellite cell-derived myoblasts in 
the injured muscle and an upregulation of Pax-7 gene expression in proliferating myoblasts.  
Satellite cells on single fibres (in vitro) become activated by an extract of crushed muscle 
(Bischoff 1986).  The relevant factors in the extract could be numerous and required more 
specific studies to be determined. Mice deficient for fibroblast growth factor (FGF)-6 (i.e., 
knockout mice at the FGF-6 locus) have impaired satellite cell proliferation and a subsequent 
defect in muscle regeneration in response to a crush injury. However, it is not only external 
factors that play crucial roles, but also the balance between factors endogenous to the 
satellite cells themselves, as these are not all similarly activated and regulated by the injury.  
Kuang et al. (2006) established that Pax-7 is a prerequisite for muscle regeneration.  With 
the use of Pax-7/LacZ and Pax-7-null/LacZ mice, it became apparent that in the absence of 
Pax-7, the presence of resident stem cells in the muscle was not sufficient to compensate for 
a loss of satellite cell function, severely affecting regenerating muscle (Kuang et al., 2006).  
In addition, several recent studies have reported that newly activated satellite cells and 
proliferating myoblasts co-express Pax-7 and MyoD in vitro (Halevy et al., 2004; Olguin and 
Olwin 2004; Zammit et al., 2004), but that overexpression of Pax-7 down-regulates MyoD in 
response to injury, and promotes cell-cycle withdrawal from the proliferating state prior to 
commitment to differentiation, therefore playing a critical role in the maintenance of the 
satellite cell pool (Olguin and Olwin 2004; Zammit et al., 2004).  The extent to which SCs 
respond to damage-induced myogenesis, relies on the expression of Pax-7 and the 
myogenic regulatory factors (MRFs) (Zammit et al., 2006), which will be the focus of the next 
section. 
 
9 
 
1.2.3 Myogenic regulatory factors 
The regeneration of muscle following injury, occurs via a series of SC stages (activation, 
proliferation and differentiation of SCs) which are subjected to positive and negative 
regulatory influences, facilitated by the myogenic regulatory factors (MRFs), MyoD, Myf5, 
myogenin and MRF4 (Yablonka-Reuveni et al., 1999a).  MRFs are only expressed in the 
nucleus when satellite cells are activated, and contain a conserved basic DNA binding 
domain (Weintraub et al., 1991).  This is in contrast to adhesion molecules which are found 
on either the satellite cell niche membrane or expressed as nuclear adhesion molecule.   
Different studies have identified specific time of first appearance/expression and function of 
the myogenic basic helix-loop-helix transcription factors, the first of which are Myf5 and 
MyoD.  MyoD and Myf5 are expressed early during satellite cell activation and proliferation, 
during muscle development, and are involved in the determination of the myogenic lineage 
(Braun et al., 1992; Rudnicki et al., 1992; Rudnicki et al., 1993; Weintraub 1993).  Myf5 and 
Pax-7 are expressed in quiescent satellite cells (Beauchamp et al., 2000), while MyoD is 
expressed as the cells become activated, proliferating and subsequently differentiate 
(Yablonka-Reuveni and Rivera 1994) (Figure 1.2).  The expression of myogenin and MRF4 
are upregulated in myoblasts beginning their terminal differentiation program, which is 
followed by permanent exit from the cell cycle (Yablonka-Reuveni et al., 1999a; Yablonka-
Reuveni et al., 1999b).   
These MRFs also activate the transcription of muscle-specific proteins through binding to a 
DNA consensus sequence known as the E-box which is present in the promoter of numerous 
muscle genes - such as acetylcholine receptor α subunit (Piette et al., 1990), creatine kinase 
(CK) (Lassar et al., 1989) and sarcomeric myosin.  In a small number of activated satellite 
cells, Myf5/MyoD expression is down-regulated, resulting in them returning to a quiescent 
state to maintain a more or less constant pool of satellite cells (Zammit et al., 2006).   
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Figure 1.2:  The role of MRFs in muscle regeneration.  In response to injury, normally 
quiescent satellite cells, re-enter the cell cycle, and start their proliferation and differentiation 
cycle in order to either fuse to produce new myofibers (hyperplasia) or fuse to damaged 
myofibers (hypertrophy) to regenerate muscle fibres.  The myogenic regulatory factors 
(MRFs) play a key role in driving the regeneration process.  Abbreviations:  AChR 
(acetylcholine receptor α); MyHC (myosin heavy chain).  Adapted from Zammit et al. (2004). 
 
1.2.4 Muscle-derived reactive species and secondary damage 
Even in the absence of injury or pathology, reactive oxygen species (ROS) are continuously 
being produced by skeletal muscle to stimulate local adaptive responses, as well as to 
mediate some degenerative processes (McArdle et al., 2001; Murrant and Reid 2001).  
Oxidative stress is quantified in more than one way:  (a) using indirect markers based on 
end-point products of the reactions of ROS and reactive nitrogen species (RNS) with lipids, 
proteins, or DNA (Davies et al., 1982; Jackson et al., 1985), or (b) by evaluating the activities 
of the main antioxidant enzymes, which include manganese superoxide dismutase (SOD), 
copper, zinc SOD, catalase, and glutathione peroxidase (Murrant and Reid 2001).  Skeletal 
muscle tissue and particularly the role of ROS within muscle have been examined using both 
in vivo (O’Neill et al., 1996) and in vitro (Reid et al., 1992) studies.  In the next few 
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paragraphs, I will focus on studies elucidating sources of ROS as well as their effect in 
muscle tissue within the context of injury. 
Nitric oxide (NO) appears to be one of the most important regulators of muscle inflammation 
and subsequent muscle damage by invading inflammatory cells and is considered to be one 
of the most common reactive species produced in muscle as a result of injury.  However, it 
should be noted that it is not clear whether NO production has a positive or negative effect 
after injury, since various studies have been done which justify both outcomes.   
By focussing on the positive effects first, an in vitro co-culture study has indicated that 
muscle-derived NO reduces neutrophil-mediated lysis of damaged muscle cells, resulting in 
decreased superoxide production (Nguyen and Tidball 2003).  A possible explanation for this 
positive effect is that NO scavenged the superoxide radicals released by neutrophils in order 
to prevent its conversion into a more cytotoxic oxidant (Rubanyi et al., 1991).  Another 
possibility is that NO inhibited the activity of NADPH oxidase, so that superoxide production 
was reduced (Clancy et al., 1992).  Satellite cells are one of the “first responders” to an 
injury-induced release of nitric oxide via nitric oxide synthase (NOS) (Schultz and McCormick 
1994), demonstrating that satellite cell activation (in vivo and in vitro) is mediated, at least in 
part, by NO (Anderson 2000).  NO is known to be released by the vascular endothelium, 
smooth muscle cells, myocardium, platelets, monocytes and macrophages after an injury 
(Moncada 1997).  Inhibition of NO, through the injection of a NOS inhibitor (Nω-nitro-L-
arginine methyl ester, L-NAME), results in the suppression of satellite cell activation 
(Anderson 2000).  NO is also able to inhibit the transcriptional activation of the intercellular 
adhesion molecule (ICAM), necessary for the adhesion of neutrophils to the vascular 
endothelium (Berendji-Grun et al., 2001), thereby limiting the number of neutrophils gaining 
access to the injured area via blood (Gauthier et al., 1994; Niu et al., 1994; Akimitsu et al., 
1995; Adams et al., 1997; Aljada et al., 2000).  Therefore, since it is known that NO inhibits 
the infiltration of neutrophils into the injured area, an injury in which the vasculature remains 
intact (e.g. mild contusion injury), will result in a decrease in neutrophils infiltrating the injured 
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area compared to an injury in which the vasculature is disrupted (e.g. severe contusion 
injury) – which will result in free flow of neutrophils into the injured area and thus 
exacerbation of injury.  These studies therefore indicate that NO plays a role in muscle 
regeneration through the activation of SCs and though the suppression of neutrophil 
infiltration into the injured area. 
Moving on to the negative aspects of NO: in vitro and in vivo studies indicate that specifically 
M1 macrophages can promote muscle damage by the production of cytotoxic levels of NO 
generated by inducible nitric oxide synthase (iNOS) (Nguyen and Tidball 2003; Villalta et al., 
2009).  This is most probably due to the fact that satellite cells, after activation and prior to 
proliferation, release factors which attract more macrophages and monocytes to the injured 
area and these cells produce more NO than needed, which could result in NO-dependent 
cytotoxicity (Chazaud et al., 2003).  These studies illustrating negative effects of NO indicate 
that the amount of NO expressed plays a very important role in facilitating either muscle 
regeneration or further muscle damage.        
Thus from these studies it is clear that NO, released by both neutrophils and M1 
macrophages, influences satellite cells, which suggests that an increase in NO should be 
expected during the early stages of muscle injury (Tidball and Villalta 2010), i.e. during day 1 
and 2 after injury (see Figure 1.1).  In a study on spinal cord injury, an increased number of 
iNOS positive cells in the perivascular space were evident on day 1 and day 2 after injury 
(Satake et al., 2000), corroborating the abovementioned statement of an increase in NO in 
the early stages after injury. 
Although one of the best known reactive species studied is NO, it was demonstrated in a 
study by O’Neill (1996) that contracting skeletal muscle is also able to generate hydroxyl 
radicals, detectable in muscle microvasculature.  The cellular origin of these radical species 
was at first not defined due to the fact that muscle tissue in vivo contains numerous other cell 
types, which includes endothelial cells, fibroblasts, and lymphocytes, that may potentially 
contribute to the generation of free radical species.  However, an in vivo study on contracting 
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myotubes, demonstrated that skeletal muscle cells, rather than other cells in the tissue, are 
able to release superoxide when stimulated by means of an acute bout of unaccustomed 
exercise (McArdle et al., 2001). 
After muscle injury, myocytes and other cells release a number of cytokines, such as 
interleukin (IL)-1β, IL-6, IL-8, and tumour necrosis factor (TNF)-α, that cause neutrophils to 
become activated (Best et al., 1999; Brickson et al., 2001).  These cytokines all stimulate 
pathways that contribute to activation of the enzyme NADPH oxidase, which generates a 
‘‘respiratory burst’’ and the subsequent release of reactive oxygen species, such as 
hydrogen peroxide (H202), superoxide anions (02-), and hydroxyl radicals (HO-) (Abramson 
and Weissmann 1989; Kerr et al., 1996; Ali et al., 1997).  Although phagocytosis and the 
neutrophil respiratory burst are important mechanisms in the early phase inflammatory 
response to muscle injury, they can damage the injured muscle even further, and may result 
in damage to the healthy tissue bordering the injured area.   
Therefore, the immune system is a critical component and is involved in both the injury and 
repair process.  
 
1.3  The inflammatory immune system 
The immune system, which involves immune organs and systems (bone marrow, spleen and 
lymphatic system), the immune cells (leukocytes/white blood cells – WBCs) and cytokines, 
plays a very important role during all types of inflammation.  For the inflammatory response 
to be beneficial it must first allow for a quick and efficient inflammatory stimulus, which then 
subsides to allow the tissue to return to its pre-inflamed state.   
Clinically, the inflammatory reaction is characterised by various symptoms, such as fever, 
redness, swelling and pain.  These symptoms are mainly caused by downstream effects of 
histamine, which include vasodilation, increased vascular permeability, oedema and 
appearance of acute phase proteins.  Within seconds after tissue injury, the permeability of 
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the surrounding capillaries is altered, leaking fluid, plasma proteins and immune cells into the 
surrounding tissue (Deal et al., 2002; Sherwood 2004b).  In case of substantial tissue 
damage, this initial reaction is quickly followed by an infiltration of white blood cells, 
predominantly neutrophils, from blood vessels into the tissue (Jarvinen et al., 2005).  This 
pro-inflammatory response can reach major proportions within a few hours of injury, most 
probably due to the increased transfer of neutrophils from the bone marrow and spleen into 
the blood, as a result of chemical mediators released from the inflamed tissue (Sherwood 
2004b; Tidball 2005).  During the next few days, neutrophil numbers decrease, while the 
affected tissue is infiltrated by mononuclear cells, primarily macrophages (Li et al., 2001).  
For the purpose of this thesis, in the next few sections, specific attention will be paid to the 
inflammatory WBCs, specifically neutrophils and macrophages, and their respective roles 
after contusion injury.  Both neutrophils and macrophages are phagocytic – however, their 
roles in inflammation are quite different, as discussed below. 
 
1.3.1 Neutrophils 
Neutrophils are blood-borne leukocytes which originate in the bone marrow, and migrate into 
the tissue upon injury or trauma.  Almost immediately following an injury (as soon as 1 hr), 
neutrophils form the predominant immune cell infiltrate.  Neutrophils migrate into the injured 
area through areas of intact capillary endothelium and across layers of basement membrane 
and sarcolemma  (Menger and Vollmar 1996).  This occurs by way of rolling along (via 
selectins), adhesion to (via integrins) and then migration into the injured tissue.  The triggers 
for neutrophils to enter the injured area are usually chemical mediators from the injured area 
itself (Sherwood et al., 2004; Tidball and Wehling-Henricks 2005) - including complement 
components (C5), pro-inflammatory prostaglandins (PGE2 and PGF2α) and leukotrienes 
(LTB4) (Shen et al., 2006), as well as factors released by activated platelets (TxA2, serotonin 
and histamine) (Marder et al., 1985).   
Neutrophils have 2 main functions after injury.  Firstly, the infiltrating neutrophils have a 
phagocytic function (Tiidus 1998), clearing the wound of blood-derived fibrin (Jarvinen et al., 
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2005) and necrotic material.  Secondly, they strengthen the inflammatory process via the 
release of pro-inflammatory cytokines such as IL-6 and TNF-α (Rosenberg and Gallin 1993; 
Cannon and St Pierre 1998; Tidball and Wehling-Henricks 2005) (For more information 
regarding the inflammatory cytokines, see section 1.5.2).  However, both these functions 
may have undesired side-effects.  Firstly, an in vivo study by Nguygen and Tidball (2003) 
reported that neutrophils lyse muscle cells through superoxide-dependent mechanisms, 
which is consistent with earlier in vitro findings (Simchowitz and Spilberg 1979; Markey et al., 
1990; Srinivasan et al., 1997).  In addition, myeloperoxidase (MPO), an enzyme present in 
neutrophils and macrophages, can generate hypochlorous acid, a highly reactive oxidising 
agent.  Secondly, pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), which result in the 
activation of more neutrophils, also stimulate pathways that contribute to activation of the 
enzyme NADPH oxidase (located on activated neutrophils), which generates a neutrophil 
respiratory burst and the subsequent release of reactive oxygen species.  Specifically, 
superoxide anions can quickly be converted into hydrogen peroxide (Best et al., 1999; 
Brickson et al., 2001) [See Figure 1.4 for more detail].  Although it has been observed in 
studies of single stretch that peak damage occurs at the same time as maximal neutrophil 
infiltration of the injured tissue (Brickson et al., 2001; Schneider et al., 2002), the exact time 
course of the appearance of inflammatory cells and secondary muscle damage may vary 
depending on the extend and type of muscle damage.  Identification and inhibition of the 
molecule(s) responsible for promoting neutrophil migration into and within skeletal muscle 
may lead to treatment options for alleviating neutrophil-mediated muscle injury.  Furthermore, 
inhibiting or limiting neutrophil infiltration into the injured area may also play an important role 
in restoring normal muscle fibre ultrastructure sooner.  Methylprednisolone (MP – a 
corticosteroid) decreased the expression levels of adhesion molecules and integrins on the 
leukocyte surface, therefore resulting in less neutrophils infiltrating the injured muscle area 
(Bartholdi and Schwab 1995; Droogan et al., 1998; Xu et al., 1998; Rabchevsky et al., 2002).  
Another study, using R(-)-2-(4-isobuthylphenyl)propionyl methanesulfonamidel (reparixin, for 
7 days), a small-molecule inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation, 
was also very effective in preventing neutrophil infiltration into injured spinal cord, and 
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therefore significant improvement in hind limb recovery of function (Bertini et al., 2004; Cugini 
et al., 2005; Garau et al., 2005).  These studies indicate that by limiting the neutrophil 
response, muscle regeneration may be accelerated. 
Various cytokines and chemokines play a significant role as chemoattractants for neutrophils.  
Skeletal muscle cells can produce and release a variety of molecules, including cytokines 
and CXC and CC chemokines (Nagaraju et al., 1998; De Rossi et al., 2000; Reyes-Reyna 
and Krolick 2000; Alvarez et al., 2002) in order to promote neutrophil chemotaxis (Olson and 
Ley 2002; Gouwy et al., 2005).  Most of these studies have focussed on IL-8, since it has 
been shown that low IL-8 concentrations (10-50 ng/ml) activate the two IL-8 receptors 
(CXCR1 and CXCR2), either by inducing neutrophil accumulation at inflammatory sites or by 
increasing the number of circulating neutrophils, and therefore resulting in neutrophil 
chemotaxis (Leonard et al., 1991; Kurdowska et al., 1994; Ben-Baruch et al., 1995; Ben-
Baruch et al., 1997a; Ben-Baruch et al., 1997b; Ludwig et al., 1997; Wolf et al., 1998; 
Zaslaver et al., 2001).  High doses on the other hand (1000 ng/ml) prevented specific 
neutrophil migration into inflamed tissue, indicating a dose dependent shift from activation to 
attenuation, which suggests that the interplay between different cellular factors are regulated 
by dose (Leonard et al., 1991; Ben-Baruch et al., 1997a; Ben-Baruch et al., 1997b; Ludwig et 
al., 1997).   
Another potential candidate is IL-1, which has been shown to be involved in the regulation of 
neutrophil adhesion and migration in vivo and in vitro in several species (Bevilacqaa et al., 
1985; Sayer et al., 1988; Moser et al., 1989).  In one of the in vivo studies, direct injection of 
0.005-5 ng/ml of either IL-1α or β resulted in increased neutrophil chemotaxis into the 
peritoneal cavity (Sayer et al., 1988).  However, the role of IL-1 in stimulating neutrophils to 
migrate across cellular barriers is a bit more complex in in vitro conditions.  When neutrophils 
were stimulated with IL-1, it did not result in neutrophil chemotaxis, suggesting that IL-1’s role 
in neutrophil chemotaxis could be more indirect than direct and possibly involve the 
activation of other cytokines or chemokines, such as TNF-α, to allow for neutrophil 
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chemotaxis.  Similar results were also evident when injecting granulocyte macrophage 
colony stimulating factor (GM-CSF), IL-6, monocyte chemotactic protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1α, and TNF-α into skeletal muscle alone or after 
mechanical loading of skeletal muscle (Cassatella 1999; Wolach et al., 2000).   
It is clear that not only one chemokine is responsible for neutrophil chemotaxis.  
Furthermore, various adhesion molecules are also involved in regulating neutrophil 
migration, e.g. ICAM and vascular adhesion molecule (VCAM).  
The pro-migratory/chemotactic responses of neutrophils and macrophages, and endothelial 
cells, are mediated by integrins, cellular adhesion and the rearrangement of the actin 
cytoskeleton.  The selectin family of adhesion molecules plays a very important role in the 
attachment or tethering of flowing neutrophils to the vessel wall through adhesions that 
permit neutrophils to roll along the blood vessel wall (Lawrence and Springer 1991; Mayadas 
et al., 1993).  Three members form part of the selectin family, namely L (leukocyte) -selectin, 
P (platelet) -selectin, and E (endothelial) -selectin (Bevilacqua and Nelson 1993).  L-selectin 
is the only selectin expressed on all leukocytes, except for a subpopulation of memory 
lymphocytes (reviewed in Springer 1995).  The immunoglobulin superfamily acts as integrin 
ligands and include the ICAM-1 (CD54), ICAM-2 (CD102), VCAM1 (CD106), platelet-
endothelial cell adhesion molecule-1 (PECAM-1 or CD31), and the mucosal addressin 
(MAdCAM-1) (Carlos and Harlan 1990).  Among these, ICAM-l and ICAM-2 are the major 
endothelial receptors for the neutrophil β2 integrins.  Activation of neutrophils by chemotactic 
factors upon injury, and the interaction between selectins, the immunoglobulin superfamily 
members and integrins, results in transmigration of neutrophils into the injured area from the 
vasculature (Jones et al., 1995; Springer 1995).   
In summary, once acute inflammation occurs, circulating peripheral neutrophils accumulate 
at the inflammatory site, a phenomenon established by the production of various 
chemoattractants, activation of neutrophils and especially the expression of ICAM on the cell 
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surface.  This, in combination with chemotactic factors will therefore result in more immune 
cells gaining access to the injured area. 
 
1.3.2 Monocytes and macrophages 
Monocytes arise from haematopoietic stem cells in the bone marrow (Sherwood 2004a).  
Under steady-state conditions, low-level recruitment of monocytes to tissues via circulation, 
followed by their transition into macrophages, accounts for resident macrophage populations 
(McLennan 1993).  Following a local insult, production and recruitment of monocytes to the 
injured area are greatly increased (Figure 1.3, p 19).  The recruited macrophage populations 
may also undergo further cytokine-mediated migration to the site of injury, resulting in even 
greater macrophage recruitment to the injured site.  Their cell numbers peak roughly on day 
5 after injury, although significant numbers are already present on day 1 or 2, when 
neutrophil numbers start to decline (Tidball and Wehling-Henricks 2005).   
Unlike neutrophils, macrophages can be divided into subpopulations depending on their 
localization (ED typing) or manner of activation (M typing).  An update on the literature 
regarding time course of macrophages and their subpopulations, as well as their specific 
roles during various types of injuries, was the focus of a recent review by Tidball and Villalta 
(2010).  M1 macrophages (ED1) are normally recruited by increased expression of interferon 
(IFN)-γ, TNF-α and GM-CSF as a result of muscle damage.  Due to the fact that M1 
macrophages are the first subpopulation of macrophages to invade the injured area, they are 
thought to be important in removing tissue debris via phagocytosis (McLennan 1996).  
However, these macrophages also promote inflammation through the release of pro-
inflammatory cytokines, such as IL-1β, IL-6, TNF-α, IL-12 and IL-23, as well as the 
production of other effector molecules such as reactive oxygen and nitrogen intermediates 
and thereby might exacerbate the injury process in a manner similar to that of neutrophils 
(Goerdt et al., 1999; Mills et al., 2000; Mosser 2003).  M1 macrophages promote muscle 
damage in vitro and in vivo in the presence of neutrophils at relatively low levels.  In an in    
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Figure 1.3:  The role of the different macrophage subpopulations in muscle recovery from injury.  Upon injury, monocytes are recruited 
to the injured area, and are activated as a result of various pro- or anti-inflammatory cues.  These macrophages can then either worsen the 
inflammatory process (M1 macrophages - early response), or result in muscle regeneration (M2 - later response), either by the factors it 
releases, or by direct interaction with injured muscle fibres and satellite cells.  Furthermore, depending on the time of the response, M1 
macrophages can switch to a M2 phenotype, although the mechanism that regulates this transition is still unclear.  Abbreviations:  IFN, interferon; 
LPS, lipopolysaccharide; GM-CSF, granulocyte macrophage colony stimulating factor; TNF, tumour necrosis factor; M-CSF, macrophage colony stimulating 
factor; TGF, transforming growth factor; IL, interleukin; ROS, reactive oxygen species; NO, nitric oxide; SCs, satellite cells.  Adapted from the following 
authors:  (Mantovani et al., 2004; Ricardo et al., 2008; Tidball and Villalta 2010).  
1
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vitro study by Nguyen and Tidball (2003), muscle membrane damage (lysis) of myotubes 
through superoxide-dependent mechanisms was also detected when macrophages (> 90 % 
ED1 and the rest ED2) were present at macrophage/neutrophil ratios (10:1).  This is the ratio 
that usually occurs in muscle injury and inflammation at the stage of injury when muscle 
membrane lysis occurs (roughly on day 2-4) (Tidball et al., 1999).  In this study, the 
neutrophils and M1 macrophages were added in relatively low numbers (500 cells/mm2 and 
5000 cells/mm2 respectively) to muscle co-cultures, compared to the normal levels (25 000 
cells/mm2) and this resulted in the activation of a greater proportion of the macrophages, 
thereby promoting their overproduction of NO and thus greater myoblast cytotoxicity.  Since it 
is also known that muscle cells can produce NO, it is quite possible that the high levels of NO 
detected in the study by Nguyen and Tidball (2003) may be as a result of myoblasts 
themselves.  SCs within injured muscle can release NO and other free radicals upon 
activation (Schultz and McCormick 1994; Anderson 2000; Chazaud et al., 2003; Pisconti et 
al., 2006), and may therefore contribute towards increased muscle membrane damage or 
lysis.  However, the increase in NO in Nguyen and Tidball’s study (2003) was as a result of 
iNOS (specific to immune cells) in macrophages and not nNOS (specific to skeletal muscle) 
in muscle, indicating that muscle cells might not have contributed to the NO-dependent 
cytotoxicity in this specific situation. 
After M1 macrophages have reached their peak concentration in injured and regenerating 
muscle, they are either replaced by or switched to a population of M2 (alternatively activated) 
macrophages that can attenuate the inflammatory response and promote tissue repair.  M2 
macrophages in general, are activated by a variety of T helper 2 (TH2) cytokines, namely IL-
4, IL-10 and IL-13 (Gordon 2003).  ED2 macrophages differ from total M2 macrophages in 
the sense that the ED2 macrophage population is comparable with M2 macrophages with an 
immunosuppressive profile, in other words the M2c macrophages (Mantovani et al., 2004).  
In a cell culture study by Massimino et al. (1997), it became evident that M2 macrophages 
played a role in activating satellite cells and myoblast proliferation, thereby contributing to 
skeletal muscle regeneration and tissue repair.  From the reviewed literature on 
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macrophages, it is evident that M1 macrophages plays a predominant role in removing 
debris but also contributing to further muscle injury, whereas M2 macrophages aid muscle 
recovery.   
It is also possible that M1 macrophages can change to M2 macrophages when stimulated 
with different factors (see Figure 1.3).  This will not only result in a shift from one phenotype 
to the next, but will also result in a shift in cytokines produced thereafter.  Although it has 
been proposed that macrophages can switch phenotypes during the course of muscle 
regeneration, little is known regarding the specific time after injury, although the trigger 
mechanisms that regulate this transition in macrophage phenotype are better understood.  
Quantifying the different macrophage subpopulations over time, after an injury, should 
provide a more complete time line of when the switch from a M1 to a M2 phenotype occurs in 
that particular injury model.  Inconsistencies also exist regarding time courses of 
inflammation in various different models of injury.  For example, ED1 macrophages are 
evident at 24 and 48 hr after downhill running (Lapointe et al., 2002; Tsivitse et al., 2003), 
while ED2 macrophages accumulate in injured muscle 2-3 days post-injury (Tidball et al., 
1999; Frenette and Tidball 2000; Frenette et al., 2002).  In one specific study, a downhill-
running study (humans), no elevations in ED2 macrophages were evident 72 hours 
afterwards (Tsivitse et al., 2003), whereas, lengthening contractions of the dorsiflexor 
muscles of the ankles (rats) resulted in elevated ED2 macrophages 48 hr afterwards 
(Lapointe et al., 2002).   
Therefore, care should be taken when comparing immune cell infiltration into the injured area 
after different exercise or different types of injury regimes, as the timing of appearance of the 
different macrophage populations will vary considerably.      
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1.4  Effect of WBCs on muscle after injury 
During acute muscle injury, the regeneration process of muscle activates a sequence of 
interactions between muscle and inflammatory cells (see Figure 1.4, pg 23).  From the 
literature it is known that an acute injury can result in the release of chemoattractant 
molecules that initially attract neutrophils or M1 macrophages into the muscle (Tidball and 
Villalta 2010) for the inflammatory response.  However, this process also differs depending 
on the amount of time that has elapsed since injury.  Human myogenic precursor cells 
(mpcs, SCs), in vitro, were found to selectively and specifically attract monocytes through an 
endothelial layer in a dose-dependent manner (Chazaud et al., 2003).  This property of mpcs 
to attract monocytes varied according to their differentiation stage: individual chemotactic 
activity of satellite cells was highest shortly after their release from quiescence and then 
declined progressively to reach levels similar to that of other cell types at a time 
corresponding to the late or terminal differentiation SC stage (Chazaud et al., 2003). 
However, not only is there communication from muscle cells to WBCs, but a close reciprocal 
relationship also exist between the WBCs and the muscle.  Upon muscle injury, neutrophils 
release several cytokines (TNF-α, IFN-γ, IL-1β and IL-12) and growth factors (transforming 
growth factor (TGF-β)) (Cassatella 1999), which are known to inhibit either myoblast 
proliferation and/or differentiation in vitro (Garrett et al., 1992; Hawke and Garry 2001; 
Langen et al., 2001).  Some of the interactions may be more direct: neutrophils have been 
shown to be involved in satellite cell activation and proliferation in vitro via the interaction of 
the neutrophil α4-integrin receptor with VCAM-1, which is expressed by both myoblast and 
myotubes (Seale and Rudnicki 2000).  Furthermore, neutrophils could also facilitate the 
resolution of the injury by releasing cytokines, (HGF for SC activation and migration and IL-6 
for maintaining SC proliferative state) (Austin and Burgess 1991; Allen et al., 1995; 
Cassatella 1999; Miller et al., 2000); and/or by promoting the accumulation of macrophages 
(Merly et al., 1999; Cantini et al., 2002).   
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Figure 1.4:  The interaction between muscle and immune cells drive the regeneration process.  At the onset of an injury, the disruption of 
muscle fibres, together with products released by activated mast cells and platelets result in the production of pro-inflammatory cytokines (IL-1β, 
IL-6 and TNF-α).  These cytokines result in selectin activation and extravasation of immune cells out of the blood into the injured area.  
Neutrophils result in ROS production, whereas macrophages produce anti-inflammatory cytokines (IL-4 and IL-10) which, together with NO, 
drives the satellite cell activation process in order to restore normal muscle fibre ultrastructure.  O2:  oxygen, e-: electron, O2.-: superoxide radical, H+: 
hydrogen ion, H2O2: hydrogen peroxide, NO: nitric oxide.      
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Macrophages on the other hand play their own vital role in muscle regeneration, since 
myogenesis is impaired in the absence of macrophage infiltration (Lescaudron et al., 1999).  
Macrophages, particularly ED2 macrophages were able to increase the number of MyoD+ 
cells and thus cause myoblast proliferation in vitro (Massimino et al., 1997; Giurisato et al., 
1998; Merly et al., 1999), indicating that they may contribute to satellite cell activation and 
proliferation in vivo as well.  This is probably likely, since it is known that M2 macrophages 
release cytokines that can promote satellite cell activation and proliferation (Tidball and 
Villalta 2010).  ED1 macrophages on the other hand have been thought to be involved in 
negatively regulating satellite cells in vivo (Kuschel et al., 2000) and can promote muscle 
damage through the production of cytotoxic levels of NO (Nguyen and Tidball 2003; Villalta 
et al., 2009).   
It is therefore apparent that immune cells do not only have a phagocytic and inflammatory 
function, but are also able to influence satellite cell activation and muscle regeneration after 
injury.  It is also evident that an inter-relationship exists between muscle cells, macrophages 
and neutrophils, in that myoblasts recruit macrophages and neutrophils to sites of muscle 
injury via secreting chemotactic factors vs. immune cells themselves secreting cytokines to 
activate more satellite cells. 
         
1.5 Other role players in restoring normal muscle function 
In addition to their roles in attracting immune cells to the injured site, cytokines along with 
growth factors also play very important roles in controlling SC activation, migration of satellite 
cells to the injury site, proliferation of SC-derived myogenic precursor cells (mpcs) and fusion 
into myotubes and myofibres.  The role of growth factors and cytokines involved in restoring 
normal muscle function will be discussed in detail in the next few paragraphs.  Due to the 
emphasis in this thesis on the immune system, the effect of growth factors will not be 
discussed in depth. 
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1.5.1  Growth factors  
Growth factors are proteins that bind to receptors on the cell surface, with the primary result 
of activating cellular proliferation and/or differentiation.  Post-injury, these factors are 
especially important for maintaining a balance between proliferation and differentiation of 
SCs to restore normal muscle architecture.  Many growth factors are quite versatile, 
stimulating cellular division in numerous different cell types, while others are specific to a 
particular cell type (see Table 1.2). 
 
Table 1.2:  Growth factors that play a role during muscle contusion injury and 
recovery.   
Growth 
factor 
Source cell Function References 
TGF-α Transformed cells May be important for normal wound healing (Peters et al., 2005) 
TGF-β Neutrophils 
Monocytes/macrophages 
T lymphocytes (TH1) 
Natural killer cells 
Platelets 
Injured skeletal muscle 
Promotes wound healing 
Promotes neutrophil recruitment 
Inhibits pro-inflammatory cytokine 
synthesis 
Increases satellite cell proliferation 
(Peters et al., 2005) 
 
For review, see (Hawke 
and Garry 2001) 
(Haugk et al., 1995) 
FGF-2 Monocytes/macrophages 
Injured skeletal muscle 
Promotes proliferation of many cells 
 
Attenuates satellite cell differentiation to 
myotubes 
Important role in muscle regeneration 
(Sheehan and Allen 
1999) 
For review, see (Hawke 
and Garry 2001) 
(Floss et al., 1997) 
IGF-1 Monocytes/macrophages 
Injured skeletal muscle 
Promotes proliferation of many cell types, 
including satellite cells 
Regulates skeletal muscle regeneration 
Increases satellite cell differentiation 
 
(Chakravarthy et al., 
2000) 
(Florini et al., 1991b) 
HGF Injured skeletal muscle Role as chemotactic factor 
Activates satellite cells and promotes their 
proliferation 
Increases mpc migration into injured tissue 
(Bischoff 1997) 
(Allen et al., 1995) 
 
(Florini et al., 1991a; 
Christov et al., 2007) 
VEGF Activated SCs 
Regenerating myotubes 
Induces vasodilation 
Enhances vascular permeability 
Stimulates proliferation, migration, and 
survival of endothelial cells 
Modulates skeletal muscle function 
(Germani et al., 2003) 
 
 
(Becker et al., 2006; 
Ochoa et al., 2007) 
   
Abbreviations:  TGF, transforming growth factor; FGF, fibroblast growth factor; IGF, insulin-like growth 
factor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor. 
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1.5.2  Cytokines 
Cytokines are small proteins that carry signals locally between cells as well as in the 
circulation, and thus have an effect on other cells.  Cytokines are also produced by immune 
cells and various other non-immune cells of the body (see Table 1.3, pg 27).  Many are 
known as interleukins, since they are not only secreted by leukocytes, but also able to affect 
the cellular responses of other leukocytes.  Cytokines play very important roles in restoring 
normal muscle structure, and specifically IL-6, IL-1β and TNF-α have been shown to be 
involved in regeneration [for review see Smith et al. (2008)].  Only the main cytokines 
important in muscle regeneration, and thus relevant to this study, will be addressed in the 
next few paragraphs. 
Tumour necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine that is produced by 
macrophages and monocytes, but also other body cells.  TNF-α is known to have pleiotropic 
effects – it mediates inflammatory and apoptotic responses, and modulates growth and 
differentiation of many cell types.  In a review regarding TNF-α, it was reported that this 
particular cytokine plays a predominant role in skeletal muscle, contributing to both 
degeneration and regeneration (Li and Reid 2001).  In a study by Wilcox et al. (1994), direct 
administration of TNF-α (60 µg/kg) to experimental animals (dogs) inhibited contractile 
function, possibly through platelet activating factor (PAF)-dependent synthesis of NO (Alloatti 
et al., 2000).  In a study by Li et al. (1998), when exposing skeletal muscle myocytes to TNF-
α (physiological doses, ranging from 1 ng/ml – 6 ng/ml), it resulted in a nuclear factor kappa 
B (NFκB)-dependent loss of protein, a process known to mediate muscle atrophy (Li et al., 
1998).  It also plays a predominant role in promoting early differentiation of C2C12 murine 
myoblasts in an autocrine fashion (Li and Schwartz 2001).  In contrast to the positive results 
found with TNF-α, other studies by this particular group, established that prolonged 
incubation with repeated higher doses of TNF-α (10 ng/ml or higher) killed cultured myocytes 
(Li et al., 1998; Li and Reid 2000).  Other studies have also reported a negative effect of 
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Table 1.3:  Cytokines with pro- and anti-inflammatory activities. 
Cytokines Cell sources Major activity References 
IL-1β Neutrophils 
Macrophages 
Fibroblasts 
B and T cells 
NK cells 
Injured skeletal muscle 
Keratinocytes 
Stimulates selectin expression 
Plays a role as chemotactic agent 
Facilitates increased expression of G-CSF and GM-CSF 
Inhibits satellite cell differentiation, thus increases 
proliferation 
Upregulates IL-6 and MCP-1 expression 
Promotes muscle inflammation 
(Cannon and St Pierre 1998) 
(Zsebom et al., 1988) 
(Allen and Boxhorn 1989) 
(Gallucci et al., 1998; Pedersen et al., 1998; Li et al., 
2001) 
(Guo et al., 2004) 
(Barr et al., 2004) 
IL-4 B and T cells (TH2) 
Mast cells 
Stromal cells 
Myotubes 
Promotes TH2 lymphocyte development 
Inhibits LPS-induced proinflammatory cytokine synthesis 
B cell proliferation 
Controls recruitment of further myoblasts 
(O'Garra and Murphy 1994) 
(Brown and Hural 1997) 
(Grabstein et al., 1986) 
(Horsley et al., 2003) 
IL-6 Neutrophils 
Macrophages 
B and T cells 
Eosinophils 
Fibroblasts 
Injured skeletal muscle 
Inhibits TNF-α, MIP-2, GM-CSF and IFNγ secretion 
Stimulates acute phase response 
Upregulates IL-1β secretion at rest only 
Stimulates proliferation of various cell types 
Promotes degradation of necrotic tissue 
Induces apoptosis of macrophages following injury 
Stimulates secretion of glucocorticoids directly 
(Caiozzo et al., 1996; Cai et al., 2000) 
(Heinrich et al., 1990) 
(Panzer et al., 1993 ) 
(Massimino et al., 1997) 
(Cantini and Carraro 1996) 
(Cantini and Carraro 1996) 
(Steensberg et al., 2003) 
IL-8 Neutrophils 
Fiboblasts 
Promotes macrophage chemotaxis 
Decreases neutrophil infiltration  
(Li et al., 2001) 
(Gimbrone Jr et al., 1989 ) 
IL-10 Macrophages 
T cells (TH2) 
B cells 
Inhibition of monocytes/ macrophages and neutrophil 
cytokine production 
Inhibits TH1-type lymphocyte responses 
(De Waal Malefyt et al., 1991; Fiorentino et al., 1991 ; 
Giannoudis et al., 2000) 
(Moore et al., 2001) 
TNF-α Macrophages Upregulates IL-1β and IL-6 secretion 
Increase selectin expression 
Indirectly related to muscle atrophy via NFκB stimulation 
Promotes muscle inflammation 
Stimulates satellite cell proliferation, not differentiation 
Induces production and attraction of macrophages to injury 
site 
(Panzer et al., 1993 ; Gallucci et al., 1998) 
(Cannon and St Pierre 1998) 
(Li et al., 1998) 
(Barr et al., 2004) 
(Foulstone et al., 2004; Langen et al., 2004; Stewart et 
al., 2004; Langen et al., 2006) 
(Tidball and Wehling-Henricks 2005) 
IFN-γ T cells 
NK cells 
Facilitate neutrophil infiltration 
Stimulates myoblast proliferation 
(Gao and Issekutz 1996) 
(Olsson et al., 1994 ) 
 
Abbr: IL, interleukin; TNF, tumour necrosis factor; IFN, interferon; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage colony 
stimulating factor; MCP, monocyte chemotactic protein; LPS, lipopolysaccharide; MIP, macrophage inflammatory protein; NFκB, nuclear factor kappa beta.
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TNF-α on muscle gene expression when treating myoblasts with repeated doses of 25 ng/ml 
(Miller et al., 1988), which is several times higher than the serum levels found in humans with 
catabolic diseases (Nakashima et al., 1995). From the above, it is therefore clear that doses 
between 1-6 ng/ml TNF-α results in positive effects, whereas supraphysiological doses may 
result in cytotoxicity and negative outcomes.   
Interleukin-6 (IL-6) is a pleiotropic cytokine mainly secreted by skeletal muscle fibres, 
fibroblasts, endothelial cells, keratinocytes and peripheral blood mononuclear cells (PBMCs), 
specifically known as TH2 cells and macrophages (Biffl et al., 1996).  Like many other 
cytokines, IL-6 has both pro-inflammatory as well as (indirect) anti-inflammatory properties.  
Most often IL-6 is referred to as a pro-inflammatory cytokine rather than an anti-inflammatory 
cytokine, as its main immune-related function is to increase lymphocyte proliferation and 
differentiation and to activate the release of other pro-inflammatory cytokines and acute 
phase proteins (Heinrich et al., 1990).  However, many of its actions also have an indirect 
anti-inflammatory outcome, via stimulating cortisol release, inducing hepatic synthesis of 
antioxidants and protease inhibitors (Steensberg et al., 2003). IL-6 is also a myokine, 
released from muscle, in response to muscle contraction, including exercise, and precedes 
the appearance of other cytokines in the circulation (Febbraio and Pedersen 2005; Petersen 
and Pedersen 2005).   
Interleukin-10 (IL-10), otherwise known as human cytokine synthesis inhibitory factor 
(CSIF) is a key regulator of immune responses.  This anti-inflammatory cytokine is produced 
primarily by monocytes and to a lesser extent by lymphocytes, TH2, B cells and mast cells 
(Asadullah et al., 2003).  IL-10 has pleiotropic effects in immunoregulation and inflammation, 
by downregulating the expression of Type 1 helper (TH1) cytokines and myosin heavy chain 
(MHC) class II antigens (Moore et al., 2001).  In vitro studies showed that IL-10 can directly 
inhibit cytokine production by TH1 and TH2 cells by acting on the antigen-presenting cells 
(APC).  Further investigations have demonstrated that the immunosuppressive effects of IL-
10 are more often at the level of the APC and not directly at the level of the T cell (Moore et 
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al., 2001).    In context of this thesis, the specific IL-10 function of inhibiting the synthesis of 
pro-inflammatory cytokines, such as IFN-y, IL-1α, IL-1β, IL-2, IL-3, IL-6, IL-8, IL-12, TNF-α 
and GM-CSF made by cells such as macrophages and the TH1 cells (De Waal Malefyt et al., 
1991; Fiorentino et al., 1991; Giannoudis et al., 2000; Hackstein et al., 2003) is most 
important.  In recent studies, it was also demonstrated that IL-10 is also able to activate and 
attract M2 macrophages to the injured area, aiding muscle regeneration by facilitating the 
synthesis of more anti-inflammatory cytokines from these macrophages (De Waal Malefyt et 
al., 1991; Fiorentino et al., 1991 ; Giannoudis et al., 2000).  
Interleukin-4 (IL-4) is produced by activated T-lymphocytes, mast cells, eosinophils and 
basophils and myotubes.  It is a highly pleiotropic cytokine that plays a major role in T cell 
development, where it induces differentiation of naive helper T cells (TH0 cells) to TH2 cells 
(Brown and Hural 1997).  TH2 cell secretion of IL-4 and IL-10, leads to the suppression of TH1 
responses by down-regulating the production of macrophage-derived IL-12 and inhibiting the 
differentiation of TH1-type cells (Levings and Schrader 1999).  IL-4 has a marked inhibitory 
effect on the expression and release of pro-inflammatory cytokines.  It is able to suppress 
monocyte-derived cytokines, including IL-1, TNF-α, IL-6, IL-8 and MIP-1α when stimulated 
with LPS, TNF-α or IL-1 respectively (Standiford et al., 1990).  It has also been shown to 
suppress macrophage cytotoxic activity, parasite killing and macrophage-derived NO 
production.  IL-4 has a direct effect on satellite cells by recruiting more myoblasts to the 
injured area upon trauma (Horsley et al., 2003).  In addition to its inhibitory effect on the 
production of inflammatory cytokines, it stimulates the synthesis of the cytokine inhibitor IL-
1Rα. 
From the abovementioned literature regarding the different cytokines, it is evident that these 
cytokines play very important roles in muscle regeneration.  These cytokines will be 
discussed in context of muscle injury in section 1.7.3. 
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1.6 Skeletal muscle contusion injury 
1.6.1  Overview 
There are many ways in which muscle fibres can be damaged.  External causes include 
contusion and laceration injuries to the body, or extremes of heat or cold, whereas internal 
causes include muscle tears and tendon ruptures following sudden forceful contractions 
(McComas 1996).  For the purpose of this thesis, only contusion injuries will be discussed in 
detail.  
Clinical contusion injuries are caused by a blunt non-penetrating impact to the muscle belly.  
The process of soft tissue wound healing is complex and progresses through 3 distinct, yet 
overlapping phases, namely: destruction, repair and remodelling, which can take between 
14-21 days for full recovery.  For a detailed description of the 3 phases, see Jarvinen et al. 
(2005).  When bone or tendon is involved during these types of injuries, it complicates the 
recovery process even further.  Bone injury occurs when an injury, including a contusion 
injury, occurs too close to the bone.  Bone healing involves physiological and cellular 
processes to regenerate broken bones (Einhorn 1998; Vortkamp et al., 1998).  New bone 
matrix mineralization can take several months before healed bone has maximum strength 
(Klug et al., 1986).  These physiological and cellular processes involved include localized 
tissue hypoxia, fracture hematoma formation, and subsequent inflammation and thus 
migration of immune cells into the fracture site, as well as fracture callus remodelling with the 
help of bone-forming cells (osteoblasts) and bone-resorptive cells (osteoclasts) (Brighton et 
al., 1991; Bolander 1992).  Production or release of specific growth factors, cytokines, and 
local hormones at the fracture site aid the recovery process (Brighton et al., 1991; Bolander 
1992).  If a contusion or any type of soft tissue injury occurs, with subsequent bone 
involvement, it results in a greater immune response.  Previous studies have demonstrated 
that 24 hr after trauma–hemorrhage (Fx-TH), proliferation of splenic T lymphocytes occurred, 
whereas IL-2, and IFN-γ expression were depressed in 2–3 month old male mice compared 
to their respective sham-injured group (Kahlke et al., 2000).  Studies by the same group 
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found a significant decrease in splenocyte proliferation and a significant increase in bone 
marrow cell proliferation in these mice following Fx-TH injury compared to their respective 
sham groups (Kang et al., 2004).  In addition, plasma IL-6 and IL-10 levels were significantly 
higher 2 hr following Fx-TH compared to control groups, as well as compared to contusion 
injury only.         
With tendon injuries, the healing tendons may take up to 1 year to reach maximal strength 
and might need reconstructive surgeries (Mishra et al., 2009).  Tendon injury also results in a 
different immune response compared to contusion injury.  A study in a rabbit model of 
Achilles paratendonitis and tendinosis, using radiolabelled microspheres, indicated that blood 
flow is increased in the damaged tendons (Backman et al., 1990).  Increased levels of TGF-
β2 have been reported in pathologically inflamed human Achilles tendons and in rabbit flexor 
tendons after injury.  TGF-β2 results in scar formation and fibrosis (Ernst et al., 1996).  The 
response to cytokines may be site-specific, and insulin-like growth factor-1 (IGF-1) induces a 
higher rate of collagen synthesis in rabbit flexor tendons than it does in rabbit Achilles 
tendons (Abrahamsson and Lohmander 1996).  The use of cytokines and growth factors to 
enhance tendon healing remains largely experimental and has been restricted to in vitro 
studies and animal models (for a review on the available literature, see Sharma and Maffulli, 
2005).  In human studies, the application of cyclic strain increases production of 
prostaglandin E2 (PGE2) in human patellar tenocytes, and also increases IL-6 secretion and 
IL-1β gene expression in human flexor tenocytes (Tsuzaki et al., 2003a; Tsuzaki et al., 
2003b).  IL-1β is released on mechanical stretching of rabbit Achilles tendons resulting in 
increased production of matrix metalloproteinase (MMP)-3 (Archambault et al., 2002).  In all 
of these studies, tendon injury resulted in higher cytokine levels when compared to muscle-
only contusion injury. 
Therefore, it is clear that when designing a study simulating a contusion injury, it is 
imperative that bone or tendon is not involved.  If contusion injuries occur in close proximity 
to bone or tendon, it will take longer for the injury to heal and other complications such as re-
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injury may occur if an athlete were to return to the sports field too soon.  Thus, ideally a study 
investigating bone or tendon injuries should look at later time points – months up to 1 year 
post-injury, while contusion injuries should usually not take longer than 21 days to heal, and 
should therefore be monitored over a more acute post-injury period.   
 
1.6.2  Models used to study mechanical injuries 
Currently, the only way to investigate the effect of contusion injury in humans, is to use 
athletes who have been injured accidentally as a result of participation in their sport.  A 
complication with such studies is that the subjects investigated will have various degrees of 
injury severity, and as such may be subjected to very different treatment modalities.  Also, no 
pre-injury control can be used, so, the effect of injury is not completely clear.  Another 
potential model to investigate muscle damage in human subjects makes use of eccentric 
exercise.  In this type of exercise, subjects have to perform various sets of repeated muscle 
contractions, which may result in morphological changes (Takekura et al., 2001) and delayed 
onset muscle soreness (DOMS) (Yu et al., 2002), and is not ideal for investigating contusion 
injuries.  Therefore, animal models may provide more information on muscle regeneration 
from impact trauma. 
Skeletal muscle contusion injury is a proven method of inducing mechanical injury in skeletal 
muscle of rodents (Bunn et al., 2004; Darmani et al., 2004; Gierer et al., 2005).  The most 
common models used are those producing a single impact trauma to a particular muscle 
group (mass-drop injury model), with or without prior surgical exposure of the muscle 
(Rushton et al., 1997; Bunn et al., 2004; Darmani et al., 2004; Gierer et al., 2005; Squarzoni 
et al., 2005; Vignaud et al., 2005).  The non-invasive model was first described by Stratton et 
al. in 1984, and involved the dropping of a solid weight with a flat impact surface, varying in 
diameter and mass, from various heights onto the specific muscle studied.  In a recent study 
by our group (MSc thesis, Kruger 2007), a moderately severe, non-invasive mass-drop injury 
model, similar to the model first described by Stratton, was employed.  A standardised injury 
to the gastrocnemius muscle of rats was delivered by dropping a mass of 200 g from a height 
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of 50 cm through a plastic tube fastened perpendicularly and directly above the muscle 
impact zone.  This model produced reproducible contusions that were moderately severe, 
and took about 14 days for full recovery in terms of inflammation.   
Variations of the mass-drop model have been described in rodents and mice.  For example, 
forceps crush injury is one of the ways used to study a contusion injury, where contusion 
injury can either be delivered invasively or non-invasively.  Prior to the injury, the muscle is 
surgically exposed (invasive), or kept intact (non-invasive), placed between the jaws of 
forceps and then bruised by either pinching the forceps manually or by dropping a weight 
onto the forceps.  Apart from the invasiveness of this method (if exposed surgically), manual 
injury is difficult to deliver in a standardised manner.  Despite these complications, this model 
has been used to study skeletal muscle regeneration following a contusion injury (Collins and 
Grounds 2001; Squarzoni et al., 2005; Vignaud et al., 2005).   
A different model entails placing a much heavier weight on the muscle (i.e. no impact force) 
for 2 or more hours, a model used when studying compartment syndrome (Rubinstein et al., 
1998; Akimau et al., 2005).  Due to its extreme nature, and the lack of perfusion followed by 
hyper-perfusion, this is not a relevant model for studying impact contusion injury.   
The current classification of muscle injuries identifies mild, moderate, and severe injuries 
based on the clinical impairment they bring about.  Mild strain/contusion represents a tear of 
only a few muscle fibres with minor swelling and discomfort accompanied by no or only 
minimal loss of strength and restriction of movement.  In moderate strain/contusion injuries, a 
greater extent of muscle damage with a clear loss in function (ability to contract) is present, 
whereas a tear extending across the entire cross section of the muscle, resulting in a virtually 
complete loss of muscle function, is termed severe strain/contusion (Jarvinen et al., 2005).  
Therefore, according to these standards, severe contusion injuries should be thought of as 
clinical, i.e. operations are often needed to repair the damage, whilst mild and moderate 
contusion injuries are more physiological.   
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1.7   Response to contusion injury 
1.7.1 Satellite cell response 
Acute skeletal muscle injuries result in enhanced recruitment and activation of satellite cells 
(Grounds 1999; Grounds et al., 2002; McComas 1996).  Satellite cell activation is usually 
restricted to the damaged area, however, if the connective tissue between muscle fibres are 
also damaged, satellite cells may also be recruited from adjacent fibres (Schultz et al., 1985; 
Schultz et al., 1986).  In general, contusion injured rat skeletal muscle rapidly regenerates, 
forming myotubes within 3-7 days after injury, with full recovery around day 14 post-injury 
(MSc thesis, Kruger 2007). 
In a study on contusion injury by Thorsson et al. (1998), the number of proliferating satellite 
cells within regenerating muscles was counted in order to provide an assessment of the 
extent of early muscle regeneration.  Satellite cells labelled with bromodeoxyuridine (BrDU – 
proliferating SC marker) were abundant in the early stages of skeletal muscle regeneration 
(day 3), both between surviving basal laminae and between muscle fibres in the regenerating 
muscle stumps, diminishing later on (Thorsson et al., 1998).  In the basic histological studies, 
all muscle injuries regenerated normally.  The first matured myofibers with desmin-positive 
cross-striation were detected at Day 9, still with some centrally located nuclei.  Similar results 
were also found in a subsequent study by Rantanen et al. (1999).  In a rodent study by our 
group (MSc thesis, Kruger 2007), it was demonstrated that in response to experimental  
gastrocnemius muscle contusion injury, SC markers CD34 and CD56 were readily expressed 
4 hr after injury, with a peak at 7 days after injury.  The peak on day 7 indicates either that 
SCs were proliferating, or that SCs had stopped fusing and were returning to quiescence.  It 
also correlated with the formation of new regenerated muscle fibres, suggesting that the time 
course for the skeletal muscle regeneration may take up to 7-14 days.   
From these studies, it is apparent that the skeletal muscle regeneration process after 
contusion injuries has not been studied as comprehensively as other models in terms of the 
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role of satellite cells.  Furthermore, questions still remain, especially regarding the effect of 
the inflammatory immune system, as well as the specific role players involved in the repair 
process.  The next section will focus on the inflammatory immune system and its role in 
myogenesis, and will specifically focus on the limited research available on the effect of 
immune cells on the regenerating process specifically related to contusion injury.   
 
1.7.2 Immune cell response 
Time courses of the immune cell response after contusion injury are quite similar compared 
to the response to other types of acute injuries, with the exception of the appearance of M2 
macrophages.  In a contusion injury study by Thorsson et al. (1998), a small number of 
neutrophils were still present at day 3 after injury, but virtually none were detected on day 6.  
In contrast, large numbers of monocytes were still present at Day 6, only disappearing by 
Day 11.   
 
1.7.3  Cytokine response   
Limited studies have been done to investigate the effect of a contusion injury on the cytokine 
response.  To date, only three research groups actually measured cytokine protein 
concentrations or gene expression levels in this type of injury (Kami and Senba 2002; Bunn 
et al., 2004; McBrier et al., 2007).  Figure 1.5A represents the muscle cytokine response 
after contusion injury of different severities, whereas Figure 1.5B illustrates the plasma 
cytokine response after exercise.   
In one particular study, (Figure 1.5A) only localized inflammation was studied extensively in 
an invasive model of contusion injury (Bunn et al., 2004).  In this study, in a model of mild 
contusion injury (100 g weight dropped from 13 cm – solid lines), similar expression patterns 
were evident for all three pro-inflammatory cytokines measured (IL-1β, IL-6 and TNF-α), with 
peak expression occurring on day 4.  Moderate contusion injury (200 g weight dropped from 
13 cm – dashed lines) on the other hand resulted in a much later peak (day 8).  However, 
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A:  Animal model – Intramuscular    
 
B:  Human subjects - Circulation 
      
Figure 1.5:  Time course pattern of the cytokines, IL-1β, IL-6 and TNF-α in animal and 
human injury.  (A) represents the cytokine pattern in the muscle after contusion injury of 
different severities, whereas (B) represents the circulatory cytokine pattern after exercise.  
Contusion injury severities include: Mild (100g from a height of 13 cm, indicated by solid 
lines), moderate (200 g from a height of 13 cm, indicated by dashed lines).  Exercise 
includes 2.5 hr of treadmill running (TR, indicated by solid lines) or an average of 3 hr 27 min 
marathon running (MR, indicated by dashed lines).  Adapted from Bunn et al., 2004 (muscle 
cytokines); Ostrowski et al., 1998 and 1999 (circulatory cytokines). 
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since no data are available for day 0 (day of injury, before injury) or even a couple of hours 
after injury, it is not clear whether these cytokines actually peaked earlier than day 2.  Also, 
no statistical analysis was performed to determine whether mild and moderate injury had a 
significant effect on cytokine levels over time.  This information would have been more 
valuable, since it is clear from the figure that there were big differences over time.  This study 
also lacked a proper control for the surgery prior to injury and therefore the cytokine levels 
reported were not corrected for cytokines released as a result of the injury caused by 
surgery.  It is imperative that in studies involving damage to the skin, proper controls are 
required due to the fact that particularly TNF-α and IL-6 are known to increase a couple of 
hours after surgery (Nossuli et al., 2000).  In a study by Farnebo et al. (2009), the 
contralateral leg was used as control when rats were exposed to severe contusion injury 
(1250 g weight dropped from 50 cm respectively).  Unfortunately, the researchers only 
investigated time points up to 3 hr after injury, and might have missed critical information 
regarding cytokine expression at later time points (not indicated in Figure 1.5).  From the 
abovementioned studies on muscle cytokines, it is clearly evident that these studies lack 
proper controls as well as the necessary statistics to investigate data over time.  Further 
research is needed to determine the effect and timing of cytokine peaks after injury.  What is 
clear though from the study by Bunn et al. (2004), is that the curve shifts to the right, with 
cytokine expression occurring later, the more severe the injury is.  A possible explanation for 
this phenomenon might be that during mild injury, cytokine expression occurred earlier, since 
there is not a lot of vascular disruption and fibre tearing.  Thus, cytokines are not that 
necessary to recruit neutrophils and macrophages to the injured area at later time points to 
mop up the debris.  Furthermore, the intact muscle could have been the main source for 
cytokine expression during mild injury.  However, after moderate injury, other cell sources, 
including the injured muscle itself, could be responsible for cytokines expression.  
Furthermore, since it is known that neutrophils are responsible for secondary damage 
roughly on day 3 after injury, it is possible that cytokine expression only peaked at later time 
points in the moderate injury group, as their expression is necessary for the recruitment of 
immune cells to the injured muscle.  However, it is important to note that no definite 
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conclusion can be made regarding the cytokine patterns from these studies, since no control 
data, or cytokine data at earlier time points were measured. 
Plasma cytokines, on the other hand, displayed different expression patterns.  No data are 
available on plasma cytokines after contusion injury.  Figure 1.5B represent plasma cytokine 
expression after different forms of exercise.  Adult men participated in either 2.5 hr of 
treadmill running (Ostrowski et al., 1998) or roughly 3 hr and 27 min of strenuous marathon 
running (Ostrowski et al., 1999).  It is evident from the graph that irrespective of the type of 
exercise, all three cytokines peaked at the end of the exercise protocol, followed by a rapid 
decrease in IL-6 and a more gradual decrease in IL-1β and TNF-α, all of which returned to 
baseline levels roughly 4 hr after exercise. 
Apart from assessment of actual cytokine levels, information can also be gained by 
considering assessment of related receptors or downstream signalling intermediates.  For 
example, the signal transducer and activator of transcription 3 protein (STAT3) was shown to 
be exclusively induced in the activated satellite cells, proliferating myoblasts and surviving 
myofibres in the regenerating muscle, but not in quiescent SCs, differentiating myoblasts or 
myotubes (Kami and Senba 2002).  However, IL-6 receptor α (IL-6Rα), the ligand binding 
site in a functional IL-6 receptor complex, was exclusively upregulated in interstitial 
mononuclear cells but not in myofibres or mpcs during muscle regeneration (Kami et al., 
2000).  This suggests that the IL-6 response is not directly induced in myofibres and mpcs 
after contusion injury, but that IL-6 merely acts on interstitial cells.  It might also suggest that 
there are sufficient receptors, or its function is not induced via the cell surface receptor.  
Investigations into the IL-6R system provided evidence that IL-6 does not act only on IL-6R, 
but can also bind to a silencing (s)IL-6R that express gp130 (receptor subunit shared by 
several IL-6 cytokine receptors).  The authors therefore suggested that IL-6 in myofibres 
might be binding to the (s)IL-6R after contusion injury instead of binding to IL-6R itself 
(Kishimoto et al., 1994).  There is also some evidence showing beneficial effects of leukemia 
inhibitory factor (LIF) on muscle regeneration (Barnard et al., 1994; Kurek et al., 1996; Kurek 
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et al., 1997).  All of these studies indicate a possible role for IL-6 and IL-6 related family 
members in regenerating muscle. 
 
1.8  Summary 
This summary will highlight some of the specific difficulties encountered in this field and 
conclusions made from the literature discussed above. 
i) Various proteins exist in order to identify satellite cells at different stages after muscle 
injury, however, not one single protein exists that can identify SCs at one specific stage.  
To date, due to the fact that Pax-7 is the major protein expressed only by satellite cells, it 
is considered to be the best suitable marker for identifying satellite cells, compared to 
other markers.   
ii) Reactive oxygen species are produced at many sites and in many cells after muscle 
injury.  Although SC are also able to generate reactive species after muscle injury and 
may contribute to secondary damage, these cells are the major role players in the 
muscle regeneration process responsible for muscle recovery.  SCs are not solely 
responsible for further damaging muscle tissue, but macrophages and neutrophils are 
also involved in this particular process.   
iii) Neutrophils are the first immune cells to infiltrate the injured area, followed by 
macrophages, both of which have two main functions, which are phagocytosis (clearing 
the wound debris) and production of pro-inflammatory cytokines and reactive species 
which will exacerbate the initial injury even further.   
iv) Many other factors also contribute to muscle injury and repair and involve the myogenic 
regulatory factors, growth factors, cytokines and chemotactic factors.  It has also 
become apparent that not only one chemokine is at play when attracting macrophages 
or neutrophils to the injured area, but rather that a combination of chemokines might be 
responsible.  Therefore, it is very important to determine which chemotactic cytokines 
are responsible for attracting immune cells to the injured area, after contusion injury.   
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v) The interaction between muscle cells and immune cells play a very important role in 
modulating the events following an injury. 
vi) A non-invasive model of contusion injury is the best suitable model to investigate all of 
these issues, as this type of model excludes the possibility of infections, as well as 
immune system activation (which could change the local and systemic oxygen radical 
absorbance capacity) as a result of tissue damage (e.g. muscle, skin etc.) due to the 
surgical procedure itself. 
vii) The specific timing of events after contusion injury could potentially be modulated by 
supplements or medication, but not necessarily at similar times or by similar 
interventions.  If known, it will allow health care professionals to administer certain 
treatments (aimed at either enhancing or suppressing certain processes) at specific time 
points which might promote quicker healing of muscle tissue after injury.  The different 
treatment regimes will be discussed in the next chapter.   
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CHAPTER 2 
 
Literature review: Treatments for muscle injury 
 
2.1  General introduction 
Muscle repair after injury involves a complex interaction between local muscle cells and 
immune cells, with interplay of other regulatory factors.  If these factors function optimally, 
muscle function and muscle fibre ultrastructure will be restored to its original form, if not, 
regeneration is delayed and scarring will occur.  Upon skeletal muscle damage, muscle 
fibres rupture at or adjacent to the impact area, and depending on the severity of the injury, 
the underlying vasculature may also be disrupted.  Neutrophils are the first immune cell type 
to infiltrate the damaged area, followed by pro-inflammatory types of macrophages, both of 
which generate free radicals, causing the area of necrosis to extend to affect surrounding 
uninjured tissue (secondary damage).  Satellite cells become activated, through the 
expression and release of many growth factors, cytokines, as well as reactive species (e.g. 
nitric oxide – NO, generated by macrophages).  These satellite cells then start to proliferate, 
differentiate, and fuse with damaged muscle fibres to repair them, with concomitant capillary 
revascularisation and the possible production of a connective tissue scar.     
Skeletal muscle injuries are a frequent occurrence in sporting events, and can produce 
significant disability because of pain and impaired muscle function often resulting in a loss of 
flexibility, and strength, placing the player at an increased risk of re-injury (Gates and Huard 
2005).  Therefore, treatments are now focused on augmenting the normal repair and 
regenerative processes in order to allow athletes to return to their previous levels of function 
as quickly as possible.  Anti-inflammatory medications (including corticosteroids), extensive 
growth enhancing treatments, and exercise protocols have been studied extensively (Beiner 
and Jokl 2001; Järvinen et al., 2007).  Other approaches include the experimental use of 
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stem cells (including skeletal muscle-derived stem cells) or biological growth factors to repair 
and/or regenerate skeletal muscle (Bach et al., 2006).  While these treatment options offer 
considerable promise for the treatment of muscle damage, side effects are also evident and 
realistically it will take many years before emerging techniques such as stem cell treatment 
are perfected and become mainstream clinical treatments.  Even then, this treatment will 
probably be reserved for the most extreme cases.  Therefore, the “ideal” treatment for the 
majority of injuries still remains to be elucidated, mainly because the large variability in the 
severity of injury and the multiple underlying processes complicate research efforts aimed at 
finding the best treatment (Beiner et al., 1999; Beiner and Jokl 2001).  In this chapter, I will 
review the existing literature on traditional clinical treatment modalities for muscle injury.  I 
will also introduce more recently identified potential therapeutic agents and finally focus on 
those most closely related to the treatment that will be used in the experimental chapters of 
this thesis.   
  
2.2  Traditional treatments 
Commonly known treatments for muscle injury are largely aimed at inhibiting the 
inflammatory response to alleviate the clinical signs of inflammation – swelling and pain – 
and to limit fibrosis.  These treatments include both steroidal and non-steroidal anti-
inflammatory drugs, as well as alternative treatments such as cryotherapy, hyberbaric 
oxygen therapy and pulsed ultrasound.  More recently, administration of growth promoting 
agents and light/moderate exercise have received more attention. 
 
2.2.1  Anti-inflammatory treatments 
2.2.1.1  Steroids 
Corticosteroids are often injected directly into the site of injury.  However, depending on the 
manner of administration (injection vs. oral ingestion), the timing of, as well as the optimum 
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dose of a specific corticosteroid, will determine whether the therapy is effective for muscle 
regeneration or not.   
In an animal study by Mitchell et al. (1991), low doses of glucocorticoids (1 and 10 µg/kg 
dexamethasone per day in the contralateral gastrocnemius muscle, starting on the day prior 
to injury, and on day 1 up to day 9 post-injury), did not significantly affect muscle 
regeneration, although glucocorticoids is known to have anti-inflammatory actions.  In this 
study, although a reduction in the proportion of necrotic muscle tissue was evident, there was 
no noticeable new muscle fibre formation.  In another animal study, oral administration of 
corticosteroids after a contusion injury resulted in delayed resolution of the haematoma, 
retarded muscle regeneration and decreased tensile properties (Jarvinen et al., 1992).  In 
contrast, in the animal  study by Beiner et al. (1999), corticosteroids (acute dose of 25 mg/kg 
methylprednisolone acetate – long acting anti-inflammatory steroid), resulted in an early, 
positive, muscle sparing effect, with improved muscle function on day 2 following the injury, 
indicating a positive effect of corticosteroids.  However, by day 7 in the post-injury period, a 
marked disruption of the healing process with poor muscle function was evident, indicative of 
an incomplete healing process.  In all these studies, induced muscle tension and basic 
structural histology were used to assess muscle function and muscle regeneration 
respectively.  No additional quantitative measurements were made to assess markers of 
muscle regeneration or mechanisms involved.   
In human studies, although corticosteroids are able to alleviate pain (Blair et al., 1996), the 
overall incidence of positive effects, as well as side effects after local corticosteroid injection 
is variable.  Corticosteroid injection into injured tendon has been shown to result in tendon 
rupture (Unverfirth and Olix 1973; Gottlieb and Riskin 1980).  Several clinical studies have 
also shown that high doses of corticosteroids in a short period of time can result in acute 
corticosteroid myopathy (van Marle and Woods 1980; Faragher et al., 1996; Hanson et al. 
1997).  This process involves general weakening of both the distal and proximal muscle 
groups with degeneration of type I and type II muscle fibres.  Muscle fibre necrosis also 
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occurs, resulting in a marked elevation of myoglobin (Hanson et al. 1997).  However, 
corticosteroids do not only affect the muscle, but can also influence the immune system, by 
decreasing the percentage of T helper cells (CD4) (Cupps et al., 1984).  Thus, although 
corticosteroids have been beneficial in alleviating pain and have early muscle sparing effects, 
it seems to inhibit the healing process later on, with no added beneficial effect on the 
regenerative capacity of the muscle, indicating that this treatment may not be beneficial to 
the athlete, and may even have undesired effects.  Animal studies that support this, include, 
the use of a higher dosage of dexamethasone than mentioned above (1 mg/kg daily for 12-
16 days subcutaneously – starting the same day as venom injection), which severely 
decreased muscle regeneration after injury (Noirez et al., 1999).  Even a dosage as low as 
100 µg/kg daily continued for 9 days, resulted in more necrotic tissue than that of controls 
indicating that doses higher than 100 µg/kg might not be beneficial (Mitchell et al., 1991).   
On the other hand, the injection of the testosterone derivative, nandrolone decanoate (20 
mg/kg, once only), was shown to result in more rapid healing and restoration of force 
generating capacity after contusion injury in rats (Beiner et al., 1999).  Also shown in this 
study, is the ability to increase the number of muscle progenitor cells in the injured area.  
These effects were all associated with an initial increase in inflammatory cells, suggesting 
that the initial inflammatory response is part of the crucial process of healing of muscle.  
Although anabolic steroids were beneficial for quicker muscle regeneration in this study, the 
continued use of anabolic steroids may increase the initial inflammatory reaction even further 
which would exacerbate tissue injury.  Due to the fact that anabolic steroids play a role in 
enhancing muscle mass, without any added effect on the tendons, athletes might be at a 
higher risk for tendon rupture as reviewed by Shahidi (2001).  
It is also important to note that the dosage of steroids needed to have a similar effect will 
differ depending on the manner of administration.  A clear example is that administering 
NSAIDs or any type of drug by means of an oral route is considered to be the most 
convenient and safest way (Birckelbaw Kopacek 2007), but, a bigger dose is needed to 
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obtain the same effect as that obtained when administering drugs by means of injection.  
This is due to the absorption rate of the specific drug, suggesting a slower and lower level of 
distribution to the muscle, which might not be sufficient for quicker healing. 
 
2.2.1.2  Non-steroidal anti-inflammatory drugs (NSAIDs) 
In conjunction with temporary immobilization, elevation and local cryotherapy, the 
administration of non-steroidal anti-inflammatory drugs has become a therapeutic standard in 
the acute routine treatment of soft-tissue injuries, particularly after an athletic injury (Cohn et 
al., 1989; Buckwalter 1995).  These drugs are still recommended and prescribed for their 
analgesic purposes rather than for enhanced healing, as the evidence to support the latter 
remains limited.  The ability of non-steroidal anti-inflammatory drugs to reduce inflammation 
and pain after injury is mainly based on the inhibition of prostaglandin synthesis by 
cyclooxygenase (COX), which has a direct effect on muscle cells (Brooks and Day 1991b).  
COX is present in at least two isoforms, namely COX-1 and COX-2.  COX-1 is a 
predominantly constitutive form and is involved in cellular homeostasis with maintenance of 
tissue physiology, whereas COX-2 is a rapidly inducible isoform upregulated by reactive 
oxygen species, inflammatory cytokines and mitogens (Dubois et al., 1998). 
Although NSAIDs are commonly used for muscle injuries (personal communication: Dr Pierre 
Viviers, Stellenbosch University Sports Performance Institute, SUSPI), studies regarding its 
ability to blunt the body’s inflammatory response to injury in order to facilitate faster recovery, 
are not in agreement, with only some reporting positive effects, while many others have 
shown quite the opposite.  Although certain concerns exist regarding the safety of these 
drugs and their involvement in causing myocardial infarction and other cardiovascular and 
gastrointestinal defects (Hippisley-Cox and Coupland 2005; Scheiman and Fendrick 2005), a 
relatively recent review concluded that certain NSAIDs have a role in both long-term or short-
term treatment of delayed onset muscle soreness (DOMS) after injuries in humans (Connolly 
et al., 2003).  This is possibly due to the fact that some NSAIDs, especially diclofenac, can 
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act as a dual-action NSAID, inhibiting both the COX and lipooxygenase pathways of 
arachidonic acid (AA) metabolism, thus providing a potentially greater anti-inflammatory 
effect (Brooks and Day 1991a).   
Different types of injuries will result in different magnitudes of the inflammatory response that 
will either be alleviated with a particular NSAID dosage or not be affected at all.  Also, the 
type of NSAID used, the specific dosage, the duration of the treatment, as well as the onset 
of first dosage might all play a predominant role in NSAIDs having a positive or negative 
outcome on muscle regeneration (Smith et al., 2008).  In a study by Vignaud et al. (2005), it 
was proposed that long-term non-steroidal anti-inflammatory and antioxidant drugs 
(NSAIAODs) could markedly reduce the speed of subsequent muscle recovery after severe 
injury.  Two models of injury were used in this study:  (1) the tibialis anterior muscle was 
injected with 20 µl of 0.9 % saline containing a myotoxic agent (2 µg/kg per muscle of snake 
venom from Notechis scutatus scutatus), or (2) it was mildly crushed twice for 5 seconds with 
forceps placed all the way from the distal tendon to the proximal extremity.  Different 
NSAIAODs [diclofenac, diferuloylmethane (DFM), dimethylthiourea (DMTU), dimethyl 
sulphoxide (DMSO), indomethacin and pyrrolidine dithiocarbamate (PDTC)], with either 
known anti-oxidant or only anti-inflammatory action, or both, were administered.  Drug 
injections began on the day of injury and lasted for up to  2 weeks.  All the NSAIAODs used 
(at low doses) resulted in a decreased accumulation of inflammatory cells in the damaged 
muscle, as well as a limited production of free radicals/oxidants, prostaglandins, cytokines 
and chemokines in the first few days after injury (Vignaud et al., 2005).  None of the drugs 
had detrimental effects on long-term (42 days) muscle functional recovery (force production), 
except when using NSAIAODs at supraphysiological doses (> 2 mg/kg).  However, it is not 
completely clear whether the inhibitory effects of NSAIAODs are due to the anti-oxidant or 
anti-inflammatory properties of these drugs, since some of the drugs displayed both anti-
inflammatory and anti-oxidant properties.  However, it is worth mentioning that no animals 
died with DMSO supplementation, indicating that this antioxidant might have protected the 
animals.  Although the results report that low doses of NSAIDs might be beneficial in 
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reducing the amount of free radicals and inflammation, other studies indicate that high doses 
have detrimental effects.   
In an earlier study, decreased neutrophil and macrophage infiltration in the recovery phase 
(day 2 post-injury) and slower resolution of inflammation was reported in response to 5 days 
of NSAID treatment (Jarvinen et al., 1992).  In a similar study, NSAID treatment resulted in 
the total inhibition of the inflammatory phase, decreasing the capacity for regeneration and 
thereby delaying muscle regeneration (Mishra et al., 1995).  Since the inflammatory 
response is a necessary phase during soft tissue healing, total inhibition of this response 
could result in poor healing (Beiner et al., 1999).  However, in a study by Thorsson et al. 
(1998), neither early nor late NSAID supplementation had any effect on muscle regeneration, 
as seen by similar SC activation and proliferation cycles in both NSAID and control groups.  
Late and early treated groups both received daily doses of 10 mg/kg naproxen 
intramuscularly.  The early treated group started naproxen 6 hr after injury and were 
sacrificed on day 1, 3, 6 and 9, whereas the late group’s treatment was delayed until day 3 
and sacrifice took place on day 5, 8 and 11.  The control animals received no injections, 
however, these animals cannot be considered to be ideal controls, since they did not receive 
placebo injections.  Studies mentioned in this section thus far have focussed on the effect of 
relatively long NSAID treatment (5 or more days) for muscle recovery, or starting 2 days after 
the initial insult and have shown either negative or no effects at all.   
In clinical practice, NSAIDs are often not prescribed for 24 to 48 hr after injury (Rahusen et 
al., 2004), which may be too late, due to the fact that neutrophils which infiltrate the injured 
area already 24 hr after injury, may already have resulted in secondary damage – 
exacerbating the injury further.  Other studies have investigated different routes of 
administration and different timing.  In a study by Gierer et al. (2005), relatively low doses of 
NSAIDs (10 mg/kg parecoxib sodium) were infused intravenously, immediately before or 2 hr 
after contusion injury.  In this specific study,  NSAID infusion both prior to and after contusion 
injury, resulted in a marked decrease in the inflammatory response and almost complete 
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restoration of microcirculation to normal by 18 hr after trauma, indicating that despite 
conflicting results, NSAIDs might be a good treatment for contusion injuries (Gierer et al., 
2005).  Administration of rofecoxib (5 mg/kg) prior to contusion injury (24 hr prior to), did not 
appear to dramatically influence muscle recovery (Rahusen et al., 2004).  This is surprising, 
since it would have been expected that administration of NSAIDs should have had some 
effect in blunting the inflammatory response as seen in the study by Gierer et al. (2005), 
rather than no effect.  A possible reason for no effect might be that NSAID administration 24 
hr prior to injury might not have been long enough to have a beneficial effect.  However, this 
cannot be considered the main reason, since NSAID administration in the previous study 
resulted in beneficial effects (Gierer et al., 2005).  The most obvious reason may therefore 
have been the relatively small dosage, which might have been too low to have had a positive 
effect, indicating that that research on the timing and dosage of NSAID administration may 
still be of some importance.  Even early post-injury rofecoxib, administered as soon as the 
animals recovered from the injury induction protocol (not mentioned in the study by Gierer et 
al., 2005), did not appear to affect the outcome of the recovery protocol.  Although earlier 
administration of NSAIDs cannot be ruled out as a possibility, more research using such 
acute, shorter-term protocols are required, for example only for 2 or 3 days.   
Traditional treatments include the use of steroids and anti-inflammatory drugs, and also 
alternative treatments.  These treatments include the use of ice (cryotherapy), therapeutic 
ultrasound, hyperbaric oxygen, growth promoting agents and exercise, all of which will be 
discussed in more detail in the next section. 
  
2.2.2  Alternative therapies 
2.2.2.1  RICE 
Rest, ice, compression and elevation (RICE) has been used extensively for the treatment of 
injured skeletal muscle as well as soft tissue injury, in order to minimize bleeding.  These 
treatments are commonly used in combination, making it difficult to determine the value of 
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one of the components alone.  However, some studies have investigated only one or a 
combination of two of these treatments in order to allow us to determine their function more 
clearly.   
a) Rest 
It has been shown that early but not immediate mobilization – walking around – after 
contusions helps restore muscle function to previous levels earlier than usual (Jackson et al., 
1974).   Mobilising the injured limb immediately after injury is not advised, since it results in 
the formation of scar tissue (Jarvinen 1975), whereas mobilisation starting 2-3 days after 
injury resulted in better healing and restoring of muscle strength (Jarvinen and Lehto 1993).  
This therefore suggests that the muscle needs to be immobilised (rested) for a couple of 
days after injury.   
b) Rest and elevation 
Rest in combination with elevation immediately after injury prevented the injured area from 
growing in size, limited the size of the haematoma and the size of the subsequent connective 
tissue scar (Jarvinen and Lehto 1993), further supporting that rest and elevation is needed 
prior to mobilisation of the injured limb.   
c) Ice and compression 
The combination of both ice application and compression can limit bleeding, reduce pain as 
well as result in a faster return to the sports field (Levy and Marmar 1993).  Although various 
studies have tried to compare the use of ice in combination with compression, as reviewed 
by Bleakly et al. (2004), it was difficult to compare the efficacy of each treatment modality 
alone, since the compression bandages varied with each study.  Most of the studies found no 
difference between the groups, in terms of function, pain or swelling.  Although two studies 
reported a difference in favour of ice and compression, inadequate data were provided and 
these studies were of low quality (see studies reviewed in Beakly et al. (2004).   
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d) Ice/cryotherapy 
The application of ice alone was shown to limit the area of the haematoma between the 
ruptured muscle stumps, resulting in less inflammation and to accelerate early regeneration 
(Hurme et al., 1993; Deal et al., 2002), indicating a possible positive outcome after injury with 
the use of this particular technique.  Cryotherapy is often prescribed for 10 to 20 min, 2 to 4 
times per day for the first 2 to 3 days (Kellet 1986). Temperatures around 25 °C are 
considered optimal for cold vasoconstriction.  Treatment with ice also seems to provide 
short-term analgesic effects (Olson and Stravino 1972; McMaster and Liddle 1980; Meeusen 
and Lievens 1986; Grana 1993; Ernst and Fialka 1994).  However, the exact mechanisms, 
as well as the specific time of administration of ice are still debated.  When applying ice 
immediately post-injury, it reduces metabolism and bleeding, thereby minimizing secondary 
hypoxic injury and the degree of tissue damage (Knight 1989; Knight et al., 2000).  In 
contrast, when applied for rehabilitative purposes, it is used primarily to relieve pain, in order 
to return to the sports field earlier than usual (Knight 1989; Knight et al., 2000).  Currently, 
many clinicians do not fully understand the pathophysiological rationale at each stage and 
may not be using ice to its full advantage (Knight et al., 2000). 
In studies by Curl et al. (1997) and Smith et al. (1994), cryotherapy resulted in an acute 
vasoconstrictive effect on capillaries and a significant decrease in tissue perfusion following 
contusion of striated muscle.  Decreased oedema after ice therapy was also apparent, but 
vasoconstriction and decreased tissue perfusion is unlikely to be the sole cause, since 
inflammatory actions could also have contributed and could have mopped up some of the 
debris (Smith et al., 1994; Curl et al., 1997).  A more recent study by Deal et al. (2002) 
illustrated that cryotherapy also decreased neutrophil-endothelial interactions, indicating that 
ice resulted in decreased microvascular permeability at a time-point at which neutrophil-
endothelial interaction would usually take place maximally.  
In various rat studies, it has been shown that decreased temperature decreases histamine 
release and is responsible for the disruption of mast cells (Chakravarty 1960; Hogberg and 
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Uvnas 1960).  In later studies, it was found that histamine release was maximal when mast 
cells were incubated with an ionophore A23187 (possibly resulting in a similar response to 
that seen during inflammation) at a temperature ranging from 33-39 °C (Johansen 1978).  
Below and above this temperature range, histamine release was significantly reduced.  Other 
studies using histamine release stimulants have shown similar results regarding temperature 
sensitivity (Kazuhiko et al., 2000; Deal et al., 2002).  These studies suggest that ice 
application would decrease histamine release and therefore decrease the number of 
leukocytes infiltrating the injured area.   
However, ice treatment can also be detrimental.  The lowering of tissue temperature 
decreases cellular metabolism and thereby diminishes oxygen and nutrient needs, but 
decreasing the temperature of muscle below 25 °C for a lengthy period can dilate blood 
vessels, resulting in increased hemorrhage and inflammatory response (Kellet 1986; 
Meeusen and Lievens 1986).  As a result of the detrimental effects of ice, as seen above, 
Hurme et al. (1993) applied ice to contusion injured muscle, immediately after trauma for 5 
min and repeated 4 times at 12 min intervals.  The intramuscular temperature was also 
measured in this study and it was found that this protocol kept the muscle at ± 3 °C of the 
recommended temperature of around 25 °C.  The same protocol was used 24 hr after 
trauma.  In this particular study it was evident that the extravasation of plasma and 
erythrocytes in and around the injured area was more limited in the cryotherapy treated 
group.  But, the muscle fiber regeneration process was slower in the cold treatment group, as 
indicated by a later appearance of desmin-positive myoblasts.  This was most probably due 
to a delayed inflammatory reaction, since phagocytosis of necrotic debris appears to be an 
important aspect for satellite cell activation (Hurme and Kalimo 1992).  However, the 
differences of regeneration between the control cryotherapy and injured cryotherapy groups 
were no longer visible towards the end of the observation period (day 7), so that cryotherapy 
did not alter the final outcome of skeletal muscle regeneration.   
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From the studies mentioned above, it is evident that early application of ice (immediately 
after injury) for a prolonged period of time can have detrimental effects.  However, limiting 
the duration of ice treatment, can decrease oedema, as well as reduce excessive leukocyte 
infiltration into the injured area.  Ice should therefore be applied as early as possible, but for 
a short period of time.  Also, although the use of the separate components in the RICE 
technique have beneficial effects on muscle healing, the combination of these treatments 
might be more beneficial if administered properly and at an adequate time after injury. 
 
2.2.2.2  Therapeutic ultrasound 
Therapeutic ultrasound is widely recommended by clinicians (physiotherapists and other 
practitioners), as this technique promotes healing with the use of high-frequency sound 
waves (Roebroeck et al., 1998; Speed 2001; Warden and McMeeken 2002).  Deep heat is 
produced (3-4 °C higher than tissue temperature) (Draper et al., 1995; Draper and Richard 
1995) when applied directly to the injured area, while its high-frequency vibrational energy 
generates friction on the interfaces of tissues, leading to a “micromassage” effect (Johns 
2002).  In a review on ultrasound, it was concluded that the deep-heating effect had no 
influence on tissue, therefore a pulsed form of ultrasound application was suggested to 
minimize the deep tissue heating and thus allow greater amounts of energy to be transmitted 
for the nonthermal effects (Holmes and Rudland 1991).   
In a study by Rantanen et al. (1999), rat muscle was treated with ultrasound starting either 3 
days or 6 hr after injury (6 min daily) for two consecutive days, followed by one day rest, until 
animals were sacrificed.  Results indicated that ultrasound can enhance both satellite cell-
derived myogenic precursor cell (mpc) and fibroblast proliferation on day 3 after injury, but 
that myotube production was unaffected.  Therefore, although ultrasound resulted in 
enhanced satellite cell proliferation, it did not translate into increased myotube formation.  
Furthermore, enhanced proliferation of fibroblasts could result in more scar tissue forming in 
the regenerating muscle.   
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In a later study, ultrasound was also applied to contused muscle, starting 6 hr after injury, for 
6 min over a period of 7 days (Wilkin et al., 2004).  In this particular study, ultrasound did not 
have any beneficial effect on skeletal muscle regeneration.  However, the markers used to 
assess muscle regeneration in this study included muscle mass, fibre cross sectional area, 
total protein content and the number of myonuclei per fibre, and might not have been 
sensitive enough to reflect changes.  Better markers include assessment of the number of 
fibres with central nuclei, or the number of activated satellite cells (see section 1.2).  In a 
study by Markert et al. (2005), ultrasound treatment was initiated 24 hr after injury (once daily 
for 5 min), starting on day 1 after contusion injury until sacrifice (day 3).  In this study, 
ultrasound was also used either with or without exercise (Markert et al., 2005).  Exercise 
alone, ultrasound alone, or a combination of the two had no effect on any markers of 
regeneration measured in this particular study, 96 hr after injury.  However, 3 days is not 
enough time to see a regenerating effect.  Furthermore, this group assessed fibre cross 
sectional area, mononuclear number, percentage of contractile protein, and gastrocnemius 
muscle mass as markers of regeneration, none of which can be considered actual markers of 
regeneration. 
In a more recent study, ultrasound (6 min duration, once only) was applied to injured animals 
(after blunt injury) at the following time points: 2, 12, 24, 48, 72, 96, and 120 hrs after muscle 
trauma (Silveira et al., 2010).  This treatment was used in combination with dimethylsulfoxide 
(DMSO, 15 mg/kg), a highly permeable, non-enzymatic, sulphur-containing antioxidant and 
primarily hydroxyl radical (OH-) scavenger.  In this particular study, markers of muscle 
damage included creatine kinase (CK) and acid phosphatase, whereas markers of oxidative 
damage included superoxide anion, lipid peroxidation, and protein carbonyls production, 
while antioxidant enzymes, such as superoxide dismutase and catalase were analysed in 
serum samples.  The results of this study demonstrated that ultrasound (only 1 application) 
was only effective in reducing the presence of muscle damage and oxidative stress after 
injury, when used in combination with DMSO treatment.  Since DMSO alone had similar 
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effects, it is believed that it is the antioxidant rather than therapeutic ultrasound that was 
beneficial.     
From the literature it is therefore apparent that ultrasound may not be an effective therapeutic 
treatment after contusion injury.  However, due to the short time frame studied after injury, as 
well as the various markers studied, which are not considered to be useful markers of 
regeneration, it is not certain whether this therapy might have been successful if better 
markers of regeneration were studied.  Further studies looking at better markers are 
therefore necessary to determine the efficiency of this particular therapy. 
 
2.2.2.3  Hyperbaric oxygen 
Hypoxic wounds often have a reduced oxygen supply (hypoxia), which impairs leukocyte 
activities and wound healing, and it has been thought that improving the oxygenation of the 
area surrounding the wound, would improve wound healing (Wang et al., 2003).  Therefore, 
the benefit of hyperbaric oxygen therapy (HBOT) for wound healing is based on the idea that 
raising tissue oxygen levels will enhance wound healing ability (Grim et al., 1990; Jonsson et 
al., 1991; Kurz et al., 1996; Hopf et al., 1997).  HBOT has been used for the treatment of 
deafness and acute tinnitus (Aslan et al., 2002), hypoxic wounds and diabetic ulcers (Wang 
et al., 2003), bone infections and osteonecrosis (Migliorati et al., 2005), radiation side effects; 
which includes mucositis (inflammation and ulceration of mucous membranes), trismus 
(spasm of the jaw muscles), dysphagia (painful and difficult swallowing) and xerostomia (dry 
mouth) (Bui et al., 2004), diving injuries (decompression illness) (Camporesi and Bosco 
2009), and burn injury (Zamboni et al., 1993).   
Possible explanations for the effects of HBOT might be attributed to its potential ability to 
inhibit the release of oxygen free radicals, which may result in decreased ability to recruit 
damaging immune cells to the injured area.  Furthermore, it is also possible that HBOT may 
result in the production of free radical scavengers that can modulate muscle healing 
(Niinikoski et al., 1970).  HBOT has also been shown to play a significant role in promoting 
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revascularization while stimulating fibroblast activity and collagen production (Niinikoski et 
al., 1970).  However, relatively few studies have investigated the effects of this non-drug 
therapy on muscle repair.  In a study by Best et al. (1998), HBOT was applied to stretch-
injured muscle during the early stages of muscle recovery.  In this particular study, HBOT 
improved muscle recovery as assessed by ankle isometric torque, and by qualitative 
investigations of muscle ultrastructure after haematoxylin and eosin staining, which indicated 
that HBOT resulted in fewer immune cells and also less muscle fibre damage (Best et al., 
1998).  In a recent review by Bennet et al. (2006) regarding different forms of exercise-
induced injury, specifically eccentric exercise, it has been shown that HBOT plays a 
significant role in reducing oedema, enhancing oxygen delivery and inactivating white cell 
adhesion by inhibiting neutrophil β2 integrin function (Nylander et al., 1985; Thom et al., 
1994; Staples et al., 1995; Hills 1999).   
Although it has been proven that hyperbaric oxygen therapy might be beneficial for wound 
healing, a great deal of uncertainty still exists concerning risks and side effects (Esterhai et 
al., 1987), especially because exposure to pressures exceeding the normal 100 kPa at sea 
level and the application of dramatically raised oxygen partial pressures of about 1500–2000 
mmHg might cause complications, for example affecting the middle ear, nasal sinuses or 
lungs, temporary worsening of short-sightedness, claustrophobia and oxygen poisoning 
(Plafki et al., 2000).  Although reports of serious adverse events are rare, the side-effects 
that do arise should still be taken into consideration when deciding on the best treatment 
option.  In contrast to the beneficial effects seen with HBOT in other models, studies in 
muscle by Nelson et al. (1994) (crush injury) and Thorsson et al. (1997) (contusion injury), 
showed no significant beneficial effects, most probably due to the fact that muscle tissue is 
still readily supplied with oxygen during muscle contusion injury and that the injury was not 
severe enough for HBOT to be able to have a beneficial effect.    
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From the studies mentioned thus far, it is apparent that HBOT may not be beneficial as 
treatment for muscle injuries.  However, positive effects in muscle regeneration have not 
been established.   
 
2.2.2.4  Stem cell therapy 
The use of muscle stem cells for therapeutic purposes holds much promise in situations 
where chronic disease affects skeletal muscle, such as muscular dystrophy (Gussoni et al., 
1997; Gussoni et al., 1999).  In one particular study, human haematopoietic stem cells (HSC) 
were infused into the muscle of mdx mice, a mouse model for muscular dystrophy (Gussoni 
et al., 1999).  Four to six weeks later, muscle fibers from the hind limb were able to express 
human dystrophin, and the synthesis of mechano growth factor (MGF), a protein that controls 
repair of normal muscle, was also restored, indicating that this particular stem cell population 
is most effective in disease states.  However, only a small population of myofibres expressed 
dystrophin, and even though the number of fibers expressing dystrophin increased later on in 
time, it suggests that in order for stem cell therapy to be successful for treatment of disease 
states, multiple local, intramuscular injections might be needed.   
Since it is known that most tissue injuries can lead to scar formation, different studies have 
turned to using adult-derived mesenchymal stem cells (MSCs) to treat animals with injuries 
or defects affecting bone, ligaments, cartilage and/or tendons, as a way in which to rather 
regenerate tissue through the anti-fibrotic properties they possess (Bruder et al., 1998; 
Young et al., 1998; Awad et al., 1999).  In a study by Pulavendran et al. (2010), they 
postulated that MSC treatment prevented fibrosis by protecting the neutrophils from 
undergoing apoptosis, as lower myeloperoxidase (MPO – index of neutrophil activity) and 
interleukin (IL)-6 expression were detected.  This was further supported in another study 
(Raffaghello et al., 2008).  These stem cells were collected from either bone marrow or 
adipose tissue and then infused back into the patients (autologous), in human studies; or 
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from a genetically different donor of the same species (animals), since the immune system 
usually mounts a response to transplanted cells (Kraus and Kirker-Head 2006).   
Studies have shown that stem cells obtained from different tissues and infused into spinal 
cord-injured animals or animals suffering from stroke have a great ability to migrate to sites 
of tissue damage and stimulate repair either by differentiating into tissue-specific cells, or by 
enhancing the repair by endogenous cells (Hofstetter et al., 2002; Li et al., 2002).  A study by 
De Bari et al. (2003) found similar results when MSCs from human synovial membranes 
were infused into the tibialis anterior muscle of nude mice after cardiotoxin injury.  In this 
study, it was found that approximately 10 % of the infused cells were present in the muscle 
after day 1, whereas almost twice as much were present between 2 weeks and 1 month after 
injury, indicating that MSCs are beneficial in repairing muscle cells.  The authors were also 
able to show that these cells differentiated into muscle cells, which indicates that stem cells 
might be potentially beneficial, but only as a longer-term treatment option.  
However, there is one particularly important aspect to take into account when applying stem 
cell therapy.  Whether the stem cells are to heal bone or any other type of tissue, the 
microenvironment into which a group of introduced stem cells is placed, is very important for 
effective healing (Singec et al., 2007).  Often platelet-rich plasma is used in conjunction with 
bone-marrow derived stem cells as a matrix which supplies growth factors and the scaffold 
needed to induce tissue regeneration (Yamada et al., 2004).  Alternatively, adipose tissue 
also contains other cell types that are rich in growth factors to support tissue regeneration 
(Nakagami et al., 2006; Varma et al., 2007).  This transfer medium is very important and has 
been shown to aid muscle healing in three ways.  Firstly, it helps the formation of new blood 
cells from endothelial progenitor cells, secondly, it prevents apoptosis of cells at the 
damaged site, and thirdly, it reduces inflammation (Singec et al., 2007).   
From this, it is evident that different stem cell treatments exist which have therapeutic 
potential in various types of muscle injury.  However, more research is needed to investigate 
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stem cells’ behaviour and their underlying mechanisms of action before these experimental 
treatments can become a reality (Singec et al., 2007) for the treatment of chronic disease.   
 
2.2.2.5  Growth promoting agents 
The rationale behind therapy employing growth promoting agents is that it may hasten 
muscle regeneration by increasing the size and number of existing and newly regenerating 
muscle fibres and thereby improving muscle function (Kasemkijwattana et al., 1998b).  
Muscle growth promoting agents include, but are not limited to, growth hormone, β2-
adrenoceptor agonists, testosterone-derived or testosterone-like hormones (anabolic 
steroids, discussed in 2.1.1.1) and growth factors such as insulin-like growth factor-I (IGF-1). 
Growth hormone:  Growth hormone has various beneficial effects after severe burn injury.  
These include the ability to: (a) decrease whole body catabolism (Byrne et al., 1993), (b) 
improve muscle protein synthesis (Gore et al., 1991), (c) accelerate wound healing (Herndon 
et al., 1990; Gilpin et al., 1994) (d) attenuate prolonged hyperactivity of the hepatic acute-
phase response (Jarrar et al., 1997; Jeschke et al., 2000) and (e) promote growth.  Although 
growth hormone is more commonly used for treatment of prolonged protein breakdown after 
burn injury (Rutan and Herndon 1990; Hart et al., 2000), no literature is available on the 
effect of growth hormone treatment on muscle following a contusion injury.  Given all the 
beneficial effects of growth hormone treatment, it might potentially aid muscle regeneration, 
since it has been shown to promote wound healing and improve muscle protein synthesis.    
Longer term administration (0.05 mg/kg daily for 12 months) after burn injury has also 
displayed improvement of metabolic disturbances (Hart et al., 2001), whilst dosages as high 
as 0.2 mg/kg have been shown to further increase wound healing abilities, although 
increasing the frequency of hyperglycemia (Herndon et al., 1990; Gilpin et al., 1994).  
β2-adrenoceptor agonists:  Skeletal muscle has a significant amount of the β2 subtype 
adrenoceptors (Kim et al., 1991; Sillence and Matthews 1994; Sillence et al., 1995).  
However, these adrenoceptors also exist in the heart and care should be taken when 
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systemically administering adrenoceptor agonists, because they could potentially be harmful 
to the heart, although having positive effects on skeletal muscle.  In a clinical trial, β2 
adrenoceptors for the treatment of different types of dystrophies resulted in heart 
palpitations, although showing beneficial effects on cardiac muscle strength (Kissel et al., 
2001).  In two specific studies, it has been demonstrated that synthetic β2-adrenoceptors 
agonists promote skeletal muscle hypertrophy via activation of the cyclic adenosine 
monophosphatase (cAMP)-dependent mechanisms that increase protein synthesis and 
inhibit protein degradation pathways (Lynch et al., 2007; Lynch and Ryall 2008).  Recently, it 
has been shown that the phosphatidylinositol-3-kinase (PI3-K)-Akt signalling pathway is also 
involved (Kline et al., 2007).  In other studies it was found that administration of the β2-
adrenoceptor agonists, feneterol (1.4 mg/kg per day, i.p.) (Beitzel et al., 2004) or clenbuterol 
(2 mg/kg per day, by means of oral gavage) (Briscout et al., 2004), were able to promote 
regeneration of injured skeletal muscles after myotoxin injury, indicating a positive role for 
these agonists.        
Growth factors:  During muscle regeneration, growth factors and cytokines released by 
the injured muscle are believed to activate satellite cells (for review, see Smith et al., 2008).  
Preliminary data suggest that growth factors play additional roles, such as promoting 
neutrophil recruitment (Peters et al., 2005), increasing satellite cell proliferation (Allen et al., 
1995), and differentiation (Haugk et al., 1995) during muscle regeneration.  A whole host of 
growth factors have been shown to affect the behaviour of skeletal muscle cells – these are 
expressed predominantly in skeletal muscle tissue itself, but also in various other tissue 
types, and include fibroblast growth factor (FGF), transforming growth factor (TGF), 
hepatocyte growth factor (HGF), IGF, platelet derived growth factor (PDGF), nerve growth 
factor (NGF).   
Three of these growth factors have shown the most promise, namely basic FGF (bFGF), 
NGF and IGF-1 (Kasemkijwattana et al., 1998a; Kasemkijwattana et al., 1998b; 
Kasemkijwattana et al., 1999; Menetrey et al., 2000).  In a study by Kasemkijwattana et al. 
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(1998), the gastrocnemius muscles of mice were subjected to experimental injury, and the 
growth factors bFGF, NGF, and IGF-1, were injected separately into the injured area.  
Although the direct injection of bFGF and NGF conveyed some beneficial effects on muscle 
healing after injury, IGF-1 mediated the greatest improvement in muscle healing across all 
muscle injury types tested (laceration, contusion and strain).  These growth factors were able 
to enhance muscle regeneration by increasing the number and diameter of regenerating 
myofibres, and thus indirectly also tetanic force of the muscles, but were not able to prevent 
the formation of scar tissue that ultimately impairs the healing process.  No study has been 
published focussing on the speed of muscle recovery following injection of growth factors 
after a injury.   
Likewise, supplementation with growth factors like LIF, HGF, and bFGF by bolus injections or 
pumps leads to increase of muscle fibre density and muscle fibre size after injury 
(Lefaucheur and Sebille 1995b).  More direct evidence for the important roles of bFGF and 
IGF-1 have also been reported, as separate injections of neutralizing antibodies against 
these two growth factors, inhibited muscle regeneration (Lefaucheur and Sebille 1995a).  
Other treatment modalities in this class are focused on limiting fibrosis as a means to 
facilitate quicker and more effective muscle functional recovery.  TGF-β has been shown in 
various studies not only to regulate proliferation, but also differentiation of skeletal muscle 
myoblasts (Allen and Boxhorn 1989; Greene and Allen 1991; Zentella and Massague 1992; 
Cook et al., 1993; Zhang et al., 2000).  In skeletal muscle, during muscle injury, TGF-β is 
released as a result of the inflammatory reaction, and triggers fibrosis via the deposition of 
the extracellular matrix and the expansion of fibrous connective tissue (Confalonieri et al., 
1997).  Three different isoforms exist, namely TGF-β1, - β2, and - β3, all of which have been 
shown to be key modulators in the wound healing process (Shah et al., 1995; Stewart et al., 
2003; Sinha et al., 2004).   
Many in vivo studies used knock-out mice in order to investigate the importance of TGF-β in 
wound healing and scar formation after skin laceration.  In TGF-β1 knock-out mice, wound 
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healing followed a relatively normal pattern for the first 10 days, followed by an increased 
inflammatory response, a decrease in the abilities of wounds to close, re-epithelialisation, 
granulation tissue formation, collagen deposition and vasculogenesis (Brown et al., 1995).  
TGF-β2 knock-out mice on the other hand, die during, shortly before or shortly after birth, 
due to developmental defects of the heart (Sanford et al., 1997).   
In contrast to TGF-β1, TGF-β3 knock-out mice have revealed an important role for limiting 
scars during wound repair (Ferguson and O'Kane 2004).  In other important studies, the 
neutralisation of TGF-β1 and -β2 resulted in improved wound repair by modulating the 
fibrotic response, whereas the addition of TGF-β1 elicited a similar response (Shah et al., 
1995).  Furthermore, both the structure and function of lacerated muscle reached near 
complete recovery when injected with suramin (2.5 mg injected daily for 7 or 14 days), a 
direct antagonist of TGF-β1, whilst the amount of scar tissue was reduced when compared to 
controls (Chan et al., 2003).  Therefore, the presence of all three TGF-β isoforms is of 
particular importance in wound healing after injury.  Despite distinct isoform-specific effects 
of TGF- β1, -β2 and –β3, a comparison of the effect of these three isoforms on myogenesis 
in vitro has not been carried out.  Only one study thus far has been able to demonstrate that 
TGF-β was able to increase proliferation and decrease differentiation of C2C12 myoblasts in 
an isoform-independent manner.  Results from this cell culture study also indicated variable 
effects regarding TGF-β treatment, depending on the muscle cell type and duration of TGF-β 
administration (Schabort et al., 2009). 
Therefore, the TGF-β isoforms are especially important in promoting tissue regeneration.  
However, since the isoforms induce different effects on wound repair, fibrosis and scarring, it 
is probably very important that all 3 isoforms are present in sufficient quantities to allow for 
optimal healing (Sporn and Roberts 1993), although TGF-β2 might not be as important.   
However, although growth factors are beneficial, various studies have also indicated that the 
overexpression of some growth factors can have negative effects.  High levels of IGF-1 are 
associated with the development of different types of cancer (Chan et al., 1998; Hankinson et 
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al., 1998; Ma et al., 1999; Yu et al., 1999), and animal experiments have indicated that IGF-1 
overexpression can result in tumour development in certain tissues (Rogler et al., 1994; 
Bates et al., 1995).  IGF-2 has also been shown to result in spontaneous lung tumours 
(Moorehead et al., 2003).  FGF-2 is overexpressed in tissues other than skeletal muscle, 
including neuronal tissues (Gonzalez et al., 1990) and the heart where it may affect growth 
and survival of cardiomyocytes and growth of the coronary blood vessels during hypertrophy 
and ischemia (Kardami and Fandrich 1989; Yanagisawamiwa et al., 1992).  These studies 
suggest that an even more increased growth hormone expression – by direct injection – may 
have detrimental outcomes on other tissues, although having a beneficial effect on skeletal 
muscle tissue after injury.  Care should therefore be taken when using growth factor 
injections.  However, since growth factors can enhance exercise performance, the use of 
growth factor injections has been banned in the sports arena. 
 
 
2.2.2.6  Exercise 
Light exercise (walking) is commonly prescribed by clinicians as treatment for 
musculoskeletal injuries, mainly to reduce DOMS.  Only one research study focused on the 
effects of exercise on markers of skeletal muscle regeneration following muscle injury using 
human subjects, which suggested that exercise is efficient in resolving injured skeletal 
muscle (Gregory et al., 1995).  There is also evidence to support the results from animal 
studies, investigating both in vitro and in vivo approaches.  In these studies, using a variety 
of species, it has been demonstrated that exercise assists in promoting normal growth and 
repair of mammalian skeletal muscle after exercise damage (Vandenburgh 1982; Darr and 
Schultz 1987; Esser and White 1995; Wanek and Snow 2000).  Furthermore, there is also 
evidence that exercise promotes myonuclear accumulation in injured muscle (Smith et al., 
2001), although factors such as species, age, and training status also play a role.       
In a review by Buckwater (1995), it was reported that the effects of activity on muscle healing 
depend to some extent on the onset of activity following injury.  If injured muscle is mobilized 
immediately following injury, it may increase scar formation and interfere with normal muscle 
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regeneration (Jarvinen and Lehto 1993).  Fibroblasts play an important role after injury, by 
invading the injured gap and producing an extracellular matrix in order to restore the 
connective tissue framework (Lehto et al., 1985; Hurme et al., 1991b), enabling the use of 
the injured limb before the completion of the repair process (Kalimo et al., 1997).  In 
extensive muscle trauma, which includes strains, contusions and lacerations, proliferation of 
fibroblasts can quickly lead to an excessive formation of dense scar tissue, which impedes 
muscle regeneration and results in incomplete recovery (Carlson and Faulkner 1983; 
Nikolaou et al., 1987; Garrett 1990; Hurme et al., 1991a; Bornemann and Schmalbruch 1992; 
Kasemkijwattana et al., 1998a; Kasemkijwattana et al., 1998b), an effect which is 
exacerbated during early mobilisation, due to the fact that early mobilisation results in 
increased blood flow (up to five-fold) and an increased influx of damaging neutrophils (results 
in secondary damage) immediately upon the release of muscle contraction (Robergs et al., 
1997).  
Furthermore, if injured muscles are immobilized for a prolonged period of time (5-7 days), it 
results in muscle atrophy and poor organization of the regenerating myofibers, due to the fact 
that blood flow is reduced (McDonald et al., 1992) to the injured area for too long to ensure 
optimal restoration.  In contrast, if injured muscles are mobilized following a short period of 
immobilization (hours), it results in a rapid disappearance of haematoma and inflammatory 
cells, followed by a more rapid and organized myofiber regeneration, with a rapid increase in 
tensile strength and stiffness (Lehto et al., 1985; Jarvinen and Lehto 1993), suggesting that a 
short period of rest, followed by controlled muscle use will provide optimal healing (Lehto et 
al., 1985; Jarvinen and Lehto 1993).  An increase in blood flow could therefore be a 
mechanism for the enhanced recovery of muscle force when light exercise is performed 
during recovery, but only when following a short period of immobilisation.  Increased blood 
flow has also been established as an important factor in reducing pain, improving the healing 
of damaged muscle, reducing swelling and improving circulation (Mohr et al., 1987), as well 
as improving the efficiency of muscle contraction (Clemente et al., 1991).   
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Therefore, exercise may be an effective therapy after injury, but timing is an important factor 
in determining whether this therapy is successful. 
 
2.2.3  Summary 
The cellular and molecular mechanisms of normal, unassisted muscle regeneration after 
injury have been described extensively in the literature.  Recovery is often not complete or 
delayed if the injury is not properly treated, regarding dosage or timing of treatment, or if the 
athlete returns to the sports field earlier than usual, resulting in re-injury and extensive tissue 
scarring.  Thus, it is crucial to consider other potentially therapeutic strategies to optimise the 
regeneration process, to hasten restoration of muscle, and shorten the time athletes are 
away from the sports field.   
From the literature presented in this section, it is clear that therapies have both positive and 
negative outcomes.  However, it is important to consider the fact that great skill and 
sometimes individualisation is required for application of these treatments, in order to ensure 
optimal results.  Since some of the treatments that might aid muscle regeneration such as 
growth factor injections are banned, it is imperative to continue the search for the optimal 
treatment, which can minimise secondary damage, minimise fibrosis and modulate 
inflammation, and can be easily administered in order to quicken the recovery process.  
One of the possible exacerbating factors in contusion injuries, is the generation of reactive 
oxygen species (ROS) during the early recovery process, which could result in oxidative 
stress and subsequent secondary damage.  The next section will review the literature on 
antioxidants and the possibility of enhancing the antioxidant status of the muscle in order to 
counteract the effect of ROS formation, thereby assisting recovery. 
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2.3  Antioxidants 
The role of oxidative stress in increasing the magnitude of damage after primary injury was 
reviewed in Chapter 1.  Given the major role that oxidants play in cellular damage, it is not 
surprising that myocytes and other cells contain several endogenous anti-oxidant defence 
mechanisms to prevent oxidative injury.  Two major classes of endogenous protective 
mechanisms work together to reduce the harmful effects of oxidants in the cell: enzymatic 
defence (e.g. superoxide dismutase - SOD, glutathione peroxidase and catalase); and 2) 
nonenzymatic antioxidants (e.g. glutathione - GSH, ascorbic acid, α-tocopherol, β-carotene, 
uibiquinol-10, albumin, ceruloplasmin (copper part of it) and ferritin) (Yu 1994; Rice-Evans et 
al., 1995; Basu 1999) – see Table 2.1.  Although mammalian cells seem to have adequate 
antioxidant reserves to cope with ROS production under normal physiological conditions (see 
Figure 2.1), these antioxidant reserves may be inadequate to cope when additional ROS is 
produced.  Therefore, supplementing the diet with dietary anti-oxidants or vitamins might 
prove beneficial to scavenge the extra ROS generated.   
Several studies have been conducted on the properties and effectiveness of dietary anti-
oxidants [which include vitamin C (ascorbic acid), vitamin E (tocopherols, tocotrienols), and 
vitamin A (retinol) or its precursor, β-carotene] to scavenge free radicals and therefore to 
decrease oxidative stress.  Their importance was highlighted in a study by Basu (1999), in 
which deficiencies in some of these anti-oxidants were associated with oxidative stress.  
Similarly, another study linked acute dietary supplementation to a decrease in lipid 
peroxidation (Brown et al., 1994).  In the following few paragraphs, the anti-oxidants used 
commonly by athletes, will be discussed in more detail.     
Vitamin C is arguably the anti-oxidant most widely used.  As a result of exercise (even in the 
absence of clinical injury, but presence of oxidative damage), there is a reduction in plasma 
concentrations of vitamin C a day after exercise (Gleeson et al. 1987), wich coincides with 
the point in time when neutrophils are present in greatest numbers in injured muscle.   
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Table 2.1:  Essential nutrients with antioxidant functions are able to scavenge multiple 
free radicals and interact with other endogenous antioxidants.  Adapted from Machlin et 
al. (1987). 
Nutrients Free radicals to scavenge Reaction 
Vitamin E (α-tocoperol) Peroxyl radical (LOO•) 
Hydroxyl radicals (OH•) 
Superoxide (O2•-) 
 
Singlet oxygen (1O2) 
LOO• + TocH → LOOH + Toc•   
OH• + TocH → H2O + Toc• 
2O2•- + TocH + H+ → Toc + H2O2 
+ O2  
1O2 + TocH → Toc-OOH 
Vitamin C (ascorbic acid) 
 
Superoxide (O2•-) 
 
Hydroxyl radicals (OH•) 
Singlet oxygen (1O2) 
O2•- + AscH + H+ → Asc + H2O2 + 
O2  
OH• + AscH → H2O + Asc• 
1O2 + AscH → Asc-OOH 
Vitamin A (β-carotene) Singlet oxygen (1O2) 1O2 + CarH → Car-OOH 
Catalase 
     Iron present 
Hydrogen peroxide (H2O2) H2O2 → O2 + 2H2O   
Glutathione peroxidase 
     Selenium present 
Hydrogen peroxide (H2O2) 2GSH + H2O2 → GSSG + 2H2O   
GSH=glutathione, reduced form  
GSSG=glutathione, oxidised form 
Superoxide dismutase 
     Zinc and copper present 
Superoxide (O2•-) 
 
2O2•- + 2H+ → H2O2 + O2 
Ubiquinone-10  
     Reduced form (UQ10H2) 
Tocopherol radicals (ToC•) 
Peroxyl radicals (LOO•) 
ToC• + UQ10H2 → TocH + UQ10H• 
LOO• + UQ10H2 → LOOH + 
UQ10H• 
 
 
Figure 2.1:  Antioxidant defence targets and locations within the cell.  Adapted from 
Machlin et al. (1987).  Abbreviations:  Cu, copper; GSH, glutathione; Mn, manganese; SOD, 
superoxide dismutase; Zn, zinc. 
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Vitamin C has been implicated in the neutralisation of phagocyte-derived oxidants, indicating 
that this antioxidant is of particular importance in injuries associated with a significant 
inflammatory component (Anderson and Lukey, 1987).   
Turning attention to administration or supplementing protocols, investigations where vitamin 
C supplementation was continued after eccentric exercise, have shown evidence of 
improved clinical recovery demonstrated by speed of recovery of muscle contraction and a 
decrease in muscle soreness (Kaminski and Boal 1992; Jakeman and Maxwell 1993).  In the 
one study, 1 g of vitamin C was taken 3 times daily, starting 3 days prior to exercise and up 
to 7 days thereafter (Kaminski and Boal 1992), whereas in the other study 400 mg was taken 
for 21 days prior to and 7 days afterward (Jakeman and Maxwell 1993).  Vitamin C 
supplementation also attenuated cortisol release after exercise in humans, and resulted in 
significantly lower levels of acute phase reactants such as C-reactive protein (CRP) and CK 
(Peters et al., 2001b), as well as significantly reduced concentrations of anti-inflammatory 
cytokines such as IL-1 receptor antagonist and IL-10 (Nieman et al., 2000; Peters et al., 
2001a).  This may be explained by the fact that high doses of vitamin C may act as a “pro-
oxidant”, rather than an anti-oxidant by reducing transition metal ions, which in turn drives the 
Fenton reaction, potentially resulting in oxidative stress through the production of superoxide, 
hydrogen peroxide, and hydroxyl radicals (Halliwell 1996), as follows: 
O2 + e– → O2•-                    Equation 1 
2O2•- + 2H+ → H2O2 + O2                         Equation 2 
Fe2+ + H2O2 →  OH• + OH- + Fe3+                       Equation 3     
In contrast, acute supplementation (300 mg, starting 2 hr prior to exercise), had no effect on 
various measures of recovery, despite increasing plasma concentrations of vitamin C 
(Thompson et al., 2001a).  In a follow-on study by the same group (Thompson et al., 2003), 
vitamin C supplementation for 14 days prior to exercise, resulted in a pronounced elevation 
in plasma IL-6, followed by a significant decline 2 hr after exercise – lower than controls 
(Thompson et al., 2001b).  However, if supplementation started 2 hr after injury (2x daily for 3 
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days), no significant effect on plasma CK, myoglobin, malondialdehyde and IL-6 was 
observed (Thompson et al., 2003).  These studies suggest that short-term as well as post-
exercise supplementation is not sufficient to allow for a beneficial effect on recovery.   
A combination of vitamin C and E (500 mg vit C and 400 mg vit E), administered daily for 2 
weeks prior to exercise and continued for up to 1 week after exercise, did not alter exercise-
induced muscle damage as measured by CK levels (Petersen et al., 2001).  There was no 
significant difference in plasma IL-1ra and IL-6ra between the supplemented and placebo 
groups after injury.  Plasma levels increased irrespective of supplementation, although 
additional vitamin supplementation resulted in even further increases.  These results suggest 
that endogenous antioxidants may be sufficient enough to quench free radicals in periods of 
greater oxidative stress, without the need for extra supplementation.  This suggestion is quite 
valid, since in one particular study it was shown that elite athletes with a higher training load 
had more elevated baseline antioxidant levels compared to sedentary subjects (Child et al., 
1999), indicating that the natural increase in plasma antioxidant vitamin concentrations 
during and after exercise could possibly abolish the effect of additional vitamin 
supplementation. 
Vitamin E can serve as a potent peroxyl radical scavenger, and recent research has shown 
an increase in its utilization following intense exercise (Mastaloudis et al., 2001).  This 
suggests that acute supplementation with vitamin E might be needed to maintain the 
antioxidant stores in situations of increased ROS production.  Even though it has been 
postulated that adequate dietary amounts of vitamins should be consumed to protect against 
free radicals, it has been thought that the liver and kidney function as vitamin reservoirs 
(Blomhoff et al., 1990; Warren and Reed 1991), and that some of the vitamins may act in 
synergy with one another to spare excess vitamin utilization.  For example, vitamin C has the 
ability to regenerate the reduced form of vitamin E (Bendich et al., 1984; Bendich et al., 
1986), thereby either decreasing the rate of vitamin E consumption or replenishing the 
reduced form of vitamin E (Niki 1991).  In muscle fibers, vitamin E may also have the added 
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ability to stabilize membranes, by anchoring to membrane polyunsaturated fatty acids 
through its side-chain (Phoenix et al., 1991), but the literature is not in agreement.  Meydani 
et al. (1993), reported that oral vitamin E supplementation (physiological dose for 48 days) 
after downhill-running resulted in a muscle protective effect 5 days after injury, based on 
decreased (compared to control) plasma creatine kinase (CK) levels, while a similar study (5 
days of intravenous injections of vitamin E (200 µl of a 70 % (w/v) α-tocopherol in ethanol)) 
reported no effect on markers of muscle damage (CK, serum pyruvate kinase) after 
plyometric contractions (Van der Meulen et al., 1997).  These two studies suggest that a 
longer intake of vitamin E is necessary to reduce muscle damage.   
For vitamin A, chronic supplementation seems the best option, as chronic vitamin A 
supplementation (1000 IU – daily for 13 weeks) resulted in suppression of lipid peroxidation 
24 hr after injury, although baseline oxygen radical absorbance capacity (ORAC) was not 
improved (Sacheck et al., 2003).  From these studies, it is apparent that vitamin 
supplementation may have positive effects on some aspects of the muscle response to 
damage.  However, these vitamin supplementation studies (exercise-related) investigated 
only pro-inflammatory markers or indicators of damage, such as plasma CK, rather than 
markers of recovery, such as satellite cell number and number of regenerating muscle fibres.  
Other important processes to consider would be satellite cell activity, formation of 
regenerated muscle fibres and the magnitude and time course of the anti-inflammatory 
response.  Thus, since the possibility exists that vitamin supplementation may have positive 
effects, more studies are needed, which include some of the abovementioned processes, in 
order to confirm a possible positive effect especially after injury.  
Plant-derived compounds, or phytochemicals, also have demonstrated anti-oxidant 
capacities.  These include carotenoids, bioflavonoids, flavonoids, and others as reviewed in 
various articles (Rice-Evans et al., 1995; Rice-Evans et al., 1996; Basu 1999).  In a study by 
Chao et al. (1999), US Marine Corps personnel participated in a 14-day field-training event 
during the winter season.  The oxidative stress in this model was associated with intense 
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physical exertion, ultraviolet light exposure, and fluctuating temperatures.  Subjects received 
a daily dose of either α-tocopherol, ascorbic acid or β-carotene, or a combination of all three.  
The combination of these antioxidant vitamins was most effective in limiting increases in 
oxidative stress from baseline.  It is possible that a synergistic effect could be achieved when 
combining phytochemicals with vitamin antioxidants or other compounds.  In an in vitro study 
by Stahl et al. (1998), combinations of carotenoids (13 different combinations) were also 
more effective in reducing oxidative stress and protecting multilamellar liposomes than 
individual carotenoids, a result ascribed to their different physiochemical properties.  The 
effects of single carotenoids and α-tocopherol on lipid peroxidation were measured by levels 
of thiobarbituric acid-reactive substances (TBARS) and indicated that the most efficient 
carotenoid was lycopene, followed by α-tocopherol, α-carotene, β-cryotoxanthin, β-carotene, 
zeaxanthin and lutein (Stahl et al., 1998).  Unfortunately, no placebo control was used in this 
study, the researchers used the total combination of carotenoids as “control”.  Thus, in light 
of these results, supplementing with a combination of vitamins, minerals, and phytochemicals 
known individually to have direct or indirect antioxidant characteristics, may therefore expand 
the body’s natural defence system against oxidative stress.   
Another potential beneficial effect of β-carotene, is its ability to protect against lipid 
peroxidation induced by methyl mercuric chloride infusion in mouse models (Andersen and 
Andersen 1993) and to reduce indices of lipid peroxidation in serum (Mobarhan et al., 1990; 
Gottleib et al., 1993).  An important consideration when investigating vitamin studies in the 
literature, is that many studies do not intervene with a potential stressor of the antioxidant 
system, thus resulting in controversial results. 
To date, only 5 studies have shown that polyphenols are beneficial for muscle repair (Kato et 
al., 2000; Buetler et al., 2002; Dorchies et al., 2006; Hofmann et al., 2006; Nakazato et al., 
2010).  Not only were they able to decrease muscle necrosis and elevate twitch tension in 
mdx mice (Buetler et al., 2002; Dorchies et al., 2006), but they also resulted in suppression 
of oxidative stress and earlier recovery due to a significantly lower force deficit in the rat 
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skeletal muscle (Kato et al., 2000) after subjection to treadmill-induced exercise.  
Furthermore, in a study by Nakazato et al. (2010), it was shown that apple polyphenols 
significantly decreased the levels of serum TBARS, the major indicator of oxidative damage 
according to the researchers, compared to the control group after lengthening contraction 
exercise.  Analysis of the mRNA expression of antioxidative proteins such as glutathione-S-
transferase α1 (GSTα1) was significantly higher in the polyphenol group, suggesting that 
these mice possessed a higher antioxidative ability (Nakazato et al., 2010).  This finding was 
also confirmed in an earlier study (Hofmann et al., 2006). 
Amongst the polyphenols that have attracted research attention recently are flavonols, 
catechins and quercetin.  Results have suggested that certain flavonols have the ability to 
prevent collagen breakdown by inhibiting collagenase (Sin and Kim 2005).  Similarly, 
catechins, in particular (−)epigallocatechin gallate (EGCG) have been shown to inhibit 
membrane type I matrix metalloproteinase (MMP), which hydrolyzes type I collagen 
(Yamakawa et al., 2004).  Therefore, since the inhibition of collagen breakdown by some 
flavonoids is a property relating positively to cases of hindered skeletal muscle healing, 
compounds capable of reducing collagen breakdown could modulate the deposition of the 
extracellular matrix, thus favouring the repair process with very little fibrosis.   
In an in vitro study it was demonstrated that quercetin (30 µM) was able to inhibit the 
expression of pro-inflammatory cytokines in human mast cell line by blocking the activation of 
p38 mitogen activating protein kinase (MAPK) and nuclear factor kappa beta (NFκB) (Min et 
al., 2007).  However, a high dose of quercetin (1,000 mg/day) ingestion over a period of 24 
days in cyclists did not alter muscle NFκB content, exercise-induced increases in muscle 
cyclooxygenase (COX)-2 mRNA or muscle mRNA expression for IL-6, IL-8, IL-1β, and TNF-α 
(Nieman et al., 2007).  It did attenuate increases in postexercise blood leukocyte IL-8 and IL-
10 mRNA and tended to lower plasma levels of IL-8 and TNF-α, whilst reducing blood 
leukocyte IL-10 mRNA expression after the first day of exercise, without any measurable 
effect on plasma IL-10 levels.  Although these data might indicate that quercetin is beneficial 
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by blocking NFκB activation in some cell types and thus attenuating pro-inflammatory 
actions, RNA levels are not conclusive evidence of clinical effects.   
Although no direct evidence exists to show efficacy of any of these substances to improve or 
hasten recovery, with the exception of polyphenols, all reviewed studies suggest that 
vitamins A and E and other dietary flavonoid antioxidants are beneficial in scavenging free 
radicals, so as to reduce oxidative stress.  However, these products are not without risks, as 
high doses of a single vitamin or high doses as a result of multiple vitamins at a time – 
particularly after physical exercise - can be toxic (Ristow et al., 2009).  Therefore, other 
products should be investigated for efficacy, but with lower associated risk to the user. 
 
Numerous plant derivatives claim to have the ability to promote wound healing, such as 
Angelica sinensis (Ye et al., 2001), Eucommia ulmoides (leaf extract) (Li et al., 2000), Arnica, 
Astragalus, Calendula, Hyssop, Myrrh and Paud’arco (Williamson and Wyandt 1997).  
Proanthocyanidins are a group of biologically active polyphenolic bioflavonoids, which are 
synthesized by many plants, vegetables and fruit, especially grape seeds.  The particular 
importance of these compounds in muscle physiology will be discussed in detail in the next 
section. 
 
2.4  Grape seed extract 
Flavonoids and other plant phenolics are reported to have multiple biological activities, in 
addition to their free radical scavenging (anti-oxidant) activity (Kandaswami and Middleton 
1994; Chen et al., 1996; Bagchi et al., 1997; Bagchi et al., 1998; Orozco et al., 2003).  
Flavonoids, which include grape seed proanthocyanidolic oligomers (PCO) were reported to 
possess cardioprotective abilities by directly scavenging reactive oxygen species such as 
hydroxyl and peroxyl radicals (Sato et al., 1999a).  Other protective abilities include 
vasodilatory (Duarte et al., 1993a; Duarte et al., 1993b; Sato et al., 1999a), anticarcinogenic 
(Hertog et al., 1992; Hertog et al., 1993; Birt et al., 2001), anti-inflammatory (Middleton and 
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Kandaswami 1992; Sud'ina et al., 1993; Salah et al., 1995; Rice-Evans et al., 1996; Cao et 
al., 1997; Bagchi et al., 1998; Birt et al., 2001), antibacterial (Surico et al., 1987), anti-allergic 
(Sud'ina et al., 1993), and antiviral effects (Surico et al., 1987).  Although most of these 
effects of flavonoids have been studied in the context of cardiovascular diseases, 
conclusions regarding some of these effects could also be applicable to injured skeletal 
muscle.  The most important effects to take note of include their free radical scavenging/ 
antioxidant properties, vasodilatory and anti-inflammatory effects.  These effects involve the 
inhibition of the enzymes in the arachidonic acid pathway, such as phospholipase A2, 
lipoxygenase and cyclooxygenase, glutathione reductase, and the xanthine oxidase pathway 
(Middleton and Kandaswami 1992; Sud'ina et al., 1993; Salah et al., 1995; Rice-Evans et al., 
1996; Cao et al., 1997; Bagchi et al., 1998; Birt et al., 2001), all of which are activated as a 
result of oxidative stress and injury and may function to hinder adequate muscle healing.   
When muscle is damaged, free radicals are formed by various cell types, which include 
satellite cells (upon activation) and immune cells, and can result in secondary damage if 
damage spreads to include the healthy surrounding tissue (Brickson et al., 2001; Schneider 
et al., 2002).  Therefore, in order to prevent secondary damage, it is necessary to have an 
increased ability to scavenge free radicals (flavonoids are oxidised by radicals, resulting in a 
more stable, less reactive radical – see equation 1) (Halliwell 1995), as well as a decreased 
production of free radicals in order to restore normal muscle structure and function and thus 
to improve muscle recovery.  Selected flavonoids can directly scavenge superoxides, 
whereas other flavonoids can scavenge the highly reactive oxygen-derived radical called 
peroxynitrite.  
Flavonoid(OH) + R· → flavonoid(O·) + RH                                                                 Equation 4    
(R· is a free radical and O· is an oxygen free radical) 
In response to injury, increased immobilization and adhesion of leukocytes to the endothelial 
wall results in the production of free radicals upon neutrophil degranulation.  This release of 
cytotoxic oxidants and inflammatory mediators is also responsible for further activation of the 
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complement system, which has been associated with an increased inflammatory reaction, 
further exacerbating the initial injury (Bury and Pirnay 1995; Belcastro et al., 1996).  This 
occurs during episodes of ischemia and inflammation, and may result in injury to other 
tissues as well.  Therefore, in order to prevent the degranulation and adhesion of leukocytes 
to the endothelial wall, one either has to mobilise the leukocytes by means of chemotactic 
factors, or prevent the degranulation of the neutrophils, thereby inhibiting the formation of 
free radicals.  However, blood-borne immune cells, including neutrophils and macrophages 
must gain direct access to the site of damage, as a result of vasodilation and a combined 
effect of adhesion molecules and chemotactic factors, to aid muscle recovery (Deal et al., 
2002; Sherwood 2004a).  Anti-inflammatory cytokines play an additional role in allowing 
immune cells to enter the injured area.  These cytokines are particularly important for 
attraction of M2 macrophages - macrophages important for muscle regeneration (Mantovani 
et al., 2004).   
Considering the fact that reactive oxygen species are such a problem after injury and the 
beneficial effects of flavonoids in scavenging these free radicals, as well as their role in 
suppressing the various enzymes and key role players in the arachidonic acid and xanthine 
oxidase pathway (Hilário et al., 2006), flavonoids might play a crucial role in possibly limiting 
the time required for muscle regeneration.  Since the focus of this thesis is 
proanthocyanidins, the next few paragraphs will focus on the available literature regarding 
proanthocyanidin and their possible beneficial effects.       
An in vivo study in mice showed grape seed proanthocyanidin extract (100 mg/kg) to be a 
better free radical scavenger and inhibitor of oxidative tissue damage than vitamin C (100 
mg/kg), E succinate (100 mg/kg), and β-carotene (50 mg/kg) (Bagchi et al., 1998).  
Proanthocyanidin monomers are rapidly absorbed into the blood, where they bind to heavy 
metal ions, resulting in the scavenging of free radicals (Gonthier et al., 2003; Sano et al., 
2003).  Oligomeric proanthocyanidin are not as readily absorbed and may therefore not be 
regarded as the main flavonoid responsible for beneficial effects (Rios et al., 2003).   
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However, when comparing studies done in rodents vs. human subjects, most of the studies 
in the past did not take the metabolic rate, or manner of administration, into account.  
Administering a similar dosage of flavonoids to humans or rats will have a different effect, 
since rats have an approximately 7-10 times higher metabolic rate, therefore one might only 
see a positive effect in rats and not humans.  Also direct gavaging (directly into the stomach) 
compared to taking a tablet will also result in a different dosage reaching the stomach, with 
gavaging allowing the full concentration to reach the stomach vs. a lower concentration with 
a tablet.  Over the past few decades, numerous in vivo studies (mainly cardiovascular, 
inflammation and cancer research) have also demonstrated that flavonoids, including 
proanthocyanidins are safe and produce no clinical side effects, except perhaps quercitin 
(Dunnick and Hailey 1992; Zhu et al., 2001).   
Specific functions of proanthocyanidins include the ability to strengthen and protect living 
tissue, through inhibiting the activity of the proteolytic enzymes collagenase and elastase, 
which are directly involved in the turnover of the main structural components of connective 
tissue, collagen and elastin (Tixier et al., 1984; Hyun et al., 2003; An et al., 2005; Balu et al., 
2005).  Proanthocyanidins have been shown to mediate several anti-inflammatory 
mechanisms, in particular those involved in the development of cardiovascular disease.  
Studies have indicated that these mechanisms are of particular importance in aiding the 
inflammatory process after atherosclerosis to allow monocytes to adhere to the endothelial 
wall and entering the “area of damage”.  In one particular in vitro study, grape seed 
proanthocyanidins were responsible for down-regulating the TNF-α-induced expression of 
vascular adhesion molecule (VCAM)-1 on human endothelial cells, therefore playing a pivotal 
role in the inflammatory process as a result of its effect on migration (Sen and Bagchi 2001).  
In contrast to the study focussing on expression of VCAM, other studies have taken into 
account the metabolism of the cell, and showed positive results:  moderate red wine 
consumption for 28 days abolished the adhesion of monocytes (isolated from healthy males) 
to endothelial cells (Badia et al., 2004; Estruch et al., 2004).  Markers influenced in these 
studies, included VCAM, intercellular adhesion molecule (ICAM), CRP and IL-1α, all of which 
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are usually elevated in vascular disease associated with inflammation.  The vascular 
endothelium is important for synthesizing and releasing nitric oxide (NO), which in turn 
promotes vasorelaxation and reduces platelet aggregation, and limits the influx of acute 
phase proteins into the injured area (Palmer et al., 1988).  Various studies have indicated 
that proanthocyanidins may have favourable effects on these vascular endothelial functions 
(Duffy and Vita 2003; Dell’Agli et al., 2004).  Furthermore, grape juice administration 
specifically was able to improve endothelium-dependent vasodilation in coronary artery 
disease patients with impaired endothelial function (Stein et al., 1999).  Although most of 
these studies investigating the positive effects of proanthocyanidins have looked at 
cardiovascular diseases, the general beneficial effect of proanthocyanidins on inflammation 
might also be true for skeletal muscle injury models.     
In order for a natural product to be considered an effective therapy for skeletal muscle injury, 
it must display the following properties.  Firstly, for effective healing, a natural plant-derived 
product should have an anti-inflammatory property – the ability to attenuate pro-inflammatory 
cytokine release, whilst increasing anti-inflammatory cytokine release.  Inflammatory 
cytokines play a predominant role in aiding muscle regeneration by facilitating immune cell 
recruitment to the injured area.  Pro- and anti-inflammatory cytokines are responsible for 
attracting macrophages, whilst only pro-inflammatory cytokines are involved in neutrophil and 
macrophage recruitment.  Therefore, a second property of a potential product is the ability to 
recruit more macrophages, whilst decreasing the number of neutrophils to the injured area.  
Thirdly, the natural product should have a potent free radical scavenging ability, eliminating 
or reducing the amount of ROS, therefore resulting in quicker and faster healing.  Fourthly, 
satellite cells should be activated earlier to facilitate faster recovery.  Lastly, if the natural 
product can strengthen plasma membranes, it will limit the amount of damage, and therefore 
healing will occur sooner.  Oxiprovin™ grape seed extract (GSE) is believed to be one such 
product (Oxiprovin™, Brenn-O-Kem, Wolseley, South Africa).  It is a natural South African 
plant antioxidant product extracted from grape seeds in a water and ethanol extraction 
process (Brenn-O-Kem 2006).  Oxiprovin™ contains 45 % proanthocyanidins and less than 5 
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% monomers, the remainder of which is made up of of long chain sugars and glycosides 
attached to the oligomers.  
With particular relevance to muscle injury, the effect of oral grape-seed derived 
proanthocyanidin (Oxiprovin™) supplementation on muscle recovery after contusion injury 
were investigated by our group (MSc thesis, Kruger 2007).  In this study, Oxiprovin™ 
supplementation resulted in faster skeletal muscle fiber regeneration, as assessed by 
magnitude and speed of satellite cell activation, and foetal myosin heavy chain (MHCf) 
expression in regenerating muscle fibres.  These data suggest that chronic Oxiprovin™ 
supplementation may facilitate quicker recovery of muscle following muscle injuries of mild to 
moderate severity.  The exact mechanism(s) by which Oxiprovin™ achieves its effect of 
increasing muscle recovery is not clear.  Furthermore, the minimum duration of 
supplementation for beneficial effects has not been determined.  
 
2.5  Summary 
The ideal treatment for skeletal muscle injuries is still lacking, mainly due to the extent and 
severity of injuries reported in the literature as well as the multiple underlying processes 
which complicate the research.   
In spite of numerous research with experimental and clinical studies, the effect of different 
treatment regimes on muscle recovery have been disappointing.  RICE has been shown to 
be beneficial, but timing is important, since the various components it consists of will allow for 
better recovery of muscle if applied at the correct time.  Cryotherapy (the application of ice), 
one of the key components of RICE, for example, should be applied as soon as possible, 
however, it only alleviates pain.  Therapeutic ultrasound on its own does not seem to be 
beneficial for muscle regeneration, however, if used in combination with antioxidant drugs it 
has been shown to be beneficial.  Light exercise or early mobilization of the injured leg after 
a short period of immobilization has proven to be beneficial for rapid regeneration.   
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Although some of the studies have shown positive effects, the negative effects cannot be 
ignored.  Steroids have only been shown to alleviate pain, with no beneficial effect on muscle 
regeneration.  NSAIDs, although showing some promise in limiting inflammation when 
administered at low doses, higher doses have been shown to be detrimental.  Furthermore, 
most studies started NSAID administration 2-5 days after injury, points in time when 
inflammation is already prominent, and neutrophils might already have contributed to 
secondary damage as a result of their respiratory burst.  Further studies looking at earlier 
time points might therefore be beneficial.  Most studies investigating regeneration have also 
looked at markers not considered to be good markers of muscle damage and recovery.  
More specific markers should therefore be investigated in order to determine if these drugs 
and treatment modalities are beneficial.  In this regard, one excellent study has investigated 
growth factor injection into the injured area, specifically IGF-1.  Beneficial effects were 
measured directly, e.g. increased number of regenerating myofibres compared to their 
respective control (Kasemkijwattana et al., 1998a; Kasemkijwattana et al., 1998b).  
With all the studies mentioned and considered in this chapter, few studies have investigated 
speed of muscle recovery, as well as the potential of the treatment to reduce reactive 
species, which are generated upon muscle injury.  Thus ideally if one can limit reactive 
species formation, one can potentially allow for quicker muscle recovery.  Treatment with 
vitamin supplements was hypothesized to be beneficial after muscle injury.  However, 
although vitamin supplements have been shown to be able to reduce oxidative tissue 
damage, the only marker of damage and recovery investigated was plasma CK, and 
therefore not conclusive enough evidence for quicker muscle recovery.  Polyphenol 
treatment, on the other hand, has been shown to be beneficial for healing of pathology, 
especially with regard to the mdx model.  The evidence for speeding up the recovery process 
after acute injury is still lacking.     
A previous study by our group has found that chronic Oxiprovin™ supplementation is 
beneficial in speeding up the recovery of rat muscles after a contusion injury (MSc thesis, 
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Kruger 2007).  However, it is not known how Oxiprovin™ exerts its beneficial effect.  In order 
to investigate Oxiprovin™’s mechanism of action (Chapter 3), the local and systemic 
cytokine profiles, as well as the infiltration of immune cells (neutrophils and macrophages) 
into the injured muscle were assessed.  Since most athletes cannot predict the outcome of a 
game, the issue of acute supplementation were also addressed (Chapter 4).  In this thesis, 
Oxiprovin™’s ability to: (a) scavenge free radicals, (b) speed up the recovery from a 
contusion injury, (c) blunt the inflammatory cytokine status and (d) drive the repair phase of 
muscle recovery in favour of early immune cell infiltration after sustaining a contusion injury 
were also investigated. 
Different macrophage phenotypes are involved in the inflammation and repair phase 
following an injury.  Macrophages can also switch from being “damaging” (M1) to “repairing” 
(M2).  Thus, investigating the presence of the different macrophage phenotypes will provide 
us a better understanding of when and how Oxiprovin™ might exert its beneficial effect 
(Chapter 5).  Also, since cytokines and chemotactic factors play a major role in attracting 
neutrophils and macrophages to the injured area, an in vitro migration assay will further 
promote our understanding of the particular mechanisms of action of Oxiprovin™ to enable 
or prevent neutrophil migration.  In this last study, neutrophils are allowed to migrate, in the 
presence of various plasma cytokines at different time points after injury, towards a specific 
chemotactic factor (Chapter 5).  This will enable the determination of the specific timing of 
neutrophil migration from circulation.  
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CHAPTER 3 
 
The effect of chronic proanthocyanidolic oligomer supplementation 
on the inflammatory response to contusion injury in rat hindlimb 
 
3.1  Introduction 
A contusion injury, an injury caused by a blunt non-penetrating object, result in the rupturing 
of muscle fibres at or adjacent to the injured area (Jarvinen et al., 2005).  The inflammatory 
process is a very important event following an injury, contributing to both secondary damage 
and recovery.  As mentioned before, neutrophils are the first immune cell to infiltrate the 
injured area, playing a predominant role, from approximately 1 hr after injury, in clearing the 
injured area of any debris (Tiidus 1998), whilst macrophage infiltration of the tissue is 
initiated roughly 24-48 hr after injury, playing a role in both phagocytosis and muscle repair 
(Duffield 2003).  Inflammation is regarded as a complex process, involving a whole host of 
events which are regulated by various role players, involving both pro- and anti-inflammatory 
cytokines and various other mediators - for a recent review on cytokines and growth factors 
in this context, see Smith et al. (2008).     
Although it is known that immune cells, as well as injured muscle cells themselves, release 
cytokines (Feldmann and Maini 2003), it is not known which cell is responsible for injury-
related cytokine release.  Nevertheless, cytokines associated with injury include the pro-
inflammatory cytokines interleukin (IL)-6, IL-1β and tumour necrosis factor (TNF)-α, which 
coincide with the early phase after injury, in other words destruction, and the anti-
inflammatory cytokines IL-4 and IL-10, which coincide with muscle recovery (Mantovani et 
al., 2007).  Pro-inflammatory cytokine expression also correlates with the activation of the 
oxidative-stress sensitive nuclear transcription factor NFκB (Blanchard et al., 2000).  These 
pro-inflammatory cytokines are produced within the injured muscle, resulting in the release of 
more cytokines into circulation.  It also results in the activation of white blood cells, as well as 
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inducing satellite cell (SC) proliferation.  For example, macrophages can stimulate pro-
inflammatory cytokine production (IL-1β and TNF-α), which recruits more monocytes and 
aids SC activation, ultimately resulting in muscle regeneration (Rosenberg and Gallin 1993; 
Cannon and St Pierre 1998; Tidball 2005). 
There is normally a fine balance between the interaction of different immune cells and the 
cytokines and growth factors in response to an injury.  This interaction will determine: 1) 
whether the immune response is of short-duration or a longer-term adaptation, 2) the speed 
of the inflammatory response and 3) whether a shift in favour of one particular response (pro 
vs. anti-inflammatory) will result in another response being compromised.   
The effect of contusion injury on immune cells and cytokines has not been studied 
extensively and data presented are not consistent.  The differences in the severity of injury 
(i.e. with or without bone or tendon involvement) and the models used to produce 
experimental contusion injury (invasive vs. not), result in variations in the inflammatory 
response reported (e.g. long vs. short duration, or no vs. extensive inflammatory responses) 
(Raj et al., 1998; Tidball et al., 1999; Kami et al., 2000; St. Pierre Schneider et al., 2002; 
Bunn et al., 2004; Farnebo et al., 2009).  Little is known regarding the involvement of the 
inflammatory immune cells and the specific cytokines in recovery from a contusion injury, 
thus more work is required to elucidate their specific contributions to skeletal muscle injury 
and recovery.   
While the phagocytic and inflammatory responses are considered critical in the recovery from 
muscle injury, oxidants released from neutrophils, macrophages and SCs can all contribute 
to promote further muscle damage, also termed oxidative stress.  Oxidative stress occurs 
when production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
overwhelms the endogenous antioxidant system of enzymes (i.e. superoxide dismutase, 
glutathione peroxidase) and substrates (i.e., vitamin E, reduced glutathione), and is 
considered to be a key contributor to inflammation (McArdle and Jackson 2000).  It has been 
suggested that the dynamic balance between inflammatory cell- and muscle-derived free 
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radicals may play important roles in modulating the course of muscle injury and repair after 
modified muscle loading (Tidball 2002).  ROS can be important in the initiation of exercise-
induced muscle damage and in the initiation and propagation of the subsequent acute 
muscle inflammatory response (Tiidus 1998).  Furthermore, in this specific study, it was 
demonstrated that oxygen radicals generated via the neutrophil respiratory burst are vital in 
clearing away the damaged muscle tissue, but that an excessive oxygen radical response 
may result in the propagation of further tissue damage (Tiidus 1998).  More specifically, 
Finkel and Holbrook (2000) proposed that oxidative stress is secondary to the recruitment of 
inflammatory cells which contain the potent NADPH oxidase system (present in neutrophils, 
macrophages, vascular cells and cell membranes), which produces large amounts of 
superoxide (O2-).  O2- reacts rapidly with nitric oxide (NO) to form peroxynitrite, 
overproduction of which is also a causative factor of tissue-damage, particularly in the case 
of chronic lung inflammation (Kooy et al., 1995), but also in brain or vessel injury (Kontos and 
Wei 1986).  Macrophages produce large amounts of NO that attract SCs to the injured area, 
and consequently result in SC proliferation and maturation, as well as recruitment of more 
macrophages (Anderson 2000; Chazaud et al., 2003), forming a positive feedback loop.  NO 
production is time and concentration dependent and that if more macrophages are present at 
a given time, this will result in the recruitment and activation of more SCs (Anderson 2000).  
Therefore, it is evident that if one can limit oxidative stress, one can also limit the magnitude 
of inflammation and associated damage in the injured area, and potentially speed up the 
recovery process.  However, it is also possible that limiting oxidative stress too much will 
lead to insufficient phagocytosis and/or too little activation of repair.  
Oxiprovin™ is a commercially available extract prepared from grape seeds, and contains the 
active ingredient proanthocyanidolic oligomers (PCO), which form part of the flavonoid 
family, and have anti-inflammatory properties (Gonzalez-Gallego et al., 2007).  Previous 
results in rats have indicated that PCO supplementation is positively associated with muscle 
recovery (MSc thesis, Kruger 2007).  In this study, chronic PCO supplementation (2 weeks 
prior to and after contusion injury) resulted in quicker SC activation (CD34 and CD56 
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expression were elevated 4 hr after injury in the PCO group, compared to day 3 and day 7 in 
the PLA group) and earlier skeletal muscle regeneration (foetal myosin heavy chain – MHCf  
was elevated by day 3 in the PCO group compared to day 7 in the PLA group, Figure 3.1), 
indicating that PCO supplementation had a positive effect on muscle recovery (MSc thesis, 
Kruger 2007).  Oxygen radical absorbance capacity (ORAC) results also indicated that 
groups supplemented with PCO had a better free radical scavenging effect, and in 
conjunction with lower plasma CK activities found in the PCO group, it was concluded that 
PCO supplementation could protect the skeletal muscle against secondary damage (MSc 
thesis, Kruger 2007).     
 
 
Figure 3.1:  Foetal myosin heavy chain (MHCf) positive myofibres with central nuclei are 
expressed as percentage of the total myofibre number (% MHCf+ myofibres) (means ± SD) at 
control levels (non-injured) and at 4 hr, day 3, 7 and 14 post-injury (* p<0.05, *** p<0.001).  
Statistics:  Factorial analysis of variance with Bonferonni post hoc test.  n = 4 rats per time 
point per group (MSc thesis, Kruger 2007). 
 
Considering the above data and other literature, it was hypothesised that PCO in Oxiprovin™ 
would alter the inflammatory response, most probably in favour of an anti-inflammatory 
response.  To assess this hypothesis, the magnitude and duration of changes in pro- and 
anti-inflammatory cytokine levels in circulation and tissue, as well as the magnitude and time 
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course of neutrophil and macrophage infiltration into the injured muscle tissue following 
chronic PCO supplementation were assessed.  In order to verify SC results seen in previous 
studies, recent and more specific marker for SCs were used. 
 
3.2  Methods 
3.2.1  Animals and interventions 
3.2.1.1  Experimental animals   
Adult, male Wistar rats (bred and housed in the small laboratory animal facility at the 
Department of Physiological Sciences, Stellenbosch University) weighing approximately 280 
g were used for this study.  All animals had access to food (standard rat chow pellets, 
supplied by the Medical Research Council animal unit, Parow) and tap water ad libitum and 
were exposed to a 12 hr light/dark cycle (lights on at 6h30).  Ambient temperature was 
controlled at 21 ºC, and rooms ventilated at a rate of 10 changes/hour.  Prior to the initiation 
of intervention protocols, rats were accustomed to the researcher by daily handling and oral 
gavage (tap water only) for a period of 2 weeks.  All experimental protocols were approved 
by the Animal Research Ethics Committee of Sub-Committee B of Stellenbosch University 
(reference # 2006 Smith01).    
Experimental rats were divided into 4 groups, a control group and an injury group (see Figure 
3.2).  The control group rats were divided into a control placebo group receiving 2 weeks of 
0.9 % saline treatment (C-PLA, n=8) and a control proanthocyanidolic oligomer (PCO) group, 
receiving 2 weeks of Oxiprovin™ supplementation (C-PCO, n=8).  Rats belonging to the 
injury group were also subdivided into two groups, an injury-placebo group, injured after 2 
weeks of placebo supplementation, with continued placebo supplementation post-injury (I-
PLA; n=48, i.e. 8 rats per time point, time points were 4 hr, 1 d, 3 d, 5 d, 7 d and 14 d post-
injury) and an injury PCO group, injured after 2 weeks of Oxiprovin™ supplementation, with 
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continued Oxiprovin™ supplementation post-injury (I-PCO; n=48, i.e. 8 rats per time point, 
time points were 4 hr, 1 d, 3 d, 5 d, 7 d and 14 d post-injury).   
 
Figure 3.2:  Experimental design. 
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3.2.1.2  PCO administration 
Oxiprovin™ is a natural South African plant antioxidant product extracted from grape seeds 
in a water and ethanol extraction process (Brenn-O-Kem 2006), which contains 45 % 
proanthocyanidins, less than 5 % monomers and the remainder made up of long chain 
sugars and glycosides attached to the oligomers.  Rats belonging to the PCO group, both 
injured and controls, were administered a daily dose of 20 mg/kg/day Oxiprovin™ (dissolved 
in 0.9 % sterile saline) by means of oral gavage (1 ml/kg body mass).  Rats in the PLA group 
received a daily dose of 0.9 % saline (1 ml/kg body mass) for 14 days, also by means of oral 
gavage.  Additionally, rats were also treated with Oxiprovin™ or saline for up to 14 days after 
injury.      
 
3.2.1.3  Induction of muscle injury 
Contusion of the hind limb was produced by a mass-drop jig (Figure 3.3), similar to the model 
first described by Stratton et al. (1984) and later used by Kami et al. (1993, 1995).  Briefly, 
the lower part of the apparatus comprised a large round metal platform, with a small 
cylindrical platform in the centre, on which the hind limb of the animal rested just prior to and 
during injury.  A plastic tube fastened perpendicularly to and directly above the smaller 
platform directed the passage of a 200 g flat, circular bottomed weight from a height of 50 cm 
onto the medial surface of the right gastrocnemius muscle.  A peg through a hole in the 
plastic tube kept the weight in place at the desired height above the muscle, so that its 
removal resulted in a standardised mass dropping speed.  Rats were anaesthetised with 75 
mg/kg ketamine, 0.5 mg/kg medetomidine and 0.9 % saline (1 ml/kg body mass), 
administered intraperitoneally (i.p.), whereafter the right hind limb was moderately extended 
away from the hip joint, and the muscle was injured.  After this procedure, the rats were 
unconscious for up to 2 hr, after which they still remained slow in motion for a further 2 hr.  
However, there was no limping and no uneven gait. 
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Figure 3.3:  Muscle contusion injury jig.  A represents a real-time photo of our muscle 
contusion injury jig, whereas B, represents a schematic illustration of the non-invasive, 
standardised ‘mass-drop injury jig’. 
 
3.2.2  Sacrifice and sample collection  
3.2.2.1  Sacrifice 
All sacrifice procedures took place between 08:00 and 10:00 in the morning, with the 
exception of the 4 hr time point.  In this group, rats were sacrificed at 12:00, 2 hr after injury 
and 2 hr after the last supplementation treatment.   
During the sacrifice procedures, all animals received an overdose of pentobarbitone sodium 
(200 mg/kg i.p.), and eight rats from each of the 2 control groups (C-PLA and C-PCO) or 
injury groups (I-PLA and I-PCO) were sacrificed at each of the following time points after 
subjection to hindlimb muscle contusion injury (4 hr, on day 1, 3, 5, 7 and 14 after injury). 
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3.2.2.2  Sample collection 
Blood collection:  Following euthanasia by pentobarbitone overdose, the chest cavity was 
opened and the heart exposed.  Whole blood samples were obtained by means of right 
ventricular cardiac puncture.  Blood was collected using a 20 gauge, 1½ inch needle into a 5 
ml syringe and immediately transferred to heparinised tubes (Vacutainer, Beckton 
Dickinson).  Blood samples were immediately mixed and placed on ice prior to centrifugation 
(within 2 hr) at 3000 g for 10 min at 4 °C.  Plasma obtained was aliquoted into 1.5 ml reaction 
vials and stored at -80 °C until subsequent analysis.   
Muscle collection:  After the procedures for cardiac puncture, the gastrocnemius muscle of 
the right (injured) hind leg was exposed by cutting and removing the skin and connective 
tissue surrounding the muscle.  The damaged/recovering medial central section of the 
gastrocnemius muscle was harvested and the section randomly divided so that one part was 
processed for immunohistochemistry, and the other snap-frozen for biochemical analysis. 
 
3.2.3  Sample analysis 
Two different analytical procedures were used:  a)  immunohistochemistry on muscle, and b) 
flow cytometry for plasma pro- and anti-inflammatory cytokines. 
 
3.2.3.1  Immunohistochemistry 
For immunohistochemistry, muscles were fixed in 4 % formaldehyde (or 10 % formal saline) 
for 7 days.  The samples were then cut to size, placed into embedding cassettes, processed 
and impregnated with paraffin wax (Histosec, Merck – see Appendix A for details of tissue 
processing) using an automated tissue processor (TISSUE TEK II, model 4640B, Lab-Tek 
division, Miles Laboratories Inc, Naperville, IL).  Impregnated tissue samples were embedded 
in paraffin wax.   
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Five µm thick cross sections were cut using a rotary microtome (Leica Microsystems 
CM1850, Nussloch, Germany).  Sections were adhered to poly-L-lysine (Sigma Aldrich) 
coated slides (3 per slide), deparaffinised, digested in 0.1 % Trypsin (Highveld) to open up 
the binding sites for antigens and then blocked with 5 % serum to limit non-specific binding.  
Donkey serum were used for all staining procedures, with the exception of Pax-7 double 
labelling with laminin, where goat serum was used.  Antibodies for pro-inflammatory cytokine 
labelling included anti-TNF-α and anti-IL-6, whereas His48 (plus nuclear presence) was used 
to label neutrophils and F4/80 to label macrophages.  Phosphate buffered saline (PBS) 
controls were used to determine the specificity of the primary antibodies and all primary 
antibodies were optimised prior to immunohistochemistry.  All antibodies used were suitable 
for recognising specific antigens on rat satellite cells, neutrophils and macrophages.  For 
detailed staining procedure, see Appendix B.   
Image acquisition:  All imaging data were obtained by analysing two serial sections from 
each muscle sample, at each time point for each antibody.  Six or more fields of view per 
section were imaged using a fluorescence microscope (Nikon ECLIPSE E400; 40x objective 
used; actual enlargement thus 400x), equipped with a colour digital camera (Nikon 
DXM1200).   
Image analysis:  All pictures were overlayed using a computer software program, Simple PCI 
(version 4.0, Compix Inc., Imaging Systems, USA).  A standard way of identifying immune 
cells, is to enlarge photos and to enhance the color of the stain after importation into Simple 
PCI.  Simple PCI was used to acquire and overlay images, whereas Image J was used in 
addition to Simple PCI for quantify cytokine levels.  Note that the images presented here are 
only partial images of those taken at 400x.  All cytokine and immune cell staining were 
assessed in sections including border zones (areas right next to the severely injured areas, 
where muscle fibres are intact) and injured areas.  The threshold for all images were set to 
the same level throughout the experiment to enable comparisons of cytokine data over time 
and between groups.  Cytokine data were expressed as the relative fluorescence area 
containing either IL-6 or TNF-α per field of view in either the injured area or border zone 
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area.  Immune cell data were counted manually and expressed as the number of positively 
labeled immune cells per field of view (350 µm2) in both the injured and border zone areas.  
To ensure accurate counting of neutrophils, multilobular nuclei had to be present.  Satellite 
cell data were assessed in border zone areas and expressed as the number of satellite cells 
per myofibre.  In order for a cell to be classified a true satellite cell, it had to comply to a few 
criteria:  (a) Pax-7+ cells had to be in contact with the sarcolemma, (b) the satellite cell had to 
form an indentation into the muscle fibre, and (c) an elongated nucleus had to be present.  If 
one of these criteria were not present, the cell could not be classified a true SC. 
 
3.2.3.2  Flow cytometry 
Plasma from controls and animals subjected to contusion injury sacrificed at different time 
points (4 hr, 3 d, 7 d and 14 d) post-injury were analysed for IL-4, IL-6, IL-10, and TNF-α with 
a Cytometric Bead Array (CBA) Rat Flex Set kit from BD Biosciences according to the 
manufacturer’s instructions using a FACSArray Bioanalyser flow cytometer (see Appendix C 
for catalogue numbers of antibodies and kits used as well as for protocol specificity).  The 
CBA assay kit consisted of four types of beads (IL-4, IL-6, IL-10, and TNF-α), uniform in size, 
each of which measures the presence of cytokines in the sample.  Each bead population 
were given an alpha-numeric position indicating its position relative to other beads in the BD 
CBA Flex Set system, therefore, beads with different positions can be combined in assays to 
create a multiplex assay, such as in this study.  The four different capture beads in this study 
were pooled, diluted 50x and added to each well (50 µl/well).  Standards from each flex set 
were diluted with 4.0 ml of Assay Diluent (Top standard) and allowed to equilibrate for 15 min 
before making the following serial dilutions: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256.  
Fifty µl of each of the diluted standards, including a blank (assay diluent only), were added to 
the first 10 wells, whereas the rest of the wells were filled with different samples and allowed 
to incubate for 1 hr.  Four different capture antibodies, each of which were covalently coupled 
to each type of bead, were diluted 50x and added to each well (50 µl/well).  Each of these 
capture antibodies have different intensities of red-emitting fluorescence dye (PE) enabling 
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detection of cytokines.  After incubation for 2 hr, the fluid was aspirated and wash buffer was 
added to each assay well (150 µl/well).  The fluorescence measured was proportional to the 
cytokine concentration in the sample and was quantified from a calibration curve.  The 
detection limits for the cytokines used in this kit are: (a) 1.4 pg/ml for IL-6, (b) 27.7 pg/ml for 
TNF-α, (c) 3.4 pg/ml for IL-4 and (d) 19.4 pg/ml for IL-10. 
 
3.2.4  Statistics 
Values presented are means ± standard errors of the mean (SEM), unless otherwise 
specified.  Differences between time points and treatment groups were analysed using 
factorial analysis of variance (ANOVA).  When significant differences were found, Bonferroni 
or Fischer’s post hoc tests were done to identify specific differences.  All statistical analyses 
were done using Statistica version 9 (StatSoft Software). The accepted level of significance 
was p < 0.05.   
 
3.3  Results 
3.3.1  Satellite cell (Pax-7) 
Repeated measures analysis of variance indicated a significant effect of both time and 
treatment separately, and treatment and time (p < 0.001 for all 3).  After injury, similar to 
previous results (MSc thesis, Kruger 2007), an increase in SC number in the PLA group was 
seen at a much later time point (evident on day 7), compared to Pax-7 expression in the 
PCO group (4 hr after injury).  Pax-7 expression in both supplementation groups also 
returned to control levels by day 14.  Figures 3.4A-D visually display representative sections 
at points in time where the PLA and PCO groups were significantly different from one 
another, whilst Figure 3.4E illustrates the number of Pax-7+ SCs per myofibre at different 
time points and for different groups. The Pax-7+ nuclei can be described as elongated 
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compared to myonuclei and are situated in the satellite cell pocket.  A clear example of a 
Pax-7+ cell is indicated by the top yellow arrow in Figure 3.4C. 
 
 
 
 
 
 
Figure 3.4:  Pax7 staining in the PLA and PCO group at 4 hr (A&B) and day 7 (C&D) 
respectively.  FITC (green) was used to visualise Pax7, Texas Red (red) was used to 
visualise laminin and Hoechst (blue) was used as a nuclear marker.  Yellow arrows indicate 
true satellite cells, whereas white arrows indicate non-satellite cells.  Scale bar represents 10 
µm.  Pax-7+ satellite cells expressed per myofibre number (Pax-7+ SC/myofibre number) 
(means ± SD; E).  Statistical analysis: Factorial analysis of variance with Bonferroni post hoc 
test (* p<0.05, ** p<0.01, *** p<0.001). n = 4 rats per time point per group.   
 
3.3.2  Plasma pro- and anti-inflammatory cytokine expression 
ANOVA indicated a main effect of time for both pro-inflammatory cytokines assessed (TNF-α 
and IL-6; p < 0.05 for both), but this seemed to only be significant in the PLA group.  PCO 
cytokine levels remained unchanged throughout the protocol.  Post hoc tests indicated a  
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significant peak in both TNF-α and IL-6 levels in PLA group on day 7  (p < 0.05 vs. control, p 
< 0.01 vs. 4 hr) (Figure 3.5A&B).      
 
 
 
Figure 3.5:  Pro-inflammatory cytokine response to contusion injury, assessed by plasma 
levels of TNF-α (A) and IL-6 (B).  Statistical analysis:  Factorial analysis of variance 
(ANOVA) with Bonferroni post hoc test (* p < 0.05 and ** p < 0.01).  n = 8 rats per time point 
per group.   
 
A main effect of time was observed for the plasma anti-inflammatory cytokine, IL-10 (p < 
0.01), but again there was no ANOVA main effect of treatment.  Although levels of anti-
inflammatory cytokines in the PLA group were similar at all time points assessed, there was 
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a statistically significant increase in IL-10 (Figure 3.6) in the PCO group on day 3, at which 
point IL-10 were significantly higher than PLA (p < 0.01).  IL-4 values were all below the 
detection limit of the assay kit used and thus excluded. 
 
 
Figure 3.6:  Plasma anti-inflammatory cytokine, IL-10 response to contusion injury.  
Statistical analysis:  Factorial analysis of variance (ANOVA) with Bonferroni post hoc test (** 
p < 0.01, and *** p < 0.001).  n = 8 rats per time point per group. 
 
3.3.3  Muscle pro-inflammatory cytokine response 
Statistical analysis of the pro-inflammatory cytokine, TNF-α in the injured area and border 
zone indicated a main effect of treatment (p < 0.05 for the injured area and p < 0.001 for the 
border zone), as well as a main effect of time (p < 0.001 for both).  In the injured area, both 
treatment groups displayed an early elevation in TNF-α, 4 hr after injury, followed by a 
significant increase on day 3 and a subsequent decline thereafter (day 5) (Figure 3.7A).  On 
day 3, the time point at which both groups had peak TNF-α levels, the PCO group’s TNF-α 
was significantly lower.   In the border zone, TNF-α peaked in both groups on day 1, followed 
by a significant decrease (day 3), only seen in the PCO group over time (Figure 3.7B).  The 
TNF-α levels in the PLA group on the other hand remained elevated throughout the rest of 
the  protocol.  Representative images of day 3 in the injured area and day 1 in the border 
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zone area, which were significantly different between the two groups are displayed in Figures 
3.8A-D. 
 
 
Figure 3.7:  TNF-α (mean ± SEM) expressed as relative percentage fluorescence in the 
injured area (A) and border zone areas (B).  Statistical analysis:  Factorial analysis of 
variance (ANOVA), with Fisher’s post-hoc test demonstrating significance between the two 
specific data points (* p < 0.05, ** p < 0.01, *** p < 0.001). n = 4 rats per time point per group. 
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Figure 3.8:  TNF-α expression (green, FITC) in muscle samples taken at 3 d post-injury in 
the injured area of the PLA group (A), and the PCO group (B), and at 1 d post-injury in the 
border zone of the PLA group(C), and the PCO group (D).  Hoechst was used to visualise 
nuclei (blue).  All images displayed are enlargements of original pictures taken at 400x 
magnification.  Scale bar represents 10 µm. 
 
IL-6 also displayed a significant effect of time in both the injured area and border zone area 
(p < 0.001 for both), however, no effect of treatment was evident.  Similar to the results seen 
with TNF-α, IL-6 was significantly increased 4 hr after injury and continued to rise further 
untill day 3 in both groups in the injured area (Figure 3.9A).  However, IL-6 decreased earlier 
in the PCO group (day 5) compared to the PLA group (day 7).  In the border zone, although 
similar elevations were seen in IL-6 compared to that observed for TNF-α, IL-6 did not 
remain elevated after peaking on day 1 (Figure 3.9B).  Both treatment groups had a 
significant decrease in TNF-α on day 3 after injury, however, the PCO group had an even 
further decrease in IL-6 on the day 3 time point compared to the PLA group at that specific 
time point.  IL-6, in both the injured and border zone areas on day 3 are displayed in Figures 
3.10A-D.    
 
3.3.4  White blood cell response 
A main effect of treatment (p < 0.001),  time (p < 0.001) and treatment and time (p < 0.001) 
was evident for neutrophils in the injured area, whereas, a main effect of time (p < 0.001) and 
treatment and time (p < 0.05) was evident for neutrophils in the border zone. 
A B C D 
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Figure 3.9:  IL-6 (mean ± SEM) are expressed as relative percentage fluorescence in the 
injured area (A) and border zone areas (B).  Statistical analysis:  Factorial analysis of 
variance (ANOVA), with Fisher’s post-hoc test demonstrating significance between the two 
specific data points (* p < 0.05, ** p < 0.01, *** p < 0.001). n = 4 rats per time point per group.  
 
           
Figure 3.10:  IL-6 expression (red, Texas Red) in muscle samples taken at 3 d post-injury in 
the injured area of the PLA group (A), and the PCO group (B), and at 3 d post-injury in the 
border zone of the PLA group (C), and the PCO group (D).  Hoechst was used to visualise 
nuclei.  All images displayed are enlargements of original pictures taken at 400x 
magnification.  Scale bar represents 10 µm. 
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The neutrophil response in the PLA and PCO group was similar in both the injured area and 
border zone (Figures 3.11A and B respectively).  No neutrophils were present in the control 
samples (i.e. no injury).  At day 1 after injury, a neutrophil peak was evident in the PLA group 
(evident in both the injured area and border zone; p < 0.001), followed by a gradual 
decrease.  No elevation in neutrophils in the PCO group was evident.  The images displayed 
in Figures 3.12 A-H and I-P are images respresenting neutrophil expression at the 4 hr and 
day 1 time point of the injured and border zone areas respectively.    
 
.   
 
 
Figure 3.11:  Neutrophil infiltration in the injured area (A) and border zone area (B) of 
muscle are expressed as the number of neutrophils per field of view (means ± SEM) at 
baseline (control) and at 4 hr, day 1, 3, 5,  7 and 14 post-injury.  Statistical analysis:  
Factorial analysis of variance and Fisher’s post-hoc test (** p < 0.01; *** p<0.001).  n = 4 rats 
per time point per group.   
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Figure 3.12:  Neutrophil (His48) expression (green, FITC) and infiltration into the injured area (A-H) and border zone (I-P) of muscle, 4 hr post-injury 
(A, B and I, J indicates the PLA group; C, D and K, L indicates the PCO group) and on day 1 post-injury (E, F and M, N indicates the PLA group; G, 
H and O, P indicates the PCO group) respectively.  Images B, D, F, H, J, L, N and P are enlargements of the area surrounded by the white block of 
the figures on the left respectively.  Hoechst was used as nuclear dye.  Scale bar represents 10 µm, with the original magnification of 400x used for 
the image acquisition.   
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Analysis of macrophage infiltration into the injured and border zone areas indicated a main 
effect of treatment, time and treatment and time (p < 0.001 for all 3).  Significant macrophage 
infiltration is visible on days 3 and 5 in the PLA group, with resolution of inflammation shortly 
thereafter.  PCO supplementation on the other hand resulted in an earlier macrophage 
response in both the border zone (Figure 3.13B) and injured areas (Figure 3.13A).  
Significant differences between the 2 treatment groups were evident on day 1 and day 5 in 
the injured area, as well as in the border zone area.  Figure 3.14 indicates the time points, 
day 1 and 5, at which the 2 treatment groups differed significantly from one another in the 
border zone and injured area respectively.   
 
 
 
 
Figure 3.13:  Macrophage infiltration in the injured area (A) and border zone area (B) of 
muscle are expressed as the number of macrophages per field of view (means ± SEM) at 
baseline (control) and at various time points after injury.  Statistical analysis:  Factorial 
analysis of variance and Fisher’s post-hoc test (*** p<0.001).  n = 4 rats per time point per 
group.   
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Figure 3.13:  Macrophage (F4/80) expression (red, Texas Red) and infiltration into the injured area (A-H) and border zone (I-P) of muscle, on day 1 
post-injury (A, B and I, J indicates the PLA group; C, D and K, L indicates the PCO group) and on day 5 post-injury (E, F and M, N indicates the PLA 
group; G, H and O, P indicates the PCO group) respectively.  Images B, D, F, H, J, L, N and P are enlargements of the area surrounded by the white 
block of the figures on the left respectively.  Hoechst was used as nuclear dye.  Scale bar represents 10 µm, with the original magnification of 400x 
used for the image acquisition.   
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3.4  Discussion 
The main findings of this study were that chronic PCO supplementation (Oxiprovin™, 14 
days prior to and after injury) resulted in: (a) a much earlier increase in Pax-7 expression on 
satellite cells, (b) a significant circulatory anti-inflammatory response (IL-10) on day 3, (c) 
attenuated pro-inflammatory responses (IL-6 and TNF-α) both in circulation and locally 
(muscle and extracellular fluid) in the border zone, and also TNF-α in the injured area 
(including injured muscle and extracellular fluid).  There were some differences between IL-6 
and TNF-α responses which will be highlighted. An important novel result was the extremely 
small number of neutrophils that infiltrated the injured and border zone areas of muscles, 
whilst macrophage numbers were elevated significantly earlier and decreased relatively 
quicker than PLA, suggesting earlier resolution of inflammation. 
 
3.4.1  Pax-7 
Post-injury in placebo: Previously, it was demonstrated that a contusion injury resulted in 
satellite cell (CD34+ and CD56+) activation on day 3 followed by significantly elevated 
numbers on day 7 and a return to control levels on day 14 (MSc thesis, Kruger 2007).  In the 
current study, Pax-7 displayed a similar expression pattern compared to CD56, possibly 
indicating co-expression of these satellite cell markers during different stages of SC 
activation and proliferation following contusion injury.  The only difference observed was in 
the absolute count of satellite cells expressing the markers.  Fewer satellite cells expressed 
Pax-7 compared to SC counts obtained with other SC markers (CD34 and CD56) as seen in 
the previous study (MSc thesis, Kruger 2007).  However, it should be mentioned that CD56, 
as well as other SC markers, are not exclusive markers of SCs.  Therefore, using a SC 
marker in conjunction with a basal lamina marker is more accurate when counting SCs.  Pax-
7 in the current study was used in conjunction with laminin, a basal lamina marker, to ensure 
that only SCs (situated beneath the basal lamina) were counted. 
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In the PLA group, a slight increase in Pax-7 is evident at 4 hr and on day 3 after injury, 
although only reaching statistical significance by day 7 after injury.  During this time SC are 
activated and start to proliferate.  NO is synthesized by activated macrophages (Nguyen and 
Tidball 2003), and has been suggested as one of the activators of SCs (Ryten et al., 2002; 
Pisconti et al., 2006).  This raises the possibility that macrophage-derived NO may be 
involved in a bigger increase in SC Pax-7 expression on day 7 after injury in the PLA group, 
but this is unlikely since no elevation in the number of macrophages infiltrating the injured 
area was observed at that time (Figure 3.13).  However, there are other sources of NO.  
Inducible nitric oxide synthase (iNOS) is expressed in a wide variety of cell types, including 
myocytes (Riede et al., 1998) and myeloid cells (Tripathi et al., 2007), and is responsible for 
NO production.  Its activity is regulated at the transcriptional level by cytokines and by 
exposure of the cells to inflammatory stimuli (Nathan 1992).  iNOS expression is also 
mediated by the activation of the transcription factor NFκB (Brady et al., 1997).  It has been 
shown in a study by Fuchs et al. (2001), that TNF-α can activate the NFκB pathway, 
therefore increasing iNOS expression and the possibility for increased NO synthesis.  Also, 
in a study by Merly et al. (1999), it was suggested that IL-6, TNF-α and probably other 
inflammatory cytokines are associated with enhanced SC proliferation.  It is therefore 
possible that an increase in TNF-α and thus a secondary increase in NO might be possible 
candidates in causing elevated SC numbers through the NFκB pathway.  This latter 
explanation is very likely, given the peak in both IL-6 and TNF-α on day 7 in the PLA group 
(Figure 3.5), which coincided with the Pax-7 peak.  Since Pax-7 is a good marker labelling 
quiescent, activated and proliferating SCs, and is subsequently absent from differentiated 
myonuclei (Halevy et al., 2004; Olguin and Olwin 2004; Zammit et al., 2004), it was expected 
that MHCf (expressed during differentiation) expression would be increased following an 
increase in Pax-7 expression.  In a previous study, MHCf (see Figure 3.1) and Pax-7 
expression were both significantly elevated by day 7 (MSc thesis, Kruger 2007), indicating 
that Pax-7 is also expressed during differentiation of myoblasts, which is puzzling, since Pax-
7 expression should be downregulated just prior to differentiation.  However, since no 
analysis was done at an early time point between day 3 and day 7, such as day 5, it is not 
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known whether Pax-7 expression could have been even more elevated compared to day 7 
after injury.  Fourteen days after injury however, the Pax-7 levels in the PLA group had 
returned to control values indicating that the SCs had fused, and this coincided with a 
decrease in MHCf expression to levels higher than that of control levels.   
Post-injury in PCO: Increases in Pax-7 expression was evident earlier in the PCO group 
(already at 4 hr following injury), compared to the PLA group.  This could possibly indicate 
that PCO supplementation indirectly played a role in secreting cytokines, which could have 
mobilized more immune cells, specifically macrophages to migrate to the injured area, as a 
result of improved blood flow to the site of injury (Shi et al., 2003).  These immune cells could 
then potentially secrete other pro-inflammatory cytokines to attract more SCs to the injured 
area.  However, it should be noted that the muscle pro-inflammatory cytokines in the PCO 
supplemented group decreased faster and thus had a shorter duration compared to the 
cytokines in the PLA group, suggesting that the pro-inflammatory cytokines in the PCO group 
were more potent for a relatively short period of time.  Macrophage numbers were elevated 
by day 1 in the PCO group (Figure 3.13) in the current study, whereas local release of pro-
inflammatory cytokines, TNF-α and IL-6, was also significantly elevated on day 1 in the 
border zone, indicating that the abovementioned statement is a valid suggestion made here.  
However, peak Pax-7 expression preceded the cytokine peak, arguing against the 
abovementioned statement.  Since Pax-7 expression on day 1 after injury were not 
investigated, it is possible that Pax-7 expression could have been further elevated at this 
time point, so that the peak may in fact have occurred in line with the above interpretation.  
Hepatocyte growth factors (HGFs) are also able to activate SCs (Allen et al., 1995) and could 
have contributed to the increase in SC expression seen early on (4 hr) in the current study.  It 
has been shown that IL-6 expression stimulates proliferation of various cell types (Massimino 
et al., 1997), therefore IL-6 expression in this study in the injured area (Figure 3.9) could also 
potentially account for the increase seen in Pax-7 expression in the PCO group.  Another 
possibility might be that SCs may also be migrating into the injured area from healthy 
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surrounding tissue, although this is less likely, since the epimysium surrounding intact 
muscles is a barrier that prevents SC migration (Schultz et al., 1985; Schultz et al., 1986).   
By day 3, a significant decrease in Pax-7 expression was evident in the PCO goup.  In a 
study by various researchers (see Table 1.3, pg 27) it was found that IL-10 resulted in the 
inhibition of macrophage and neutrophil pro-inflammatory cytokine production (De Waal 
Malefyt et al., 1991; Fiorentino et al., 1991; Giannoudis et al., 2000), and thus may result in a 
decreased ability of attracting SCs to the injured area.  IL-10 in the current study was 
significantly elevated by day 3 in the PCO group, compared to a blunted pro-inflammatory 
cytokine response, indicating that PCO administration may have blunted or decreased pro-
inflammatory cytokine production at that specific time point (seen in this study), which could 
explain the reduction in Pax-7 expression seen at this time point.  By day 14, the PCO group 
had similar Pax-7 levels to that of controls indicating that SCs have fused and regeneration is 
almost complete. 
 
3.4.2  Cytokine release in circulation 
3.4.2.1  Pro-inflammatory cytokines 
From the literature it is known that skeletal muscle and various immune cells continuously 
produce cytokines at low levels (IL-6: ± 2 pg/ml and TNF-α: ±3.5 pg/ml) in order to maintain 
homeostasis and to regulate cell function (Lu et al., 2004).  These cytokines bind at the 
surface of the target cells and mainly alter cell function.  Changes in skeletal muscle fibre 
ultrastructure, as reported after eccentric exercise or injury (Malm et al., 2000), result in 
marked increases in the release of pro-inflammatory cytokines, of which IL-1β and TNF-α are 
mainly the focus in research reports.  The increase in circulatory IL-6 post-eccentric exercise-
induced damage or contusion injury has long been assumed to originate from the 
inflammatory cells infiltrating damaged skeletal muscle (Hellsten et al., 1997; Pedersen et al., 
2001).  However, it is also known that contracting muscle can produce and secrete relatively 
large amounts of IL-6 (Steensberg et al., 2000).  Therefore, although it is quite feasible that 
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inflammatory cells infiltrating the injured area prior to day 7 might be responsible for the 
increase in IL-6, one cannot rule out the possibility that muscle contraction during normal 
activity could also have contributed.  However, this interpretation does not explain the 
elevation seen in PLA plasma IL-6 on day 7, since the changes in everyday activity are too 
small to cause differences of this magnitude.  Also, rats in both the injured groups were 
handled and injured in exactly the same way, with no elevation in IL-6 in the PCO group.  A 
more likely explanation is that these cytokines are leukocyte-derived.   
Post injury in placebo:  In the current study the circulatory pro-inflammatory cytokines TNF-α 
and IL-6 were significantly elevated on day 7 after injury in the PLA group, compared to 
control values.  However, research regarding the systemic inflammatory cytokine response is 
conflicting in nature mainly due to the difference in the type of injury, as well as the severity 
of injury when the same model is used.  In a recent study, the bilateral femoral vessels in the 
lower limb of rats were ligated with microvascular clamps for 3 hr and then reperfused for 3 
hr in order to study ischemia/reperfusion injury (Shih et al., 2010).  In this particular study, 
circulatory IL-6 (probably mostly muscle-derived) increased almost 5-fold after injury 
compared to sham, whereas no significant difference in TNF-α was evident.  A possible 
explanation for only an increase in IL-6 and not TNF-α is that IL-6 down-regulates TNF-α 
levels (Caiozzo et al., 1996; Cai et al., 2000).  Ischemia/reperfusion injury is very different 
from contusion injuries, as it prevents the normal circulation of cytokines from the blood into 
the muscle, which is possibly why circulatory IL-6 in their study is more elevated, and also 
why circulatory IL-6 in the current study was approximately 10 times lower compared to their 
study.  However, due to the fact that muscle also produces IL-6 and TNF-α (see Table 1.3, 
Chapter 1), and the researchers did not investigate the contribution of pro-inflammatory 
cytokines from the muscle, it is not known whether muscle-derived cytokines could have 
leaked into circulation.  Also, since the researchers only investigated plasma cytokine levels 
on the day of injury (6 hr afterwards), it is likely that they missed the peak in TNF-α, since it is 
known that IL-6 is the earliest cytokine expressed after contraction-type injuries a couple of 
hr after injury (Febbraio and Pedersen 2005; Petersen and Pedersen 2005).  Although this is 
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a likely conclusion, other studies have shown elevated TNF-α levels early (2-6 hr) after injury 
(Warren et al., 2002; Vassilakopoulos et al., 2003).  TNF-α expression in sham rats was also 
relatively high, and even in the presence of injury, no significantly higher level of TNF-α was 
evident, suggesting that the elevated TNF-α levels (irrespective of injury), might be due to the 
invasive procedure prior to injury and not the injury itself.  On the other hand, in a study by 
Schmidtz et al. (2010), blunt trauma in mice resulted in no significant differences in TNF-α or 
IL-6 over time (3 hr, 24 hr, 36 hr, 48 hr and 72 hr).  The researchers argue that their model of 
blunt trauma might not have been severe enough to result in changes in circulating 
cytokines.  However, it could also be argued that their model of injury was severe enough or 
even more severe than the current model - 20 g from a height of 120 cm in mice.  It has also 
been suggested that the TNF-α response coincides with inflammatory cell infiltration, 
predominantly macrophages (Ralph et al., 1983), which occurs only at later time points than 
those assessed in the study by Schmidtz et al. (2010).  Therefore, if later time points were 
assessed, they might have seen significant differences in TNF-α.  In the current study, 
macrophage infiltration in the PLA group preceded circulatory TNF-α release (see Figure 
3.5), suggesting that local TNF-α production rather than circulatory cytokine production might 
be involved in attracting more macrophages to the injured area.  Furthermore, it should also 
be noted that immune cells also produce inflammatory cytokines (see Table 1.3), allowing for 
the possibility that relatively high macrophage counts on day 3 and 5 in the muscle may have 
been responsible for the systemic increase in cytokines on day 7.  Already mentioned in the 
Pax-7 section, it has been suggested that TNF-α expression is associated with enhanced SC 
activation and proliferation (Merly et al., 1999), which is a likely possibility, since SC 
activation and circulatory TNF-α release in this study coincided (day 7 in both).    
Post injury in PCO:  In order to test the effectiveness of chronic PCO supplementation in 
blunting the inflammatory response, rats were supplemented prior to and after contusion 
injury.  The few studies addressing the role of antioxidants in strenuous exercise-induced 
cytokine production in humans were not able to show significant effects, although a tendency 
for a blunted IL-6 response was reported after vitamin C supplementation (Nieman et al., 
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2000; Petersen et al., 2001).  Treatment with a combination of vitamins C and E (29 days), 
followed by 3 hr of dynamic two-legged knee extensor exercise and 3 hr of recovery, 
inhibited IL-6 release into circulation and mRNA expression in contracting muscle (Fischer et 
al., 2004).  Similarly, in the current study, 2 weeks of PCO supplementation also resulted in 
significantly decreased IL-6 levels both in circulation and in muscle.  Pre-treatment with 
vitamin D3 for 5 days prior to bilateral femoral artery occlusion for 3 hr, followed by 3 hr 
reperfusion, also resulted in a marked decrease in IL-6 after injury, with no effect on TNF-α.  
This is not surprising, since it is known that IL-6, rather than TNF-α, is considered to be an 
early phase indicator of inflammation (Shih et al., 2010).  However, it should be noted that in 
the presence or absence of vitamin D3, with or without injury, TNF-α was already elevated, 
indicating that vitamin D3 had no effect on TNF-α levels.  In a study by Vassilakopoulos et al. 
(2003), a combination of antioxidants (vitamin A, C, E, N-acetylcysteine (NAC) for 60 days) 
after 45 min of cycling, resulted in plasma IL-1β to be undetectable, and the TNF-α and the 
IL-6 responses to be blunted compared to PLA, suggesting that a combination of antioxidant 
vitamins might be more promising.  The antioxidant supplementation blunted but did not 
completely abolish the cytokine response to exercise, and this effect is most likely as a result 
of the combined effect of the antioxidants used in their study (Vassilakopoulos et al., 2003).  
However, increased cytokine clearance cannot be ruled out since a complex relationship 
between cytokine production and clearance is known to determine the concentration of 
cytokines, and the effect of oxidative stress on cytokine clearance is largely unknown.  In 
another study, Yamashita et al. (1999), an acute bout of treadmill exercise increased the 
TNF-α and IL-1β content of the myocardium, whereas in the presence of the antioxidant N-2-
mercaptoproprionyl glycine, no increase in either cytokine was observed, because of 
abolishment of ROS production.  Similar to the abovementioned studies, the current study 
also provided evidence that the antioxidant Oxiprovin™ played a significant role in blunting 
the pro-inflammatory cytokine response in the circulation. 
Possible mechanisms whereby antioxidants might exert beneficial effects have been 
investigated to some extent.  For example, resveratrol, an antioxidant found in grapes, was 
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able to suppress rat carrageenan-induced paw oedema (Jang et al., 1997) by the selective 
inhibition of cyclooxygenase (COX)-1, via impairment of prostaglandin (PG) synthesis.  
Furthermore, in an in vitro study by Subbaramaiah et al. (1998) using human mammary and 
oral epithelial cells, it was reported that resveratrol was also able to inhibit protein kinase C 
(PKC) translocation and the enhancement of COX-2 promoter activity (mediated by PKC) 
through extracellular signal-regulated kinase-1 (ERK-1), and c-Jun (Lee and Lin 1997).  Also, 
when resveratrol was administered to murine peritioneal macrophages (stimulated by 
lipopolysaccharides (LPS) or phorbol myristate acetate (PMA), it suppressed the production 
of O2- and hydrogen peroxide (H2O2), impairing arachidonic acid (AA) mobilization, COX-2 
overexpression, and subsequently PGE2 release, indicating that antioxidants found in grapes 
might work through the AA and mitogen activating protein kinase (MAPK) pathways 
specifically (Martinez et al. 2000).  Similar macrophage stimulation studies (in vitro) were 
also done with vitamin E (Hempel et al., 1994; Rao et al., 1994; Tetsuka et al., 1996; Davi et 
al., 1997) and showed similar results.  In future studies, one should investigate whether the 
PCO, Oxiprovin™, is able to inhibit or suppress certain upstream targets involved in the AA, 
MAPK or NFκB pathway in order to determine whether PCO also has the same effect as 
those seen in the studies mentioned above. 
Inflammatory cytokines (specifically IL-6 and IL-1β), injury, and oxidative stress can activate 
NFκB (Schreck et al., 1992) via the phosphorylation and release of the inhibitory subunit 
(IκB) from NFκB in the cytoplasm, rendering NFκB inactive.  This pathway is one of the most 
important ones in the inflammatory process, and is usually activated when oxidant production 
(ROS) overwhelms the antioxidant system, resulting in oxidative stress.  A potential 
mechanism through which oxidant production can increase with inflammation and thus 
contribute to skeletal muscle atrophy or damage and weakness is iNOS, possibly activated 
by NFκB (Kondo 2000).  Due to the fact that PCO supplementation in the current study 
resulted in a reduction in TNF-α and IL-6 in muscle, it is quite possible that this supplement’s 
mechanism of action is by blunting NFκB or some of the upstream targets involved in this 
specific pathway.  In a study by Nakao et al. (2000), it was demonstrated that the free radical 
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scavenger pyrrolidine dithiocarbamate (PDTC) inhibited NFκB activation, after inhibiting 
tyrosine kinase phoshorylation in the Janus activating protein kinase/signal transducer and 
activator transcription protein (JAK/STAT) pathway in human gingival fibroblasts, and 
subsequently reduced PGE2 production.  This suggests that other antioxidants, such as 
PCO in the current study, might also result in a blunted inflammatory cytokine response, 
which subsequently blunts/inhibits NFκB activation and thus COX-2 activation and PGE2 
production.   
In a study by Aronson et al. (1998), it was demonstrated that injury to skeletal muscle of 
human subjects, either by needle biopsy or surgical open muscle biopsy, resulted in the 
activation of multiple components in the MAPK signalling cascade (Raf-1/MEK-1/ERK/RSK) 
and increased the activity of both c-Jun NH2-terminal protein kinase (JNK) and p38, possibly 
as a result of an increased TNF-α expression.  However, the MAPK pathway and its 
downstream targets have not been studied as extensively as the NFκB and AA pathway after 
an injury.  Thus, since its known that TNF-α and IL-6 can result in MAPK activation (Baud 
and Karin 2001), it’s quite possible that PCO also inhibits the MAPK pathways as a result of 
TNF-α and IL-6 inhibition.  Therefore, applying standard western blotting techniques one can 
test whether PCO supplementation prior to and following injury, influenced the various 
components of the MAPK pathway.   
 
3.4.2.2  Anti-inflammatory cytokines 
Post-injury in placebo:  Most studies on the effects of mechanical trauma on circulating 
cytokine profiles do not include anti-inflammatory cytokines in the assessment panel.  Only 
two studies investigated anti-inflammatory cytokines.  In the study by Schmitz et al. (2010), 
although the anti-inflammatory cytokine IL-10 was measured, no data were displayed as it 
was below the detection limit (17.5 pg/ml) for both uninjured and injured mice.  This might 
indicate that the injury in their study was not severe enough, however, their injury was more 
severe than the injury used in the current study.  Another possibility might be that the assay 
kits used to analyse IL-10 were not sensitive enough, however, the assay kit in the current 
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study was less sensitive.  Their study is not considered an optimal study for comparison, 
since the increased TNF-α, seen even in the sham group (discussed in the previous section), 
indicates that their model is pro-inflammatory in nature and could have accounted for 
undetectable IL-10.  In another study in mice, elevated serum levels of IL-10 were found after 
fracture-associated soft tissue injury (Kobbe et al., 2008).  However, in their study, both 
upper legs were injured, the bone was fractured and the mass-drop protocol more severe.  
The severity of injury could have played a role in the expression pattern of anti-inflammatory 
cytokines.  In the current study, the injury was much less severe than that of Kobbe et al. 
(2008).  It is not surprising that in this particular study, the anti-inflammatory cytokine IL-10 in 
the PLA group was unchanged over time.  Another possibility might be that IL-10 levels in the 
PLA group never increase, because it is secreted and works locally, and therefore never 
clears into the circulation.  However, this suggestion is unlikely, given the increased IL-10 
seen in the PCO group.  
Post-injury in PCO:  In the PCO group, an elevation in circulatory IL-10 level was evident on 
day 3 after injury, indicating that PCO has a primary or secondary anti-inflammatory property 
and aids the recovery process by resulting in increased anti-inflammatory actions.  It is 
known that M2 macrophages are primarily responsible for IL-10 expression (Asadullah et al., 
2003).  Therefore, it is likely that PCO elevated M2 macrophage levels in the injured area 
and border zone earlier when compared to PLA, accounting for increased circulatory IL-10 
expression on day 3.  However, the different subpopulations and their contribution towards 
muscle recovery were not investigated in this particular study.  
The mechanism of IL-10 action is widely accepted to be inhibition of the expression of pro-
inflammatory cytokine genes, as well as inhibition of the production of granulocyte 
macrophage colony stimulating factor (GM-CSF), granulocyte colonly stimulating factor (G-
CSF), macrophage colony stimulating factor (M-CSF) and platelet activating factor (PAF) 
produced by activated monocytes/macrophages (De Waal Malefyt et al., 1991; Fiorentino et 
al., 1991; D’Andrea et al., 1993; de Waal Malefyt et al., 1993; Gruber et al., 1994).  These 
inhibitory effects of IL-10 are thought to be crucial and may reduce the responses of the pro-
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inflammatory cytokines, as seen in the current study.  One of the best characterized IL-10 
signalling pathways is the JAK/STAT system (Shimodo and al 1996; Takeda et al., 1996).  
IL-10 induces tyrosine phosphorylation and activation of the transcription factors STAT3 and 
STAT1 (Finbloom and Winestock 1995; Lai et al., 1996; Weber-Nordt et al., 1996; Wehinger 
et al., 1996).  STAT3 is recruited directly to the IL-10/IL-10R complex via either of the two 
tyrosine residues in the IL-10R1 cytoplasmic domain that become phosphorylated in 
response to IL-10 (Weber-Nordt et al., 1996) and is required for IL-10 signalling (Ho et al., 
1995; O’Farrell et al., 1998; Riley et al., 1999).  It has also been demonstrated that IL-10 is 
able to inhibit macrophage activation, as well as NFκB activation in response to stimuli in 
vitro (Wang et al., 1995; Clarke et al., 1998; Ehrlich et al., 1998; Schottelius et al., 1999), the 
latter in two different ways: either by inhibiting activation of IκB kinase (Yin et al., 1998), or by 
inhibiting NFkB DNA binding activity (Schottelius et al., 1999), although, the latter 
mechanism is not properly understood.  It should be mentioned that the majority of studies 
investigating the role of IL-10 have been done in vitro using monocytes/macrophages, T 
cells, and B cells, which would exclude the possibility of involvement of other signalling 
pathways, so results may not be directly applicable to an in vivo situation.  Since satellite 
cells are also involved in this particular in vivo model, it is not clear which pathway might be 
activated, or whether the same pathways are involved when PCO is administered.  Although 
SCs themselves do not secrete IL-10, the pathways mentioned above are also involved here.  
From this section, it is evident that PCO can also be considered to be an effective anti-
inflammatory supplement, since it is able to increase anti-inflammatory cytokines, whilst 
blunting pro-inflammatory cytokines. 
  
3.4.3  Cytokine levels in muscle 
In the current model of contusion injury, IL-6 and TNF-α had similar patterns in the injured 
area in the PLA group, but different in the border zone.  Only one previous study has 
investigated muscle pro-inflammatory cytokine levels after a invasive contusion injury (Bunn 
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et al., 2004).  In Bunn et al.’s study, mild contusion injury (100g from a height of 13 cm) 
resulted in an increase in pro-inflammatory cytokines on day 4, whilst moderate injury (200 g 
from a height of 13 cm) resulted in an even later peak – on day 8 (Bunn et al., 2004).  TNF-α 
and IL-6 in the PLA group in the current study (200 g from a height of 50 cm) peaked on day 
3 (injured area) and day 1 (border zone) respectively, although being elevated already 4 hr 
after injury in the injured area.  However, although the current results deviates from that of 
Bunn et al. (2004), there are many differences between the 2 studies that may account for 
inconsistencies.  Firstly, the effect of cytokine release as a result of invasiveness of the 
intervention (removing skin from muscle and incisions into the muscle) was not quantified in 
the earlier study, while the current study was non-invasive.  Secondly, the study by Bunn et 
al. (2004) was done in mice, and this study used rats.  From Bunn’s study, it is possible that 
with bigger injuries, inflammatory cytokine release is sustained longer.  It has also been 
suggested that if the centre of the injured area lies too far from an intact blood supply, it will 
result in a delayed release of cytokines from the blood into tissue and thus delayed 
progression of inflammation (Bunn et al., 2004).  This may be true in the current study, since 
the increase/changes in cytokine expression in the border zone occurred earlier compared to 
the injured area.         
In a freeze-injury study by Warren et al. (2002), the time courses were similar for IL-6 and 
TNF-α mRNA expression in the tibialis anterior (TA) muscle post-injury.  In their study, an 
increase in TNF-α mRNA expression occurred within 5 hr following injury and peaked at 24 
hr after injury, followed by a gradual decline from days 3-7 and a return to control levels by 
day 13.  mRNA levels were measured to assess the cytokine response in the study by 
Warren et al. (2002), while protein levels were measured in the current study.  Results 
indicate that for IL-6 release in the border zone, the protein levels correspond to mRNA 
levels observed in Warren et al.’s study.  On day 1, IL-6 levels in the PLA group were at their 
highest, at a point in time when neutrophils are the predominant immune cell infiltrate in the 
injured area, suggesting that neutrophils in both the injured area and border zone were the 
source of the elevated IL-6 levels in the muscle.  In a study by Kami and Senba (1998), it 
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was found that IL-6 expression in injured muscle does not increase SC proliferation.  
However, although in the PLA group, an increase in Pax-7 SCs was only observed on day 7 
– a point in time when IL-6 expression was already decreasing (in both the injured area and 
border zone) – the possibility that IL-6 is responsible for SC activation cannot be ruled out, 
since increases in  Pax-7 expression and elevations in muscle IL-6 levels in the PCO group 
coincided. 
TNF-α (in the border zone) of PLA displayed a somewhat similar pattern, also peaking on 
day 1, but in this case, TNF-α levels were still significantly elevated up to day 14.  A likely 
reason for this sustained elevated TNF-α level is the possibility that TNF-α could have 
circulated in from blood, given the increased TNF-α in the plasma on day 7 after injury.  
Another possibility could be the production of cytokines by immune cells at different time 
points after injury.  Collins and Grounds (2001) observed the presence of increased TNF-α in 
the TA muscle following crush or autograph (stretch injury until muscle failure), localized to 
inflammatory cells as well as atrophic muscle fibres.  During the early time points after injury 
in the current study, a high number of immune cells were evident in the injured area, 
therefore it is not surprising that cytokine expression is at its highest on day 1 and day 3 after 
injury, points in time when neutrophils and macrophages respectively infiltrated the injured 
area maximally.     
In the injured area, TNF-α and IL-6 displayed similar inflammation resolution patterns, and 
even though both IL-6 and TNF-α were expressed early in the PLA groups (4 hr), only TNF-α 
expression was further increased by day 3.  Determining the effect of PCO supplementation 
on muscle cytokines after injury indicated that PCO was also effective in blunting the 
inflammatory response in the muscle, similar to that seen for plasma cytokines.  
To determine the mechanisms responsible for the increases in IL-6 and TNF-α production in 
skeletal muscle following exposure to ROS-quenching agents (PCO), it is necessary to 
investigate signalling pathways and downstream targets involved.  The three main pathways 
involved after injury, as already discussed in the section on circulatory cytokines, are the 
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NFκB, AA and the MAPK pathways.  However, since a variety of other cells could have 
contributed to the increases in inflammatory cytokines, such as SCs, macrophages, 
neutrophils, etc., different inflammatory pathways might be activated in different cell types in 
response to different treatment regimes.   
Of interest, in the current study, when assessing muscle IL-6 and TNF-α expression by 
means of immunohistochemistry (qualitatively), these cytokines seemed to be localized 
predominantly within inflammatory cells at the early time points (1 day and 3 days post-
injury), similar to the observations made by Warren et al. (2002).  However, on days 5 and 7, 
inflammatory cytokine levels were decreased in white blood cells, while in the regenerating 
myofibers, slight cytoplasmic staining and staining around the borders appeared. 
 
3.4.4  Immune cell infiltration into the injured area 
Immune cell infiltration have been studied extensively in various models of injury, which 
include stretch (St. Pierre Schneider et al., 2002), hindlimb-suspension (Tidball et al., 1999; 
Frenette and Tidball 2000; Frenette et al., 2002), exercise (Fielding et al., 1993), downhill 
running (Tsivitse et al., 2003), Achilles tendon injury (Marsolais et al., 2001) and cardiotoxin-
injury (Sun et al., 2009).  However, very little is known regarding the effect and specific time 
frame of immune cell infiltration after a contusion injury.  The only study regarding immune 
cell infiltration after contusion injury was performed by Thorsson et al. (1998), who assessed 
whether neutrophils were present after injury, but no actual cell counts were performed.  
Neutrophil numbers peak predominantly on day 1 after injury, followed by resolution of 
inflammation roughly on day 2-5.  However, time points at which neutrophils start to infiltrate 
the injured area and resolution of inflammation differ when different injury models are used.  
For example, after excessive and invasive non-physiological stretch injury in rabbits, 
neutrophils were already evident 4 hr after injury and undetectable 48-72 hr later (St. Pierre 
Schneider et al., 2002).  In contrast, after exercise (in men) and Achilles tendon injury (in 
rats), neutrophils were still elevated for up to 5 days after injury (Fielding et al., 1993; 
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Marsolais et al., 2001).  In the current study, 4 hr after contusion injury, a large number of 
neutrophils were evident in the injured area of the PLA group, and also to a lesser extend in 
the border zone, adjacent to the injured area.  On day 1 after injury, a 30-fold increase is 
evident in the injured area, whereas the neutrophils in the border zone increased only 10-
fold, a point in time corresponding to maximal neutrophil numbers similar to all studies 
mentioned.  In most studies mentioned, the results only mentioned the most predominant 
increase in neutrophils on day 1, without actually quantifying it.  The big difference in 
neutrophil numbers between the border zone and injured area in the current study can 
predominantly be attributed to the fact that injury was more severe in the injured area 
compared to the border zone.   A minor contribution might be attributed to vascular disruption 
which is evident in the injured area, allowing free flow of red blood cells and immune cells 
into the injured area, compared to less or no vascular disruption in the border zone.  Also, 
similar to the previous studies mentioned, in the current study in the PLA group, increased 
neutrophils were still evident on day 3 after injury, but significantly lower, indicating resolution 
of inflammation, with no detectable neutrophils on day 5.     
On the other hand, in this study, macrophages started to infiltrate the injured area roughly 4 
hr to day 1 after injury, peaking on day 3, a point in time when the number of neutrophils 
started to decrease.  At day 5 after injury, macrophage numbers were still significantly 
elevated and only started to decrease on day 7 onwards.  In contrast to this study’s findings, 
almost no detectable macrophage levels were evident in the study by St Pierre Schneider et 
al. (2002) on stretch injury, assessing time points 4 hr, 24 hr, 48 hr and 72 hr post-injury.  
However, the antibody used to identify macrophages in that study does not bind to any 
peripheral blood cells, including monocytes and granulocytes, and is therefore not ideal for 
identification of all macrophages in skeletal muscle after injury (St. Pierre Schneider et al., 
2002).  Also, with stretch injury, the basal lamina is usually not disrupted and might not have 
the need for macrophages to infiltrate the injured area, since damage was not as excessive 
as with other injury types.  In agreement with this study’s data, in the contusion injury study 
by Thorsson et al. (1998), macrophages were still numerous at Day 6, but they too had 
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disappeared by Day 11.  However, again this phenomenon was only qualitatively assessed.  
In the current study, the co-localisation of both local pro-inflammatory cytokines (IL-6 and 
TNF-α in the injured area) and macrophages were evident on day 3 after injury, indicating 
macrophages as predominant cytokine source.   
With PCO treatment, almost no neutrophils were detected in the border zone or injured area, 
indicating that at least one mechanism of PCO is the blunting of neutrophil infiltration into the 
injured area.  It is known that PCO binds to collagen, thereby strengthening the vasculature, 
especially capillaries (Teixeira 2002).  It is possible that in the current study, there is a 
decrease in hypoxia as a result of a strengthened vasculature and therefore a decrease in 
damage.  Also, a lower number of neutrophils infiltrated the injured area, since damage of 
the vasculature results in a free flow of immune cells into the injured area, which although 
excessive, is short of duration.  This is corroborated in previous experiments, where 
haematoxylin and eosin (H&E) stains indicated less vascular disruption in the PCO group 
(MSc thesis, Kruger 2007).  It is also possible that PCO supplementation resulted in better 
suppression of cell surface or chemoattractive proteins (chemokines) for neutrophil migration 
to the injured area.  In support of this, Sato et al. (1996) illustrated that the antioxidants NAC 
or 2-oxothiazolidine-4-carboxylate (OTC) inhibited the TNF-α-mediated stimulation of 
chemokine expression, critical for neutrophil migration (IL-8 and monocyte chemoattractant 
protein (MCP)-1).  This therefore suggests that PCO’s effect of limiting the number of 
neutrophils infiltrating the injured and border zone area on day 1 might have occurred via its 
blunting of plasma pro-inflammatory cytokines IL-6 and TNF-α.  Alternatively, there may not 
be an inhibition of the neutrophil response, and PCO could increase the activity of individual 
neutrophils, thereby allowing fewer neutrophils to infiltrate the injured area, ultimately having 
a greater effect.  This latter hypothesis was also tested and will be discussed in Chapter 5, 
where the aim was to identify why fewer neutrophils infiltrate the injured area after PCO 
supplementation.   
Macrophages infiltrated the different muscle areas earlier in PCO, indicating that Oxiprovin™ 
accelerated the macrophage response (day 1 vs day 3 and 5 in the PLA group).  The 
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macrophage response in the PCO group also coincided with the cytokine patterns. Two 
distinct subpopulations of macrophages are known to invade injured muscle tissue at 
different time points after injury (Chazaud et al., 2009; Tidball and Villalta 2010).  The early 
invading macrophages, M1, have been shown to reach maximal numbers in damaged 
muscle at about 24 hr after the onset of injury and then rapidly decline (Chazaud et al., 2009; 
Tidball and Villalta 2010).  These inflammatory macrophages secrete pro-inflammatory 
cytokines, such as TNF-α and IL-1β, and are responsible for the phagocytosis of necrotic 
tissue (Chazaud et al., 2009; Tidball and Villalta 2010).  The second population of 
macrophages, M2, possibly derived from inflammatory macrophages by phenotype switch, 
reach their peak at 2 to 4 days after injury (Chazaud et al., 2009; Tidball and Villalta 2010).  
These macrophages secrete anti-inflammatory cytokines, such as IL-10, that contribute to 
the termination of inflammation and thus muscle regeneration (Chazaud et al., 2009; Tidball 
and Villalta 2010).  In the current study, the appearance of macrophages in the border zone 
and injured area in the PCO group coincided with the increases in pro-inflammatory 
cytokines in the border zone.  Also, on day 3 after injury, the macrophage population in the 
injured area and border zone were still high, coinciding with increased circulatory anti-
inflammatory cytokine, IL-10.  Although the different subtypes of macrophages were not 
characterized, current macrophage infiltration and cytokine time courses suggest that chronic 
PCO supplementation can result in an earlier macrophage phenotype switch in favour of an 
M2 response following injury. 
 
3.5  Conclusion and directions for future research 
The results obtained in this study indicate that (a) the earlier satellite cell activation response, 
and (b) the changed inflammatory response in favour of (c) a blunted neutrophil response 
and (d) an anti-inflammatory reaction are the result of chronic PCO supplementation.  This 
study also highlights the importance of illuminating the precise mechanism of action of anti-
oxidants such as PCO in Oxiprovin™.  From the literature it is known that IL-6 and TNF-α are 
important activators of three main inflammatory pathways, namely NFκB, AA or MAPK.  
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Since PCO significantly blunts the pro-inflammatory response, it therefore suggests that PCO 
might function by blunting or completely inhibiting one or all of these signalling pathways.  
Assessment of the anti-inflammatory cytokines (IL-4 and IL-10) in the muscle, as done in the 
plasma, could have provided a better indication of what anti-inflammatory processes occur 
within the muscle.  Also, the two macrophage subtypes, M1 and M2, were not determined 
which could have provided for a better interpretation of the data (one of the focus points in 
Chapter 5).  Considering the positive effects of chronic PCO supplementation, it is also of 
particular interest to note whether acute supplementation might have similar effects, which is 
the focus of the next chapter.      
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CHAPTER 4 
 
Effect of acute proanthocyanidolic oligomer (PCO) supplementation 
on muscle recovery and the inflammatory response to contusion 
injury in rats 
 
4.1  Introduction 
Various therapeutic interventions exist for treating muscle after injury.  Currently, all of these 
treatments are directed to the restoration of full skeletal muscle function, augmenting normal 
repair and regeneration processes and limiting inflammation and muscle fibrosis to reduce 
scar formation.  The basic biological processes which occur during the healing of muscle are 
similar, irrespective of the underlying cause of the injury (Hurme et al., 1991a; Kalimo et al., 
1997).  However, differences may occur, since the severity of injury plays a predominant role 
in determining the magnitude and possibly onset and/or duration of these phases (Bunn et 
al., 2004).  This suggests that timing of first treatment, will play an important role in 
determining the best treatment options for muscle following injuries of different severities.   
For example, actively using the injured muscle after a short but adequate period of rest (hr), 
results in faster disappearance of haematoma and inflammatory cells, followed by a more 
rapid and organized myofiber regeneration (Lehto et al., 1985; Jarvinen and Lehto 1993).  
However, premature mobilisation of the injured leg can have detrimental outcomes and may 
result in increased scar formation and increased potential for re-injury of the muscle 
(Jarvinen and Lehto 1993).   
Other non-invasive strategies are often used in combination.  Rest in combination with 
elevation may decrease the accumulation of blood in the injured limb, thus reducing swelling 
and pain (Zhang et al., 2001).  The combination of ice and compression limits bleeding, 
reduces pain and facilitates healing and thus faster return to the sports field, while 
121 
 
compression alone does not seem to have any significant effect (Levy and Marmar 1993).  
Ice is usually applied 2 to 4 times per day, starting on the day of the injury (Olson and 
Stravino 1972; McMaster and Liddle 1980; Kellet 1986; Meeusen and Lievens 1986; Grana 
1993; Ernst and Fialka 1994).  What is also important is that understanding the basic 
principles of muscle healing and the physiological or biochemical effect of the treatment, will 
allow for more informed choices. 
Ice applied immediately post-injury reduces metabolism and bleeding, which decreases 
neutrophil infiltration and minimizes secondary hypoxic injury (Knight 1989; Knight et al., 
2000; Deal et al., 2002).  However, if  one lowers the temperature of the muscle below 25 °C, 
it can dilate blood vessels, which increases hemorrhage and exacerbates the inflammatory 
response (Kellet 1986; Meeusen and Lievens 1986). 
Hyperbaric oxygen therapy (HBOT) has been shown, in in vivo and in vitro studies, to be an 
effective treatment for different forms of exercise-related damage, reducing oedema, 
enhancing oxygen delivery and inactivating white cell adhesion (Nylander et al., 1985; Thom 
et al., 1994; Staples et al., 1995; Hills 1999).  However, it does not seem to be effective after 
muscle crush or contusion injury (Nelson et al., 1994; Thorsson et al., 1997), possibly due to 
the fact that blood flow is too severely disrupted, thus limiting oxygen delivery to the injured 
tissue early after injury.  Stem cell therapy has also been shown to be potentially effective 
after various types of muscle injury (Singec et al., 2007), but more research is needed to 
determine these beneficial effects. 
Although short-term corticosteroid usage is known to benefit muscle regeneration (Beiner et 
al., 1999), long-term use may increase the initial inflammatory reaction even further and may 
inhibit the healing process later on, resulting in exacerbation of tissue injury.  Non-steroidal 
anti-inflammatory drugs (NSAIDs) are commonly used after sports-related injuries, and are 
prescribed by clinicians quite often for their analgesic purposes rather than for enhanced 
healing, as the evidence to support the latter remains limited (Ong et al., 2007; Xian and 
Zhou 2009).  The most common clinical approach is to start treatment two days after injury, 
122 
 
when swelling caused by inflammation results in pain, and to continue treatment for up to 7 
days (personal communication:  Dr Pierre Viviers, Stellenbosch University Sport 
Performance Institute, SUSPI).  Although this regime results in a decreased inflammatory 
response (decreased neutrophil and macrophage infiltration) and alleviation of pain and 
swelling, it may also delay muscle regeneration (Jarvinen et al., 1992; Mishra et al., 1995).  
Research using small animals and in vitro models, have shown that short-term NSAID 
treatment during the early repair phase (1-3 days) may result in the reduction of inflammatory 
symptoms (swelling and pain) (Tidball and Wehling-Henricks 2007), which suggests that if 
treated earlier (as soon as possible after injury) but for a much shorter period (discontinued 
after two days), it could potentially limit the side-effects of the treatment (e.g. bleeding 
complications – personal communication:  Dr Pierre Viviers, SUSPI).   
Therapeutic ultrasound is another treatment option, usually started a couple of hr after injury, 
and done for a couple of minutes each day (Rantanen et al., 1999; Wilkin et al., 2004).  
Ultrasound on its own normally does not have any beneficial effect on skeletal muscle 
regeneration (Wilkin et al., 2004; Silveira et al., 2010).  However, if administered in 
combination with antioxidants (dimethylsulfoxide – DMSO), it effectively reduces the 
presence of muscle damage (creatine kinase – CK and acid phosphatase), oxidative stress 
(superoxide anion, lipid peroxidation and protein carbonyls production) and possibly 
secondary damage after injury (Silveira et al., 2010).  Most ultrasound studies however 
assessed sub-optimal markers for determining muscle regeneration, so that the effectiveness 
of this therapy is largely based on clinical observations of parameters such as decreased 
pain, which is not necessarily indicative of recovery.   
Upon muscle injury, cells are continuously attacked by reactive oxygen species (ROS), which 
arise as natural byproducts of metabolic processes – this occurs no matter what type of 
injury.  Normally, most of these ROS produced are neutralized by natural antioxidant 
defences such as glutathione peroxidase and catalase (Rice-Evans et al., 1995; Basu 1999).  
However, in situations where ROS production is increased, e.g. after injury or any type of 
“hyper” inflammatory response, these natural antioxidants are often not enough to neutralise 
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the free radicals generated (Bowles et al., 1991).  Despite the increase in clinical use of 
antioxidants and the interest in nutrition for treatment of muscle injuries, only a limited 
number of studies have focussed on antioxidant treatment of muscle injury in otherwise 
healthy individuals.   
The most comprehensively researched antioxidants in exercising subjects are the vitamins C 
and E.  Chronic supplementation with vitamin C, has improved muscle recovery (speed of 
recovery of muscle contraction and a decrease in muscle soreness), and decreased plasma 
interleukin (IL)-6, 2 hr after injury (Kaminski and Boal 1992; Jakeman and Maxwell 1993; 
Thompson et al., 2001b), whereas acute treatment had no effect on various measures of 
antioxidant status and damage (plasma CK, myoglobin, malondialdehyde and IL-6) 
(Thompson et al., 2003), despite increasing plasma concentrations of vitamin C (Thompson 
et al., 2001a).  Acute oral vitamin E supplementation yielded variable results: protection was 
reported after downhill-running (Meydani et al., 1993), but no effect after plyometric 
contractions (Van der Meulen et al., 1997).  From these studies, vitamins may have positive 
effects when consumed as a chronic supplement, but short-term supplementation may not 
be sufficient enough to allow for a beneficial effect on recovery.   
Most often antioxidants such as vitamin C and E are taken chronically as a means of 
boosting the immune system.  However, since most recreational and especially competitive 
athletes take a variety of supplements chronically, they may be at risk for toxicity, since 
megadoses of vitamins and other antioxidants can be toxic (Ristow et al., 2009).  Therefore, 
the ideal antioxidant treatment for muscle injury would be one that can be administered 
acutely post-injury rather than by preventative supplementation.   
Recently, polyphenols have been shown to benefit muscle repair (Kato et al., 2000; Buetler 
et al., 2002; Dorchies et al., 2006; Hofmann et al., 2006; Nakazato et al., 2010) via 
suppression of oxidative stress (Kato et al., 2000).  The efficacy of chronic PCO 
supplementation was discussed in the previous chapter.  The aim of the following study was 
to determine whether acute post-injury PCO supplementation might prove as beneficial for 
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muscle recovery as chronic PCO treatment.  We hypothesized that acute PCO 
supplementation will have similar effects on muscle recovery after a contusion injury, but that 
its effects on the acute period after injury (neutrophil phase and satellite cell activation) may 
not be optimal, due to the time required for its absorption into blood and tissue.  The main 
objectives of this study were to determine (a) changes in satellite cell (SC) activation and (b) 
foetal myosin heavy chain (MHCf) expression as an indication of muscle regeneration, and 
(c) the effects on the inflammatory immune cells and (d) cytokines.  
   
4.2  Methods 
4.2.1  Study design 
4.2.1.1  Experimental animals 
Adult, male Wistar rats, weighing approximately 280 g were used for this study.  All animals 
were handled exactly the same and were subjected to exactly the same conditions inside the 
animal house as the animals in the previous study (see chapter 3). 
Preceding the contusion injury protocol, experimental rats were randomly divided into three 
groups:  a placebo control group receiving 2 weeks of 0.9 % saline treatment without injury 
(C-PLA, n=8), a placebo post-injury group, injured and then treated with placebo for up to 2 
weeks after injury (PI-PLA; n=38, i.e. 6-8 rats per time point, time points were 4 hr, 1 d, 3 d, 5 
d, 7 d and 14 d post-injury) and a proanthocyanidin post-injury group, injured and then 
supplemented with Oxiprovin™ for up to 2 weeks post-injury (PI-PCO; n=38, i.e. 6-8 rats per 
time point, time points were 4 hr, 1 d, 3 d, 5 d, 7 d and 14 d post-injury).  See Figure 4.1 for 
more detail.   
 
4.2.1.2  PCO administration 
Rats were orally gavaged with tap water for two weeks prior to injury, followed (post-injury) 
by a daily dose of 20 mg/kg/day PCO (dissolved in 0.9 % saline) or 0.9 % saline (placebo) for 
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up to 2 weeks after injury.  The first post-injury dose was administered 2 hr after injury, when 
the rats where fully conscious.  Control animals received 2 weeks of placebo treatment, 
without any injury intervention.   
 
Figure 4.1:  Experimental design. 
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4.2.1.3  Induction of muscle injury 
Contusion of the hind limb was produced by a mass-drop injury jig.  This method was fully 
described in Chapter 3, section 3.2.1.3. 
 
4.2.2  Sacrifice and sample collection 
All sacrifice and sampling procedures were exactly the same as those in the previous 
chapter.  For a detailed description of sacrifice and sample collection, see the previous 
chapter, section 3.2.2. 
 
4.2.3  Sample analysis 
The analytical profile included the following parameters and procedures:  a) plasma CK 
concentration, b) plasma C-reactive protein (CRP) level, c) plasma and muscle oxygen 
radical absorbance capacity (ORAC), d) protein concentration, e) immunohistochemical 
staining and visualisation of muscle sections for SCs measuring Pax-7, f) qualitative 
histological analysis of muscle recovery and g) western blotting for quantification of cytokines 
(IL-1β, IL-6 and tumour necrosis factor (TNF)-α) and MHCf (indication of regenerating muscle 
fibres). 
 
4.2.3.1  CK concentration 
Total CK, an indirect marker for the presence of muscle damage, was determined by 
PathCare pathology laboratory (Vergelegen Medi Clinic, Somerset West, South Africa) using 
an automated enzymatic method.  The normal range for rat plasma CK concentration is 15 – 
195 international units per liter (IU/L) at 37 oC.  
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4.2.3.2  CRP level 
Total CRP, an indirect marker for the presence of inflammation, was determined by means of 
a 96-well high sensitivity ELISA assay (eBioscience, 88-7501-28).  CRP standards and 
plasma samples were prepared according to the manufacturer’s instructions.  Standard or 
sample (100 µl) were added to each CRP-antibody-pre-coated well in duplicate and allowed 
to incubate for 2 hr.  After washing, 100 µl of diluted HRP-conjugated anti-rat CRP were 
added to each well and allowed to incubate for 1 hr.  The plate was washed again and 100 µl 
of TMB substrate solution was added to each well for 5-10 min.  The reaction was stopped 
by adding 100 µl of stop solution (H2SO4) and the absorbance was read on an ELISA plate 
reader equipped with a 450 nm filter, corrected to 570 nm.  A standard curve was used to 
determine the amount of rat CRP present in the samples. 
 
4.2.3.3  ORAC assay 
The ORAC assay was performed on plasma no later than 10 days after collection and is 
based on the measurement of oxygen radical-induced quenching of a fluorescent probe 
(Huang et al., 2002).  Through the change in the fluorescence intensity of the probe in 
solution over time, an index of the extent of oxygen radical quenching capacity of the probe 
in the sample solution can be determined. In the presence of antioxidants, oxygen radical-
induced quenching of the probe is inhibited, and the extent of delay in quenching reflects the 
antioxidant capacity of the sample and is called the ORAC (Meeusen and Lievens 1986; 
Safran et al., 1989; Noonan et al., 1993; Olson and Ley 2002).  After antioxidant 
supplementation, a higher ORAC compared to the controls is expected.  See Appendix D for 
a summary of reagents and the laboratory method.   
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4.2.3.4 Determination of protein concentrations 
To estimate muscle total protein concentrations, either for making up of samples for western 
blotting or to include as measurement in the ORAC assay, the Bradford method was used 
(Appendix E).   
 
4.2.3.5 Histopathology and immunohistochemistry 
All histopathological and immunohistochemical evaluations were conducted on at least four 
rats per time point per treatment group.  
Haematoxylin and eosin (H&E) stained sections were used to qualitatively assess the 
recovery process.  For H&E staining, 5 µm muscle cross-sections were briefly deparaffinised 
and then stained with H&E (Appendix F).  Haematoxylin stains the basophilic structures blue-
purple and alcohol-based eosin stains the eosinophilic structures bright pink.  The basophilic 
structures include nucleic acids, such as in ribosomes and cell nuclei, and cytoplasmic 
regions rich in RNA.  The eosinophilic structures are intra- or extracellular proteins (mostly 
cytoplasm and red blood cells).  
Using immunohistochemistry techniques, 5 µm cross-sections were labelled with: (a) Pax-7 
for labelling SCs, (b) His48 for labelling neutrophils and (c) F4/80 for labelling macrophages.  
PBS controls were also used in this part of the study and the antibodies used were specific 
for rat samples.  For appropriate dilutions and suppliers of antibodies used, see Table 1 in 
Appendix B.   
 
Image analysis:  All imaging data were handled and analysed exactly as previously 
described in Chapter 3. 
 
4.2.3.6  Western blotting analysis for cytokine and MHCf levels 
Protein levels were determined by standard Western blotting techniques.  Briefly, 40 µg 
muscle homogenate of each sample was prepared with sample and RIPA buffer.  Samples 
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were then analysed by either 8 or 12 % gel electrophoresis and were immunoblotted for pro-
inflammatory cytokines, IL-6 and TNF-α, as well as for MHCf.  β-actin was used to determine 
equal loading.  For a full-detailed description of all the reagents used, as well as the method, 
see Appendix G. 
 
4.2.4  Statistics 
Results are presented as means ± standard error of the mean (SEM), unless otherwise 
specified.  A regression analysis was performed to compare growth curves in the different 
experimental groups. Differences between time points for other parameters within and 
between groups were analysed using factorial analysis of variance (ANOVA).  When 
significant interactions were found, Bonferroni post hoc tests were performed.  However, for 
immune and cytokine data, a Fisher’s post hoc test was used.  All statistical analyses were 
done using the computer software Statistica version 9 (StatSoft Software).  The accepted 
level of significance was p < 0.05. 
 
4.3  Results 
4.3.1  Body weight 
Rats in the different groups were matched for body mass at the start of the protocol.  
Contusion injury in the two injury groups resulted in a slight decrease in body mass 4 hr after 
the injury (Figure 4.2), which might be attributed to the fact that rats were asleep for up to 2 
hr after anaesthesia and probably dehydrated.  However, approximately 1 day after the 
injury, rats had recovered this loss. 
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Figure 4.2:  Comparison of mean body mass in control PLA rats and in rats supplemented 
with either PLA or PCO, after subjection to contusion injury. Days -14 to 0 represent 2 weeks 
prior to injury, whereas time point 0 indicates the day of injury and the start of the 
supplementation procedure (2 hours after injury).  n = 8 rats per time point per group. 
 
4.3.2  H&E 
Figure 4.3 illustrates histological staining with H&E.  Using this staining technique, qualitative 
changes in the muscle can be visualised over time.  In the muscle of the control group (A), 
no ultrastructural damage is apparent.  Soon after injury (4 hr, B and H), the disruption of the 
muscle fibre ultrastructure and vascular disruption are apparent in both treatment groups.  
Immune cell infiltration was seen at 4 hr (H) in the PCO group and on day 1 (C) in the PLA 
group.  Immune cells stayed visible in the injured area up to day 7 (F) in the PLA group, 
compared to day 5 in the PCO group (K).  Newly formed/ regenerating muscle fibres were 
only apparent at day 14 (G) in the PLA group, while peaking already at day 7 in the PCO 
group.  By day 14, the PCO and PLA group did not display normal muscle 
ultrastructure, indicating that regeneration is not complete, however, the PCO group’s 
ultrastructure were almost complete. 
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Figure 4.3:  H& E staining illustrating the clearing of inflammation after injury.  Photo A represent control samples with no injury.  Photos B–G 
represent samples taken from PLA-injury animals at (B) 4 hr, (C) 1 d, (D) 3 d, (E) 5 d, (F) 7 d and (G) 14 d post-injury.  Photos H-M represent 
similar time points in the PCO group. Scale bar represents 40 µm.  Photo B and H represent muscle fibre destruction and vascular disruption.  
Immune cells infiltrated the injured area (photo C and I) and remain visible for up to day 7 in the PLA group and day 5 in the PCO group.  
Neither the PLA, nor the PCO group displayed normal muscle fibre ultrastucture 14 days after injury, indicating that muscle fibre regeneration is 
not complete.  
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4.3.3  Plasma CK level 
There was a trend towards a time effect (p = 0.068) for CK, with a slight increase in plasma 
CK in both the PLA and PCO group 4 hr after injury (Figure 4.4).  No treatment effect was 
evident. 
 
Figure 4.4:  Total plasma creatine kinase (CK) activity (mean ± SD) of the acute 
supplemented control and injury groups at several time points after the contusion injury.  
Statistical analysis:  Factorial analysis of variance (ANOVA) with Bonferroni post hoc test, n = 
4 rats per time point per group. 
 
4.3.4  Plasma and muscle ORAC assay 
Statistical analysis of the results of plasma ORAC indicated a main effect of time (p < 0.001), 
and a main effect of treatment-time (p < 0.05) (Figure 4.5A).  In the PLA group, a significant 
but transient decrease in plasma ORAC was evident on day 3 compared to day 1 after injury.  
This was followed by a significant increase by day 5, whereas ORAC values in the PLA 
group on day 14 were similar to that of controls.  No significant changes were seen in the 
PCO group, however, on day 14, the PCO group had a significantly higher plasma ORAC 
compared to the PLA group. 
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Figure 4.5:  The effect of muscle contusion injury with or without acute PCO 
supplementation on plasma (A) and muscle (B) oxygen radical absorbance capacity (ORAC) 
over time.  (Figure details:  * p < 0.05; ** p < 0.01; *** p < 0.001).  Statistics:  Factorial 
analysis of variance and Bonferroni post-hoc test. n = 8 rats per time point per group. 
 
In the muscle samples, statistical analysis also indicated a main effect of both time and a 
treatment-time effect (p < 0.001 for both) (Figure 4.5B).  Muscle ORAC were significantly 
elevated by day 7 in the PLA group, whilst the PCO group displayed a more variable ORAC 
2500
2700
2900
3100
3300
3500
Control 4 hours day 1 day 3 day 5 day 7 day 14P
la
sm
a 
O
R
AC
 
(m
ic
ro
m
o
l T
ro
lo
x
 
eq
u
iv
/L
)
Time post-injury
PI-PLA
PI-PCO
0
100
200
300
400
500
600
700
800
Control 4 hours day 1 day 3 day 5 day 7 day 14
M
u
sc
le
 
O
R
AC
 
(m
ic
ro
m
o
l T
ro
lo
x
 
eq
u
iv
/m
ic
ro
gr
am
 
pr
o
te
in
)
Time post-injury
PI-PLA
PI-PCO
A 
* 
* 
** * 
B 
  ** 
 ** 
** *** 
*** *** ** ** *** 
*** ** 
*** *** *** *** *** 
*** *** 
CTRL 
CTRL 
134 
 
status.  ORAC in this group increased significantly earlier (day 3), with a secondary peak on 
day 14 after injury, compared to control.  Significant differences between groups were also 
evident on day 7 – the PLA group had a higher ORAC – and day 14 post-injury – the PCO 
group had a higher ORAC. 
 
4.3.5  Plasma CRP level 
No effect of time or treatment or treatment-time on plasma CRP was evident (Figure 4.6).     
 
Figure 4.6:  Plasma C-reactive protein (CRP) activity (mean ± SD) of the control non-injured 
groups and the injury groups at several time points after contusion injury and acute 
supplementation.  Statistical analysis:  Factorial analysis of variance (ANOVA) with 
Bonferroni post hoc test indicated no effect of treatment or time.  n = 8 rats per time point per 
group. 
 
4.3.6  Immune cell infiltration   
4.3.6.1  Neutrophils 
Repeated measures ANOVA indicated a similar and significant effect of treatment (p < 0.01), 
time, and treatment-time (p < 0.001 for latter 2) in both the border zone and injured area.  No 
neutrophils were present in control pre-injured samples, whereas neutrophils peaked on day 
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1 in the PLA group, a point in time when the PCO group had a significantly lower number of 
neutrophils (Figure 4.7).  This significant early increase was followed by a quick decrease on 
day 3 after injury.  Almost no neutrophils were detected in the PCO group.  Neutrophil 
 
 
 
 
 
Figure 4.7:  Neutrophil infiltration into the injured area (A) and border zone (B) after 
contusion injury and subsequent supplementation.  Statistics: Factorial ANOVA with Fisher’s 
post-hoc test; n = 4 per time point per group.  Significance (*** p < 0.001). 
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numbers were generally higher in the injured area than in the border zone.  Neutrophil 
infiltration on day 1 after injury is represented by Figure 4.8 – note that more neutrophils are 
apparent in the PLA group.  
     
 
Figure 4.8:  Neutrophil (His48) expression (green, FITC) and infiltration into the border zone 
(A-D) and injured area (E-H) of muscle, on day 1 post-injury (A, B and E,F indicates the PLA 
group; C, D and G, H indicates the PCO group).  Images B, D, F, and H are enlargements of 
the area surrounded by the white block of the figures on the left respectively.  Hoechst was 
used as nuclear dye.  Scale bar represents 10 µm, with the original magnification of 400x 
used for the image acquisition.   
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4.3.7.2  Total white blood cells (WBC) and macrophages 
White blood cells and macrophages showed similar results and it was therefore decided to 
discuss these results together.  A main effect of time and treatment-time (p < 0.001 for both) 
were evident in the injured area for both WBCs and macrophages (Figures 4.9 A&C).  There 
was a trend towards a main effect of treatment alone (p = 0.065).  In the PLA group, only 
WBCs infiltrated the injured area  on day 1 after injury, whereas macrophages were only 
detected by day 3 after injury.  However, both macrophages and WBCs reached peak values 
by day 5 after injury.  In the PCO group on the other hand, macrophages and WBCs had 
already infiltrated the injured area 4 hr after injury, followed by a significant elevation by day 
5.  Other time points where macrophage and WBC levels significantly differed between the 
groups were the 4 hr (both macrophages and WBCs) and day 1 time point (only for WBCs).  
The factorial analysis of variance indicated a main effect of treatment (p < 0.001), time (p < 
0.05 for WBCs and p < 0.01 for macrophages) and a treatment-time (p < 0.05 for WBCs and 
p < 0.01 for macrophages) effect in the border zone area (Figures 4.9 B&D).  Both WBCs 
and macrophages in the PLA group were significantly elevated already on day 3 after injury, 
and even more so on day 5 after injury.  No elevation in WBCs or macrophages in the PCO 
group were evident at any point in time.  Treatment groups differed from one another in 
terms of WBCs and macrophages numbers, with the PLA group having significantly more 
WBCs and macrophages on day 1 (only for WBCs), 3, and 5 compared to the PCO group.  
Figure 4.10 (A-H) indicates WBC infiltration in the injured area, whilst Figure 4.10 (I-P) 
indicates WBC infiltration in the border zone, on day 1 and 5 respectively, where significant 
differences between groups were evident.  Figures 4.11 (A-H) and (I-P) is representative of 
macrophage infiltration in the injured area and border zone respectively on days 3 and 5.   
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Figure 4.10:  White blood cell (CD45) expression (red, Texas Red) and infiltration into the injured area (A-H) and border zone (I-P) of muscle, on day 
1 post-injury (A, B and I, J indicates the PLA group; C, D and K, L indicates the PCO group) and on day 5 post-injury (E, F and M, N indicates the 
PLA group; G, H and O, P indicates the PCO group) respectively.  Images B, D, F, and H are enlargements of the area surrounded by the white block 
of the figures on the left respectively.  Hoechst was used as nuclear dye.  Scale bar represents 10 µm, with the original magnification of 400x used for 
the image acquisition.   
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Figure 4.11:  Macrophage (F4/80) expression (red, Texas Red) and infiltration into the injured area (A-H) and border zone (I-P) of muscle, on day 3 
post-injury (A, B and I, J indicates the PLA group; C, D and K, L indicates the PCO group) and on day 5 post-injury (E, F and M, N indicates the PLA 
group; G, H and O, P indicates the PCO group) respectively.  Images B, D, F, and H are enlargements of the area surrounded by the white block of 
the figures on the left respectively.  Hoechst was used as nuclear dye.  Scale bar represents 10 µm, with the original magnification of 400x used for 
the image acquisition.   
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4.3.7  Inflammatory cytokines 
4.3.7.1  IL-1β content 
No main effect of time or treatment on IL-1β content was evident (Figure 4.12).  However, 
there was a main treatment-time effect (p < 0.05), with the PCO group displaying a higher IL-
1β content on day 1 compared to the PLA group. 
 
 
Figure 4.12:  IL-1β expression in skeletal muscle following a contusion injury.  (A) represents 
a western blot probed for IL-1β and β-actin and (B) represents a bar graph illustrating the 
date observed in A.  Values are expressed relative to the control values (mean ± SEM).  
Statistics:  Factorial analysis of variance with Fischer’s post-hoc test, n = 3 per time point per 
group (* p < 0.05).   
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4.3.7.2  IL-6 content 
A main effect of treatment and time (p < 0.01 for both) were evident when analysing IL-6 
content.  Although IL-6 content in the PLA group was similar at all time points assessed, a 
gradual, but significant decrease in IL-6 content was visible in the PCO group over time 
(Figure 4.13).  Significant differences were also evident between the two groups, with the 
PCO group having less IL-6 at both time points (day 3 and 5). 
 
 
 
Figure 4.13:  IL-6 content in skeletal muscle following a contusion injury.  (A) represents a 
western blot probed for IL-6 and β-actin and (B) represents a bar graph illustrating the date 
observed in A.  Values are expressed relative to the control values (mean ± SEM).  Statistics:  
Factorial analysis of variance with Fischer’s post-hoc test, n = 3 per time point per group (* p 
< 0.05, ** p < 0.01, *** p < 0.001).   
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4.3.7.3  TNF-α content 
No main effects were evident when TNF-α was compared between groups or over time.  
However, there was a trend towards a main effect of time (p = 0.07).  No significant 
differences were evident in the PLA group over time (Figure 4.14).  However, the PCO group 
also displayed a gradual decrease in TNF-α (from 4 hr to day 5), similar to that observed with 
IL-6. 
 
 
 
Figure 4.14:  TNF-α expression in skeletal muscle after contusion injury.  (A) represents a 
western blot probed for TNF-α and β-actin and (B) represents a bar graph illustrating the 
date observed in A.  Values are expressed relative to the control levels (mean ± SEM).  
Statistics:  Factorial analysis of variance with Fischer’s post-hoc test, n = 3 per time point per 
group (* p < 0.05; ** p < 0.01).  
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4.3.8  Pax-7+ cell count 
Repeated measures analysis of variance indicated a significant effect of time, as well as a 
treatment-time interaction (p < 0.001 for both).  Similar to the results obtained with chronic 
supplementation, an increase in SCs/myofibre in the PLA group was evident at a later time 
point than that observed for the PCO group (day 3 compared to 4 hr).  SC expression in the 
PCO group also returned to values seen in control groups earlier than that observed for the 
PLA group (Figure 4.15).  Significant differences between the two treatment groups were 
also evident at 4 hr (PCO group had more SCs, thus activation and/or increased migration) 
and on day 3 (PLA group had more SC, indicating activation).  
 
 
Figure 4.15:  Pax-7+ satellite cell (SC) count normalised for the myofibre number 
(SC/myofibre) (mean ± SD).  Statistical analysis:  Factorial analysis of variance (ANOVA), 
with Bonferonni post-hoc test demonstrating significance between the two specific data 
points (* p < 0.05, ** p < 0.01, *** p < 0.001). n = 4 rats per time point per group. 
 
Due to the large standard deviations at various time points (Figure 4.15), in part due to 
varying degrees of fibre damage and swelling (more swelling and thus fewer intact myofibres 
evident in the PLA group on day 3 – figure 4.17C), the number of Pax-7+ SC per area (field of 
view - 350 µm2) were also taken into account.  Similar to the previous results, a main effect of 
treatment, time and treatment-time interaction were evident (p < 0.05 for all).  In Figure 4.16, 
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it is apparent that the number of Pax-7+ SCs in the PLA group is unchanged at all time points 
following injury.  The PCO group on the other hand showed a significant increase in Pax-7 4 
hr after injury, with normalisation by day 3 after injury.  Post hoc tests indicated that PCO 
Pax-7 was significantly higher than PLA 4 hr after injury.  Figure 4.17 illustrates Pax-7 
expression at 4 hr and on day 3 after injury in representative sections.  Take note that at both 
the 4 hr and day 3 time point, the PLA group had relatively fewer myofibres per field of view, 
as these fibres were more swollen compared to the fibres in the PCO group.  
 
 
Figure 4.16:  Pax-7+ satellite cell (SC numbers per field of view (mean ± SD).  Statistical 
analysis:  Factorial analysis of variance (ANOVA), with Bonferonni post-hoc test 
demonstrating significance between the two specific data points (*p < 0.05, ** p < 0.01).  n = 
4 rats per time point per group. 
 
 
Figure 4.17:  Pax-7 staining in the PLA and PCO group at 4 hr (A&B) and day 3 (C&D) 
respectively.  FITC (green) was used to visualise Pax-7, Texas Red (red) was used to 
visualise laminin and Hoechst (blue) was used as a nuclear marker.  The yellow arrows 
indicate true satellite cells, whereas the white arrows indicate non-satellite cells.  Scale bar 
represents 10 µm. 
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4.3.9   Foetal myosin heavy chain (MHCf) expression 
ANOVA indicated a main effect of time (p < 0.05) for MHCf content.  After injury, the PLA 
group displayed no difference, whereas MHCf expression in the PCO group was significantly 
elevated on day 5 after injury (Figure 4.18B).  Figure 4.18A indicates a representative 
western blot probed for MHCf and β-actin respectively. 
 
 
 
Figure 4.18:  MHCf expression in skeletal muscle after contusion injury. (A) represents a 
western blot probed with MHCf and β-actin, and (B) represents a bar graph illustrating the 
data seen in A.  Values are expressed relative to the control values (mean ± SEM).  
Statistics:  Factorial analysis of variance with Fischer’s post-hoc test, n = 3 per time point per 
group (* p < 0.05, ** p < 0.01). 
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4.4  Discussion 
The main findings of this study were that acute PCO supplementation blunted the pro-
inflammatory response and possibly promoted an earlier anti-inflammatory response.  The 
evidence for the former was three-fold:  faster decline in TNF-α and IL-6 levels and a blunted 
neutrophil response in both the border zone and injured area.  The evidence for the latter 
was an earlier macrophage infiltration in the injured area.  Other main findings were a 
decreased number of macrophages infiltrating the border zone which appeared to limit 
secondary damage in this area, and an earlier increase in SC count.  
However, before considering results of individual parameters, it is necessary to consider the 
relative severity of primary damage in PCO vs. PLA, since differences between groups over 
time will impact on the interpretation of data. 
 
4.4.1  Creatine kinase (CK) activity 
CK is still used as gold standard for measuring damage (Neubauer et al., 2008).  In this 
study, CK did not change significantly over time in either PLA or PCO, except for a similar 
tendency for increased CK 4 hr after injury in both groups, which did not reach significance 
due to the increased inter-individual variability in response.  However, since day 1 and day 5 
time points were not investigated, the peak in CK could have been missed, which probably 
would have been evident on day 1 or 2.  Since the responses in the two groups were similar 
(peaking non-significantly at 4 hr compared to all other time points), one can assume that the 
technique indeed produced a similar, standard injury across groups, so that observed 
differences between groups may be ascribed to treatment only.  On a qualitative level. The 
histology sections at 4 hr post-injury also reveal a similar degradation pattern. 
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4.4.2  Antioxidant capacity 
The ORAC assay measures the total amount of antioxidants present in an aqueous system, 
and since the PCO supplement was dissolved in 0.9 % saline, an aqueous solution, the 
ORAC assay was used.  A decreased ORAC is indicative of a decreased ability of the total 
antioxidants present in plasma or muscle to scavenge free radicals, whereas a higher ORAC 
correlates with an increased ability to scavenge free radicals (Cao et al., 1998; Mazza et al., 
2002).  However, in a dynamic system of free radical overload, such as contusion injury, the 
ORAC can also reflect how many free radicals were in the area that have used the 
quenching ability already, so that the ORAC measured is interpreted as the remaining ability.  
Because of this, the interpretation of results should be cautious.    
The finding in the PLA group of a significant decrease in plasma ORAC from day 1 to day 3 
is possibly due to the generation of reactive species (Abramson and Weissmann 1989; Kerr 
et al., 1996; Ali et al., 1997) by predominantly circulating neutrophils (Li et al., 2004), and 
possibly also macrophages (Knight 1999; Jackson 2000; Fialkow et al., 2007).  However, the 
conditions in the interstitial space of the injured area also influences the conditions in the 
plasma.  This is most likely since in this study this decrease in plasma ORAC followed after 
an increased neutrophil invasion into the muscle, therefore corresponding with neutrophil 
oxidative burst in muscle or interstitial space rather than circulation.  Further support for this 
interpretation is the decreased IL-1β content on day 1 in the PLA group compared to PCO, 
which suggests that the activation of NADPH oxidase and xanthine oxidase (involved in 
respiratory burst) is inhibited or suppressed (Abramson and Weissmann 1989; Kerr et al., 
1996; Ali et al., 1997), whilst an increase in muscle IL-6 in the PLA group on day 3 after 
injury (significantly higher than PCO) suggests the stimulation of the pathways mentioned 
above, and thus respiratory burst.  Although the respiratory burst activity of blood neutrophils 
was not measured, by specifically investigating MPO (expressed on activated neutrophils) 
activity, NADPH oxidase and xanthine oxidase, the possibility that circulating neutrophils 
could have contributed to the decrease in plasma ORAC on day 3 cannot be excluded.     
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Macrophages were also significantly elevated in the injured area on day 3 compared to 
control levels and might also result in the release of free radicals.  However, it is not known 
whether the pro- or anti-inflammatory subtypes are responsible, making it difficult to draw a 
clear conclusion.  Another potential contributor to the decreased ORAC is the satellite cell 
population, which are known to generate reactive species upon activation, proliferation and 
fusion (Scime and Rudnicki 2006).  In the PLA group, Pax-7+ SC were significantly increased 
on day 3.  From day 3 to 5, ORAC increased significantly in the PLA group, possibly as a 
result of the decline in pro-inflammatory signal, as well as a decrease in neutrophils and 
potentially M1 macrophages.  On day 5, in accordance with the literature, macrophage 
infiltration was at its peak.  It is possible that on approximately day 5 after injury, a switch 
from M1 to M2 macrophages occurred, with M2 macrophages playing a predominant role in 
muscle regeneration and thus the decrease of free radical production (Massimino et al., 
1997).  The fact that muscle IL-6 level was still significantly elevated in the PLA group on day 
5 argues against this and thus it is more difficult to explain, given its many sources even 
within muscle.  It may indicate a continued inflammatory signal in the early stages of a 
macrophage phenotype switch.  On day 14, the ORAC of the PLA group was similar to that 
of controls.   
In contrast to PLA, PCO administration prevented significant changes in plasma ORAC over 
time, and on day 14 significantly higher ORAC compared to PLA group was observed.  This 
suggests that more free radicals were still being generated in the PLA group at this specific 
time point, or that the PCO group had a better ability to respond to free radical production, 
possibly as a result of an increased antioxidant enzyme activity (Gulgun et al., 2010).  This 
result corresponds to a study in humans, which reported improved ORAC after post-exercise 
supplementation with vitamin C (12.5 mg/kg body weight) and N-acetyl-cysteine (NAC – 10 
mg/kg body weight) (Childs et al., 2001).   
Most studies on the effect of antioxidants investigate ORAC in plasma only, without any 
indication of what is actually happening in the muscle.  This is one of the few studies that 
measured ORAC in the muscle. 
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Muscle ORAC results differed from plasma results, since a whole host of cells, including 
injured muscle fibres can all contribute to an increase or decrease in antioxidant status and 
thus overall ORAC status.  In muscle, no difference in the ORAC in the PLA group is evident 
until day 7 after injury, at which time the PLA group had a significantly higher ORAC 
compared to control levels, which was sustained at day 14 (similar to the results seen with 
chronic supplementation).  This suggests that the PLA group’s antioxidant status has 
probably recovered only on day 7, with replenishment of the endogenous antioxidant pool, 
leaking into the interfiber muscle space (Jackson 2000).  This is possible, since muscles are 
starting to regenerate in the PLA group as seen with H&E staining, although not to the same 
extent as with PCO supplementation.       
In the current study, PCO, a water-soluble antioxidant was used and rats were only 
supplemented starting 2 hr after injury, daily.  Muscle ORAC in the PCO group increased 
significantly on day 3 (an earlier response was probably prevented by the fact that the first 
supplement was only administered 2 hr after injury).  In a study by Kayali et al. (2005), it was 
shown that β-Glucan, an antioxidant, worked as a scavenger and had suppressive effects on 
lipid peroxidation after spinal cord contusion injury.  Furthermore, in a review by Teixeira et 
al. (2002), it was concluded that PCO has the ability to limit oxidative stress via several 
mechanisms, including decreased tissue degradation by inhibition of proteolytic enzymes, 
limiting the production of oxygen free radicals and limiting hypoxia by improving local tissue 
circulation.  In the current study, a low number of macrophages and neutrophils were present 
on day 3 in both the injured area and border zone, supporting the idea of a limited free 
radical production by these cells.  On day 5, ORAC in the PCO group was decreased again 
compared to day 3, possibly as a result of satellite cells fusing, and therefore increased MHCf 
expression (evident in the current study on day 5), which suggests regeneration and higher 
metabolism.  By day 14 after injury, average ORAC was at its peak, and even more 
increased than both control and PLA (day 14), indicating that PCO was being restored in 
response to the daily supplementation, rather than actively participating in any further 
quenching requirement.  This is supported by histology (H&E – Figure 4.3), where the PCO 
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group displayed better structural recovery by day 14 after injury compared to the PLA group.  
Chronic PCO supplementation on the other hand (MSc thesis, Kruger 2007) resulted in 
complete muscle regeneration on day 14 after injury, suggesting that chronic rather than 
acute supplementation is more beneficial for a quicker recovery. 
    
4.4.3  Satellite cells 
The process of SC activation in muscle regeneration has been described in detail in many 
recent studies and has been used as a basic measurement of initiation of muscle 
regeneration (Grounds 1991; Hurme et al., 1991a).  Although the activation of SCs have 
been studied extensively in models of injury and disease, the time course of first appearance 
as well as their persistence differs depending on the type of injury or severity.  In a study by 
Kuang et al. (2006), it was established that Pax-7 is very important in the muscle recovery 
process, and that if Pax-7 is absent (knocked out), it can severely inhibit muscle 
regeneration.   
In the current study, the number of Pax-7+ SCs per myofibre in the PLA group was relatively 
high on day 3 after injury compared to the control group.  This suggests that satellite cells 
were activated on day 3 in response to injury and might have proliferated significantly 
thereafter (Garry et al., 1997; Garry et al., 2000).  IL-6 (produced by activated macrophages 
and injured muscle fibres themselves) is one of the cytokines which has been shown to 
stimulate SC activation and proliferation (Merly et al., 1999).  In the current study, 
macrophages were elevated in the border zone on day 3, which may have stimulated SCs to 
proliferate, increasing Pax-7+ SC numbers.  However, since IL-6 was not significantly 
elevated on day 3 compared to day 1 in the PLA group, it could not explain the increase in 
Pax-7.  Other potential role players in SC activation that were not assessed, included 
neutrophil or macrophage-derived NO and growth factors (released by injured fibres and 
macrophages) including hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and 
insulin-like growth factor (IGF) (Ryten et al., 2002; Pisconti et al., 2006).  From day 5, 
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however, fewer Pax-7+ SCs are present in the PLA group, and numbers stayed low until day 
14 after injury, suggesting that SCs are returning to quiescence or differentiating.  This is a 
likely conclusion, since after cardiotoxin-injury in mice, activated SC numbers remained 
elevated up to day 5 (as seen with immunohistochemistry), whereafter they started to 
differentiate (Garry et al., 1997; Garry et al., 2000).  This early decrease (day 5) in Pax-7+ 
SCs in the PLA group is quite surprising, since chronic PLA supplementation resulted in Pax-
7+ SCs still being elevated on day 7, suggesting that chronic supplementation resulted in 
increased proliferation and thus more stem cells involved in improving the quality of recovery.  
Prompted by large standard deviations for this parameter in most groups, raw data were re-
assessed.  This revealed that the muscle fibres in the PLA group were rather swollen, 
resulting in few intact muscle fibres per field of view (see Figure 4.17), which may have 
influenced results.  On the other hand, SCs are usually associated with fibres, so it remains 
problematic how to quantify SCs when fibre size changes so much.  When plotting Pax7+ SC 
per field of view in Figure 4.16, no significant increase in Pax-7+ SCs/field of view were 
evident in the PLA group over time, suggesting that SC response to contusion injury – where 
sever fibre disruption is clearly evident – is difficult to quantify.   
In contrast, Pax-7+ SC number in the PCO group was significantly elevated 4 hr after injury 
and on day 1, suggesting significant recruitment of SCs to the injured area or possibly an 
increase in Pax-7 expression by existing SCs.  A study by Dumont et al. (2008), showed that 
depletion of neutrophils may spare muscle from excessive membrane damage, suggesting 
that PCO’s mechanism of action might be through limiting neutrophil infiltration, followed by 
reduced sarcolemma damage, thereby allowing SC to migrate to the injured area despite 
excessive basal lamina damage.  However, this is unlikely, since PCO here was first 
administered at 2 hr after injury and by 4 hr, there were no neutrophils evident in the injured 
area.  Further, these early increases did not correspond to any changes in leukocyte 
infiltration or cytokine levels assessed, therefore, other cells, or even the damaged muscle 
itself, must have been responsible for signalling the increases seen in SC activation or 
migration, or both.   From day 3, Pax-7 numbers were similar to that of control, indicating that 
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these SCs are undergoing terminal differentiation to form new muscle fibres or fusing with 
injured fibres, whereas a subgroup returns to quiescence.  MHCf was also significantly higher 
on day 5 in the PCO group compared to the PLA group, making this a likely conclusion 
(when plotting Pax-7+ SCs per field of view, similar results were evident in the PCO group 
over time than for Pax-7+ SCs per muscle fibre).  These findings of earlier SC activation and 
return to quiescence in the PCO group over time is similar to the findings seen when rats 
were supplemented chronically with PCO.  
   
4.4.4  MHCf 
The embryonic or foetal myosin heavy chain isoform is expressed predominantly in 
developing skeletal muscles, but can also be detected in the adult muscle in regenerating 
fibres, where central nuclei are apparent (d'Albis et al., 1988).  When immunohistochemically 
staining muscle sections for MHCf, it not only labels regenerating muscle fibres with central 
nuclei, but also some muscle fibres without central nuclei.  Therefore in order to distinguish 
and accurately count regenerating fibres, one should take central nuclei into account.  Since 
the specific time course of appearance and disappearance of MHCf after injury and chronic 
supplementation is known (MSC thesis, Kruger 2007), the next study was only aimed at 
determining whether a similar MHCf time course is evident with acute supplementation.   
Post-injury in placebo:  No significant difference was seen in MHCf content in the PLA group 
over time (4 hr to day 5), suggesting that no significant muscle differentiation had taken place 
yet.  This finding of no change in MHCf was also similar to no change in Pax-7+ SCs per 
muscle area (Figure 4.16) corroborating the abovementioned statement that regeneration 
has not occurred yet significantly.  By day 14 it is more clearly evident (see Figure 4.3 G).  In 
a previous study using the same contusion injury model, MHCf expression was only evident 
on day 7 in the PLA group (MSc thesis, Kruger 2007).  Similar qualitative histological findings 
of regenerating myofibres by day 6-8 were also found in PLA controls in the current study 
and other studies (Fisher et al., 1990; Kami et al., 1993; Beiner et al., 1999).  Since only the 
154 
 
acute post-injury time points were assessed, it is possible that a peak could have been 
detected if later time points were included in the analysis.  Also, since tissue used for 
western blotting analysis in this study included a mixture of both injured and border zone 
areas, it is possible that effects in the injured area could have been different from effects of 
the regenerating fibres in the border zone area, which most probably have not regenerated 
yet.     
Post-injury in PCO:  In the PCO group on the other hand, MHCf was elevated on day 5 after 
injury (compared to PLA), suggesting that acute PCO resulted in earlier regeneration of 
muscle fibres.  From previous studies regarding chronic PCO supplementation (MSc thesis, 
Kruger 2007), it was evident that MHCf was present already on day 3 after injury, indicating 
that acute supplementation had a response that occurred slightly later in the recovery 
process.      
 
4.4.5  Immune cells 
In earlier studies, inflammatory cell infiltration in the injured muscle (after stretch-injury) was 
assessed using general H&E staining (Best et al., 1999) and the biochemical assay, muscle 
myeloperoxidase (MPO) activity (Brickson et al., 2001).  These studies suggested that 
neutrophils infiltrate the injured area 24 hr post-injury and that this is associated with 
indicators of fibre tearing and oxidative stress (Best et al., 1999; Brickson et al., 2001).  
Results from the studies in this thesis regarding neutrophils are in agreement with these 
studies.  Neutrophil numbers in the PLA group after contusion injury were significantly 
elevated on day 1 in both the injured area and border zone, followed by a significant 
decrease from day 3 onward, similar to the results obtained with chronic PLA 
supplementation.  However, the peak increase in the injured area was 25-fold and in the 
border zone 4-fold, compared to a 30-fold increase and 10-fold of the injured area and border 
zone respectively of chronically supplemented rats.  One possibility is that acute 
supplementation reduced neutrophil infiltration.  The decrease in neutrophil numbers by day 
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3 could indicate that neutrophils have undergone respiratory burst and that free radicals were 
already released into the injured area (Best et al., 1999; Brickson et al., 2001).  Plasma 
ORAC was significantly decreased in the PLA group on day 3, indicative of a decreased 
ability of the antioxidants present in a sample to scavenge free radicals.  This would suggest 
that significant scavenging ability had been utilised to quench free radicals prior to this time 
point, corroborating the abovementioned statement.  Similar to data presented in Chapter 3 
regarding chronic PCO supplementation, acute PCO was also responsible for blunting the 
neutrophil response, even if taken acutely.  A potential mechanism whereby PCO blunts the 
neutrophil response may be reduction of the adhesion molecule expression on circulating 
immune cells.  In one particularly relevant study, a grape seed-derived PCO was indeed able 
to reduce the disease-associated increase in circulating soluble adhesion molecules, 
intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM), endothelial 
(E)-selectin and platelet (P)-selectin, thereby reducing the number of neutrophils migrating to 
muscle (Kalin et al., 2002).    
However, neutrophils may not be solely responsible for inducing oxidative stress in injured 
skeletal muscle.  Other non-immune cells are also responsible for increases in MPO activity 
and not all neutrophils express MPO (Derby-Dupont et al., 1999).  These neutrophils are 
normal and even have a normal or increased metabolic burst by means of other 
mechanisms, such as the enzyme NADPH oxidase (Best et al., 1999; Brickson et al., 2001).  
Macrophages should also be considered as sources of increased oxidative stress (Ysebaert 
et al., 2000; Sugiyama et al., 2001).  This is a likely possibility, since macrophages were 
detected already 48 hr after a single stretch injury (Almekinders and Gilbert 1986; Nikolaou 
et al., 1987), a point in time when MPO activity was significantly increased (Brickson et al., 
2001).  However, other studies suggested that activated adult macrophages lack MPO 
(Yamada and Kurahashi 1984; Koeffler et al., 1985; Tobler et al., 1988; Ulvestad et al., 
1994), and also have other ways of undergoing respiratory burst.  Thus, although MPO is 
high when macrophages are at their peak number, as in the study by Brickson et al. (2001), it 
does not necessarily imply that MPO is synthesized by macrophages.  Rather, MPO is more 
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associated with the time of neutrophil respiratory burst, which occurs after day 1, and it is 
possible that it remains elevated for a few days.  This interpretation would require a sampling 
time at 2 days as well.   
Macrophages in the PLA group significantly increased on day 3 after injury in both the border 
zone and injured area.  In the border zone however, by day 5 after injury, there was an even 
more significant increase in the PLA group.  On the other hand, a low number of 
macrophages were present in the PCO group in the border zone.  Differences between 
treatment groups were evident on day 3 and day 5, with the PCO group exhibiting a lower 
number of macrophages in the border zone.  This could indicate that there is less secondary 
damage in the border zone in the PCO group compared to the PLA group.  In the injured 
area however,  there are more macrophages in the PCO group compared to the PLA group 
at the 4 hr and day 5 time points.  Two different types of macrophages exist, M1 
macrophages are involved in further promoting muscle damage, and infiltrate the injured 
area early after injury, whereas M2 macrophages promote muscle repair and infiltrate the 
injured area somewhat later (Frenette and Tidball 2000; Frenette et al., 2002; Tsivitse et al., 
2003).  Therefore it is possible that 4 hr after injury, M1 macrophages were present to 
enhance the pro-inflammatory phase, whereas on day 5, M2 macrophages might be present 
to enhance resolution of inflammation.  A more detailed analysis of macrophages is required 
to elucidate this.      
 
4.4.6  Pro-inflammatory cytokines 
Post-injury in placebo:  According to Ostrowski et al. (1999), and Xing et al. (1998), the 
magnitude and duration of an inflammatory response may be restricted, due to the balance 
that exists between the pro-inflammatory cytokines, such as IL-6, and their inhibitors 
(including, but not exclusively the anti-inflammatory cytokines).  IL-1β, IL-6 and TNF-α are 
released in response to injury, as a result of the rupturing of the muscle fibres and the 
release of histamine from mast cells and platelets exposed after injury (Rosenberg and Gallin 
157 
 
1993; Cannon and St Pierre 1998; Tidball and Wehling-Henricks 2005).  One might therefore 
expect increased levels of all three cytokines after a contusion injury.  Even though this injury 
is similar to the injury produced in the experiment described in Chapter 3, different cytokine 
patterns were observed in the PLA group in the previous study vs. this one.  With chronic 
PLA treatment, TNF-α and IL-6 peaked on day 3 and day 1 in the injured area and border 
zone respectively.  However, no changes in IL-6 and TNF-α levels were evident with acute 
PLA treatment.  Similarly, IL-1β also showed no change over time compared to the control 
group.  In this particular study, western blotting was used to determine the levels of 
cytokines, whereas in the previous chapter, immunohistochemistry was used to identify 
cytokines in both the injured area and border zone area.  The rationale behind using western 
blotting was to determine in a more time-efficient manner whether the cytokine profile will be 
affected to the same extent following acute supplementation.  A confounding factor in using 
western blotting is that it is not known whether the muscle sample used contains only injured 
area or possibly some intact or border zone areas.  Therefore, no response does not 
necessarily indicate no cytokine response at all – it might only indicate that the combination 
of either the injured or border zone areas might have masked the real effect.  The possibility 
of such technical masking was less apparent in the PCO group.   
Post-injury in PCO:  IL-1β was significantly higher than PLA in the PCO group on day 1 after 
injury, however, both treatment groups were not significantly different from control.  This 
might indicate an earlier or more potent inflammatory response in the PCO group.  Neutrophil 
numbers in the PCO group were low throughout.  On day 1, macrophage number was also 
not elevated and could therefore not have contributed to the increase in IL-1β on day 1.  
However, 4 hr after injury, macrophage numbers were significantly higher in the injured area 
and might have contributed to an increase in IL-1β on day 1 if this effect is delayed.  
Fibroblasts express IL-1β and are also present early in the injured area (Jarvinen et al., 
2005).  Fibroblasts rather than macrophages and neutrophils may therefore be responsible 
for the increase on IL-1β on day 1.  Regardless of the origin of the increased IL-1β, it is 
known that IL-1β facilitates increased expression of macrophage colony stimulating factor 
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(M-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) by endothelial 
cells, which both play a predominant role in attracting more neutrophils and/or macrophages 
to the injured area (Zsebom et al., 1988; Allen and Boxhorn 1989).  We did observe 
increased macrophage number on day 3 and a more significant increase on day 5 in the 
injured area, although not the border zone.   
The other inflammatory cytokines (IL-6 and TNF-α) measured, significantly decreased earlier 
(day 3) over time compared to the PLA group, in which cytokine concentrations remained 
constant, indicating an active anti-inflammatory response in PCO.  Further studies are 
needed to determine if this effect of PCO supplementation is directly/indirectly blunting the 
inflammatory process.  
 
4.5  Conclusion 
The results obtained in this study indicate that, similar to chronic preventative 
supplementation, acute post-injury PCO supplementation also influenced muscle fibre 
regeneration, as seen through MHCf, which was elevated on day 5.  It is also apparent that 
acute PCO supplementation resulted in a better ability to maintain oxygen radical scavenging 
capacity after injury compared to PLA.  Contusion injury resulted in an inflammatory 
response, but PCO supplementation altered the inflammatory response, through limiting 
neutrophil infiltration into the injured area and allowing an earlier macrophage response.  A 
decrease in pro-inflammatory cytokines within 3 days supports this anti-inflammatory action.  
  
4.6  Limitations  
In this study, all cytokine and immune cell data only represent time points up to day 5.  Since 
previous results in the chronic supplementation study showed all differences in responses 
prior to day 5 after injury, it was not considered necessary to investigate time points further 
than day 5.  In retrospect, it would potentially have been better to be able to determine 
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whether resolution of inflammation did actually occur earlier in PCO, by addition of one or 
two later time points.  A major limitation was not typing macrophages in order to better make 
sense of results obtained.  Since it is known that the ORAC only measures the water-soluble 
portion, another potential limitation is that the lipophilic component of plasma were not 
assessed in addition to the water-soluble portion.  However, a study by Wu et al. (2004) 
found that the antioxidant capacity in the lipophilic content after proanthocyanidin 
supplementation (in berries and fruits) is negligible.  Since the manner in which satellite cell 
numbers were expressed changed the outcome of the results in the PLA group, determining 
satellite cell numbers in the interstitium between fibres, in addition to the numbers at the fiber 
surface, could also illuminate whether satellite cell migration or proliferation were primarily 
affected in the treatment groups over time. 
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CHAPTER 5 
 
Effect of chronic oligomeric proanthocyanidin supplementation on 
in vivo macrophage subpopulation distribution and in vitro 
neutrophil migration following contusion injury 
 
5.1  Introduction 
Results from Chapter 3 and 4 indicated that both chronic and acute PCO supplementation 
were able to hasten the regeneration response.  Chronic PCO supplementation resulted in 
earlier and increased satellite cell activation or migration or both, and earlier synthesis of 
foetal myosin heavy chain (MHCf), indicative of muscle regeneration.  Furthermore, the same 
treatment protocol was also able to blunt the pro-inflammatory cytokine response, both in 
circulation and in the injured muscle.  Two of the most significant and consistent findings at 
muscle level, was that both acute and chronic PCO not only blunted the neutrophil response 
substantially, but also resulted in a shift to the left in time course for macrophage infiltration 
and resolution.   
Various plant-derived antioxidants have been shown to exert anti-inflammatory effects.  
Vitamin E and C are considered two of the most important dietary antioxidants.  Previous 
studies have shown that short-term supplementation with high doses of vitamin E (600-1200 
I.U./day) resulted in decreased production of pro-inflammatory cytokines, tumour necrosis 
factor (TNF)-α (Mol et al., 1997; Devaraj and Jialal 2000b; van Tits et al., 2000), interleukin 
(IL)-1β (Devaraj et al., 1996; Devaraj and Jialal 2000b; van Tits et al., 2000) and IL-6 
(Devaraj and Jialal 2000a) by blood monocytes in vitro.  However, long-term 
supplementation (3 years) with a combination of α-tocopherol (vitamin E; 91 mg or 136 
I.U./day) and vitamin C (250 mg) had no detectable anti-inflammatory effect in healthy men 
(Bruunsgaard et al., 2003), most probably due to the low concentration of vitamin E 
compared to that used in the other studies mentioned above.  Resveratrol is one of the most 
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researched grape-seed derived antioxidants.  In a recent review, all its anti-inflammatory 
mechanisms were summarized in detail, in terms of model used, mechanism and effective 
concentration (de la Lastra and Villegas 2005).  The anti-inflammatory mechanisms of 
resveratrol include (a) its ability to inhibit the production of pro-inflammatory mediators, IL-8 
and IL-6 (Donnelly et al., 2004), (b) alter eicosanoid synthesis, and (c) inhibit the action of 
activated immune cells, primarily neutrophils and macrophages.  More specifically resveratrol 
supplementation resulted in the inhibition of neutrophil adhesion to stimulated human 
umbilical vein endothelial cells (HUVEC) by directly inhibiting the expression of the adhesion 
molecules, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule 
(VCAM)-1 (Ferrero et al., 1998; Bertelli et al., 2001).  The effect of resveratrol on eicosanoid 
production was demonstrated in a rat model of carrageenan-induced paw oedema (Jang et 
al., 1997).  In this study, resveratrol inhibited the synthesis of prostaglandin (PG) via the 
direct inhibition of the cyclyooxygenase (COX) activity of COX-1, but not COX-2.  In contrast, 
another study investigating resveratrol activity in human mammary epithelial cells suggested 
quite the opposite, that PG expression via COX-2 specifically was affected (Subbaramaiah et 
al., 1998), which clearly demonstrated that depending on the model of inflammation, and the 
cell type involved, the arachidonic acid pathway will be influenced differently either through 
COX-1 or COX-2.  Collectively, these studies indicate that plant-derived antioxidants have 
anti-inflammatory properties, some of them similar to that seen in our previous studies. 
Since it has been shown that other plant-derived antioxidants were able to exhibit anti-
inflammatory properties, similar to those found in previous studies in this thesis (Chapter 3 
and 4), the ability of PCO to inhibit/blunt neutrophil recruitment to injured tissue may be due 
to PCO’s effect on (a) reducing the number of circulating neutrophils, (b) limiting the number 
of activated neutrophils, or (c) interfering with mechanisms for neutrophil migration into the 
injured tissue.  The latter include the inhibition of neutrophil chemotaxis, possibly due to (a) 
the decrease in pro-inflammatory cytokine expression (seen in this thesis in Chapter 3), (b) 
alterations in expression of other chemotactic factors, or (c) reduced expression of adhesion 
molecules on neutrophils.  
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Neutrophil adhesion to and migration through the vascular endothelium is mediated by 
membrane adhesion molecules (β2 integrins) expressed on neutrophils, which include 
leukocyte function antigen-1 (LFA-1/CD11a), Mac-1 (CD11b/CD18), and very-late antigen 4 
(VLA-4) (Smith et al., 1989; Furie et al., 1991) and their respective vascular endothelial 
ligands, endothelial (E)-selectin, platelet (P)-selectin, ICAM-1, VCAM-1, and connective 
tissue components such as fibronectin (Albelda et al., 1994; Carlos and Harlan 1994).  
Neutrophil migration into the injured area is further mediated by chemical mediators released 
from the injured area itself (Sherwood et al., 2004; Tidball and Wehling-Henricks 2005), 
which include pro-inflammatory prostaglandins (PGE2 and PGF2α) and leukotrienes (LTB4) 
(Shen et al., 2006), as well as factors released by activated platelets (thromboxane (Tx)A2, 
serotonin and histamine) (Marder et al., 1985).  Chemoattractants (cytokines and CXC and 
CC chemokines) released from the injured area as well as from immune cells also play a 
very important role (Nagaraju et al., 1998; De Rossi et al., 2000; Reyes-Reyna and Krolick 
2000; Alvarez et al., 2002).  In in vitro studies by Cassatella (1999) and Wolach et al. (2000), 
it has been demonstrated that neutrophil migration was either directly or indirectly influenced 
by granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1, IL-6, IL-8, monocyte 
chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, and TNF-α after 
mechanical loading of skeletal muscle, due to their effect on the inflammatory response. 
Granulocyte colony-stimulating factor (G-CSF) also enhances neutrophil motility and 
chemotaxis, thereby increasing the ability of neutrophils to migrate across the vascular 
endothelium (Dale et al., 1995; Nelson and Bagby 1996).  Pro-inflammatory cytokines, 
including IL-1β, TNF-α, and IFN-γ, have the ability to increase ICAM-1 expression on 
different cell types (Dustin et al., 1986; Pober et al., 1986a; Pober et al., 1986b), and TNF-α 
specifically, have been shown to be responsible for upregulating the expression of some of 
the β2 integrins (CD11b/CD18) (von Andrian et al., 1992; Condliffe et al., 1996; Yoshida et 
al., 1997).  Controversy exists regarding the expression of the different adhesion molecules 
in different types of tissue injury, since CD11b/CD18 or expression of ICAM-1 may or may 
not be responsible for neutrophil migration out of circulation (Doerschuk et al., 1990; Bullard 
et al., 1995).  Since the previous studies in this thesis were able to indicate that PCO was 
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able to blunt the neutrophil response at tissue level, the first step would be to prove an effect 
on migration in vitro, followed by a second step, which would be to determine the exact 
molecule(s) involved in neutrophil migration.   
Turning attention to macrophages, those found in injured tissue have been linked to both 
inflammation and repair (Leibovich and Ross 1975; Tsunawaki et al., 1988; Diez-Roux and 
Lang 1997; Kodelja and al 1997; Zhang-Hoover et al., 2000; Danenberg and al 2002).  
Following neutrophil invasion, macrophages of a M1 phenotype (classically activated, ED1, 
phagocytic) enter tissue, reaching significantly elevated concentrations at about 24 hours 
post-injury and continuing to increase in numbers until about 2 days post-injury, whereafter 
their numbers begin to decline rapidly (St. Pierre and Tidball 1994; Tidball et al., 1999; 
Frenette and Tidball 2000; Selva-O’Callaghan et al., 2006; Contreras-Shannon et al., 2007).  
Although the specific timing of the M1 phenotype seems to remain similar irrespective of 
injury type, limited studies are available on the onset of M2 (alternatively activated) 
macrophage infiltration.  Only two models of injury thus far have reported on the presence of 
these different macrophage phenotypes, which include downhill running (Tsivitse et al., 
2003) and hindlimb unloading (Tidball et al., 1999; Frenette and Tidball 2000; Frenette et al., 
2002).  In these models it was shown that ED2 macrophages infiltrated the injured area on 
day 2 or 3.  Further proof of macrophages of a M2 phenotype were evident in a study by 
Tidball and Wehling-Henricks, (2007), where it was shown that depleting injured muscle of 
macrophages on day 2-4 during hindlimb reloading, resulted in an inability to regenerate, 
suggesting that macrophages at this time point are required for muscle regeneration.   
Considering the positive effects of PCO (at tissue level) to hasten the macrophage response, 
secondary to a blunted neutrophil response, we hypothesized that chronic PCO 
supplementation will result in an altered monocyte phenotype expression during resolution of 
inflammation.  PCO may also be directly involved in limiting the ability of neutrophils to 
migrate to the injured area at circulatory level.  In order to investigate these hypotheses, the 
number of macrophages (M1 – CD68+ and M2c – CD163+) and neutrophils in circulation 
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were quantified.  The possible mechanisms whereby PCO blunted the neutrophil response 
were also investigated, by determining changes in in vitro neutrophil migration, in the 
presence of conditioned plasma collected at different time points from PLA and PCO-
supplemented rats subjected to contusion injury.   
 
5.2  Method 
5.2.1  Animals and interventions 
5.2.1.1  Experimental animals 
Fifty five male Wistar rats were used in this study.  All rats were housed in groups of 5 in 
standard rat cages and fed rat chow and tap water ad libitum.  All conditions inside the 
animal house were kept exactly the same as those mentioned in the two previous chapters 
(Chapter 3 and 4).  Fifty animals were used for in vivo compartment of the study, while 5 
extra control animals (non-injured and non-supplemented) were used for preparation of 
primary neutrophil cultures used in the in vitro study.  
Preceding the onset of the supplementation protocol and contusion injury, experimental rats 
were randomly divided into 4 groups (see Figure 5.1).  These groups consisted of a control 
placebo (C-PLA; n=5), a control proanthocyanidin (C-PCO; n=5), a chronic injury placebo (I-
PLA; n=20, i.e. 5 rats per time point which include 12 hr, 1 d, 3 d, and 5 d post-injury) and a 
chronic injury proanthocyanidin (I-PCO; n=20, i.e. 5 rats per time point which include 12 hr, 1 
d, 3 d, and 5 d post-injury) group.  All groups were treated with either placebo or 
proanthocyanidin similar to that of the rats used for the study in chapter 3, with the exception 
that the protocol here was terminated at day 5 after injury and not day 14 as in chapter 3, 
since this time point was deemed long enough after injury to inform on inflammatory cell 
behaviour. 
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Figure 5.1:  Experimental design 
 
 
5.2.1.2  PCO administration 
Rats, with the exception of the animals used for neutrophil isolation, were orally gavaged with 
either 20 mg/kg/day Oxiprovin™ (dissolved in 0.9 % saline) or 0.9 % saline (placebo) for the 
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duration of the experimental procedure.  Control (C) rats were gavaged for 2 weeks without 
injury and contusion injury groups received Oxiprovin™ or placebo for 2 weeks prior to injury, 
as well as up to 5 days after injury. 
 
5.2.1.3  Induction of muscle injury 
Rats were anaesthetised with isofluorane (inhaled anaesthetic, Isofor, Safe Line 
Pharmaceutricals, South Africa) 5 minutes prior to injury (as described in chapter 3) by 
means of a vaporiser (Ohmeda Isotec 3 unit) and kept under general anaesthesia while 
injury was experimentally achieved [an anaesthetic environment was induced in rats with 4 % 
(v/v) isoflurane in medical oxygen (Affrox, South Africa), and anaesthetic conditions were 
maintained with 2 % (v/v)].  In this specific study, animals regained consciousness within 1 
minute of removal of the anaesthesia.  All rats were injured at 8:00 in the morning, with the 
exception of the 12 hr group, where rats were injured at 20:00 to allow all sacrifice time 
points to coincide.  
 
5.2.2  Sacrifice and sample collection 
Sacrifice procedures and sample collection in this study is similar to that already described in 
Chapter 3, section 3.2.1, with the exception that muscle samples were not obtained.  
Sacrifice took place at 12 hr, day 1, 3, and 5.  Another exception was that plasma samples 
were aliquoted into sterile 1.5 ml eppendorff tubes and stored at -80 °C until needed for the 
migration assay.  After plasma collection, the whole blood was reconstituted with sterile PBS.   
 
5.2.3  Sample analysis 
5.2.3.1  Total and differential white blood cell and subpopulation counts 
Heparinised whole blood samples were analysed for total and differential white blood cell 
count using a CellDyne 3700 CS Haematology Analyzer (Abbott Diagnostics, Fullerton, CA).    
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Whole blood was used to determine total and differential white blood cell counts, as well as 
selected macrophage subpopulation at various time points after injury, whereas plasma 
samples were used to study neutrophil migration.  Whole blood samples from the extra 5 rats 
were used to isolate neutrophils, which were also used in the migration study. 
For flow cytometry (BD FACSAria™ Cell Sorter, BD Biosciences, San Jose, CA), monoclonal 
antibodies were used to identify neutrophils (FITC-conjugated anti-His48), total macrophages 
(Texas Red-conjugated anti-F4/80) and the two different macrophage subpopulations (FITC-
conjugated anti-CD68 for M1 and APC-conjugated anti-CD163 for M2c) in samples of PCO 
and PLA-treated rats at different time points after injury.    
Briefly, this entailed incubation of whole blood with CD32, an Fc block antibody, to block the 
Fc receptors on particularly monocytes and macrophage surfaces.  This will limit background 
staining, since some antibodies may bind to specific cells via antibody Fc portions.  
Thereafter, the whole blood was incubated with the respective antibodies and red blood cells 
lysed before flow cytometry (see Appendix H for detailed method).  A PBS control (whole 
blood incubated with PBS instead of antibodies) was also used to optimise the method.  The 
neutrophil population was set as gate and M1 and M2c macrophages were calculated per 
5000 neutrophils.  Since 500 µl of whole blood was used for flow cytometry purposes for 
neutrophil or macrophage runs, and the total number of neutrophils were also quantified, the 
volume used to count 5000 neutrophils could be calculated.  Macrophage counts were 
multiplied with this volume and expressed as the number of cells per µl. 
 
5.2.3.2  Cell migration 
Cell migration of neutrophils from control rats was measured using 24-well plates (BD 
Biosciences) with 3 µm pore size polycarbonate inserts (Falcon, BD Biosciences) (see 
Appendix I).  Briefly, RPMI 1640 media with the chemotactic factor, N-formylmethionyl-
leucylphenylalanine (fMLP, 1x10-7 M) were added to the bottom wells, whereas RPMI media 
containing 200 000 cells/well with 100 ng/ml G-CSF (stimulate neutrophils) and 20 % 
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conditioned plasma from either control (C-PLA or C-PCO) or supplemented rats (I-PLA or I-
PCO) at different time points after injury were added to the inserts (see Figure 5.2).  The 
inserts and bottom wells were then allowed to incubate for 15 minutes at 37 °C separately 
prior to migration, after which the inserts were placed into their respective wells using sterile 
tweezers and allowed to migrate for 2 hr at 37 °C.  Neutrophils still left in suspension in the 
top chamber (A) and migrated but non-adherent neutrophils (D) were collected into 
eppendorff tubes (Figure 5.2), transferred to TruCOUNT tubes (BD Biosciences) and 
analysed using a Flow Cytometer (see Appendix I for specifics).  Cells attached to the insert 
filter (top – B; bottom – C) and to the bottom of the culture well (E) were stained with anti-
His48 (the `neutrophil marker) and Hoechst (nuclear marker) and visualised with a 
fluorescent microscope (see section 5.2.4.1).   
 
 
Figure 5.2:  An illustration of the neutrophil migration study setup.  Neutrophils, together with 
G-CSF and conditioned plasma were added to the top of the insert and allowed to migrate 
towarts fMLP in the bottom of the well.  (A) and (D) represents non-adherent neutrophils still 
in suspension, (B) and (C) represent neutrophils adherent to the top en bottom of the insert 
filter respectively and (E) neutrophils adherent to the bottom of the culture well.  
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In order to identify and utilize the best possible method to isolate neutrophils prior to 
migration, as well as to identify and quantify non-migrating and migrating neutrophils 
following the migration assay, several methods were tested.  The next section will focus only 
on the methods used. 
Neutrophil isolation:  Neutrophils were isolated, making use of a two-step process involving 
Ficoll-Histopaque-1077 (Sigma) and BD Cell lysis solution (BD), which yielded almost 95 % 
pure neutrophils.  See Appendix I for a full detailed description of the method.  
Non-migrated neutrophils in suspension:  BD TruCOUNT tubes may be used for determining 
absolute counts of leukocytes in blood.  For the purposes of this study, neutrophils (in 
suspension) were added directly to the TruCOUNT tubes.  After the pellet was allowed to 
dissolve, a known number of fluorescent beads was released and used to obtain the 
absolute number of neutrophils (cells/µl) in the sample, compared to 1000 bead events.  This 
method allowed for an accurate estimation of neutrophils, relative to manual counting of cells 
using a haemocytometer or on a slide after haematoxylin and eosin staining or staining with 
Rapidiff.   
Migrated neutrophils:  After cell migration, the media was aspirated and the insert and bottom 
well fixed in acetone:methanol (50:50) and airdried.  Inserts and wells were then stained with 
His48 (1/1000) and Hoechst (1/200).  This staining method resulted in clear staining of 
neutrophils on top of the insert and those busy migrating through the pores, as well as 
neutrophils adherent to the bottom wells.  This method also resulted in preserving neutrophils 
during staining, compared to methods where cells were fixed after staining using 2 % 
paraformaldehyde.    
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5.2.4  Data collection 
5.2.4.1  Immunofluorescent image collection with the Olympus Cell-R system 
Neutrophils adherent to the top and bottom of the insert filter, as well as to the bottom of the 
well, were visualised on an Olympus Cell-R system attached to an IX-81 inverted fluorescence 
microscope equipped with a F-view-II cooled CCD camera (Soft Imaging Systems).  Using a 
Xenon-Arc burner (Olympus Biosystems GMBH) as light source, images were excited with 
the 360 nm or 472 nm excitation filter for DAPI and FITC respectively.  Emission was 
collected using a UBG triple-bandpass emission filter cube (chroma).  The cells on the 
bottom surface of the culture well (migrated and adherent) were evenly distributed in all 
samples and thus only one 20x image was taken.  Using this image, an area of 39.6 µm2 of 
the total area of 132.67 mm2 (insert) and 606.5 mm2 (well) was analysed for number of 
neutrophils.  Due to the conical shape of the insert, there was a greater density of cells in the 
peripheral regions and a lower, even distribution of cells towards the centre of the insert.  
Images were thus taken in the central region, and the left top quarter of the image analysed.  
Since cells were also adherent to the bottom of the insert, the microscope focus was 
repositioned and cells viewed and counted in the same relative regions on the bottom 
surface of the insert filter.  Hoechst staining for nuclei was used to assist counting cells, since 
visibility was a bit impaired when His48 was also present. 
 
5.2.5  Statistical analysis 
Data were analysed using a Factorial ANOVA with Fisher post hoc tests to assess 
differences between subgroups.  All data are presented as means ± SEM, with p < 0.05 
regarded as statistically significant.  All statistical analyses were done using the computer 
software Statistica version 9 (StatSoft Software).   
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5.3  Results 
5.3.1  Total and differential white blood cell counts in peripheral blood 
5.3.1.1  Neutrophils 
For neutrophils, a main effect of time (p < 0.05) was observed in both PLA and PCO groups 
for circulating neutrophil numbers (Figure 5.3).  Over time, both groups showed an early 
increase 12 hours after injury, with an early reduction on day 1 after injury in the PLA group 
which was not apparent in the PCO group (p < 0.05) which remained high.  Both groups were 
at normal levels on day 3. 
 
 
Figure 5.3:  Number of neutrophils present in whole blood in control PLA and PCO rats and 
PLA and PCO rats with continued supplementation after contusion injury.  Statistical 
analysis: Factorial analysis of variance with Fischer post hoc test (* p<0.05, ** p<0.01).  n = 5 
rats per time point per group.  Error bars indicate SEM.   
 
5.3.1.2  Macrophage subtypes in circulation 
The scatter plot in Figure 5.4A illustrates the typical distribution of neutrophils (in the P3 
zone) compared to all other white blood cells in the P1 zone.  Figure 5.4B represent the 
typical scatter plot of macrophages co-stained with anti-CD163 (FITC-labelled M2c 
macrophages) and anti-CD68 (APC-labelled M1 macrophages).  Cells in Q1 are positive for 
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CD68, whilst cells in Q4 are positive for CD163.  Cells in Q3 are negative for both CD68 or 
CD163.    
 
Figure 5.4:  Representative image of a scatter plot of all white blood cells (A) and the 
macrophage subtypes (B).  Neutrophil identity (P3) were confirmed with FITC-anti-His48, 
whereafter macrophage numbers were normalised to neutrophil counts based on forward 
and side scatter characteristics (A).  Q1 indicate all macrophages of an M1 phenotype, 
whereas Q2 indicate all macrophages of an M2c phenotype.  
 
A main effect of time (p < 0.01) and a treatment-time effect (p < 0.01) was evident for M1 
macrophages.  The PLA group showed a significant transient increase in M1 macrophages, 
peaking on day 5 after injury (Figure 5.5), whilst M1 macrophages in the PCO group peaked 
significantly earlier (day 3).  Differences between groups occurred on day 3, with the PCO 
group having more M1 macrophages, and day 5, with the PLA group having more M1 
macrophages.      
Pre-injury the PLA and PCO groups differed significantly, due to the chronic nature of the 
PCO supplementation.  Main effects ANOVA indicated an effect of time (p < 0.01) and a 
time-treatment effect (p < 0.01) for M2c macrophages.  In response to injury, the PLA group 
displayed a significant early decrease in M2c macrophage number 12 hours after injury 
compared to its respective control, followed by a significant increase on day 3 (vs. 1d - 
Figure 5.6).  M2c macrophage numbers in the PCO group were unchanged over time, untill a 
significant increase was evident on day 5 after injury (different from all other PCO time 
A B 
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points), a point in time when the PCO group had significantly more M2c macrophages 
compared to the PLA group.  Overall, the M2c macrophages were lower and had a lower 
response than the M1 macrophages.   
 
 
Figure 5.5:  Number of M1 macrophages present in 1 µl of whole blood samples of control 
and injury rats expressed per number of neutrophils.  Statistical analysis: Factorial analysis of 
variance with Fischer post hoc test (* p<0.05, ** p<0.01, *** p < 0.001). n = 5 rats per time 
point per group.  Error bars indicate SEM. 
 
 
Figure 5.6:  Number of M2c macrophages present in blood samples of control and injury rats 
expressed per 5000 neutrophils.  Statistical analysis: Factorial analysis of variance with 
Fischer post hoc test (* p<0.05, ** p<0.01, *** p < 0.001). n = 5 rats per time point per group.  
Error bars indicate SEM. 
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5.3.2  Neutrophil migration in vitro 
5.3.2.1  Fractions probably not indicative of migratory ability 
No effect of time or treatment or a treatment-time effect was evident when neutrophils in 
solution in the top (A) and bottom wells (D) were analysed.  Neutrophils from these fractions 
probably do not represent significant phases of neutrophil migration, or that the timing of 
migration (2 hr) may have been too short for cells to adhere.  Table 5.1 represent the total 
number of cells that stayed in suspension and did not contribute to neutrophil migration. 
 
Table 5.1:  Total number of non-migrated neutrophils in solution on top of the insert filter, as 
well as non-adherent neutrophils in the bottom well 2 hr after initiation of the migration assay.   
 
Days post-injury PLA PCO PLA PCO 
Day 0 39535 ± 1861 
 
36637 ± 3032 26207 ± 1048 28116 ± 1711 
12 hours 33611 ± 3439 39922 ± 2416 26233 ± 911 24703 ± 1256 
Day 1 37789 ± 1688 42916 ± 2390 26809 ± 1127 25838 ± 3271 
Day 3 38211 ± 1766 36104 ± 2045 26655 ± 1467 29251 ± 936 
Day 5 42364 ± 1883 
 
41134 ± 3030 25373 ± 1326 27738 ± 1597 
 
 
Assessing the number of adherent neutrophils at the bottom of the well, factorial ANOVA 
indicated no main effects.  Although not statistically significant, 25 % fewer neutrophils 
adhered to the bottom of the culture well as a result of plasma from PCO-supplemented rats 
on day 1 after injury compared to the PLA group on that specific time point (Figure 5.7).  
Top of the insert  filter                Bottom well 
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Figure 5.7:  Number of migrated neutrophils adherent to bottom well after 2 hours of 
migration stimulated by fMLP (bottom well) and in the presence of plasma from either PLA- 
or PCO-supplemented rats (in the insert) harvested at various time points after injury.  
Statistical analysis: Factorial analysis of variance (ANOVA) with Fischer post hoc test 
indicated no statistical significance.  n = 5 rats per time point per group.  Error bars indicate 
SEM. 
 
5.3.2.2  Migrating neutrophils 
Cells migrated through and adherent to the bottom of the insert filter:  Repeated 
measures ANOVA indicated a main effect of treatment (p < 0.05), time (p < 0.001) and a 
treatment-time effect (p < 0.05).  Major responses were seen in the PLA group on day 1 after 
injury, a point in time where the PLA group had significantly more neutrophils in this position 
compared to all other PLA time points and compared to the PCO group on that day (Figure 
5.8).    
Cells adherent to the top of the insert filter:  Both a main effect of treatment (p < 0.01) 
and a treatment-time effect (p < 0.05) were evident.  The major difference was seen on day 
1:  significantly fewer neutrophils in the PLA group were present in comparison to all other 
time points in this group, and also when compared to day 1 PCO (Figure 5.9).  Figure 5.10 
illustrates representative images of a field of view of cells adhering to the top of the insert 
filter (A) and the bottom of the insert filter (B). 
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Figure 5.8:  Number of migrated neutrophils adherent to bottom of the insert after 2 hours of 
migration stimulated by fMLP (bottom well) and in the presence of plasma from either PLA- 
or PCO-supplemented rats (in the insert) harvested at various time points after injury.  
Statistical analysis: Factorial analysis of variance with Fischer post hoc test (* p<0.05, *** p < 
0.001).  n = 5 rats per time point per group.  Error bars indicate SEM. 
 
 
Figure 5.9:  Number of non-migrated neutrophils adherent to top of the insert after 2 hours of 
migration stimulated by fMLP (bottom well) and in the presence of plasma from either PLA- 
or PCO-supplemented rats (in the insert) harvested at various time points after injury.  
Statistical analysis: Factorial analysis of variance with Fischer post hoc test (* p<0.05, *** p < 
0.001).  n = 5 rats per time point per group.  Error bars indicate SEM. 
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Figure 5.10:  Representative image of cells adherent to the top of the insert filter (A) and the 
bottom of the insert filter (B).  Note that the cells adherent to the top of the insert filter were 
relatively few, compared to those adherent to the bottom of the insert filter (representative 
image of the PLA group on day 1). The trans image was used to visualise the filter pores for 
easy identification.  Neutrophils were labelled with His48 (FITC, green) and the nuclei with 
Hoechst (blue). 
 
5.4  Discussion 
We report 3 main findings for this study.  Firstly, circulatory neutrophils were significantly 
reduced on day 1 after injury in the PLA group whilst they were significantly elevated at this 
time point following chronic PCO supplementation.  Secondly, chronic PCO supplementation 
resulted in a significantly early increase and then decrease in M1 macrophage numbers (day 
3 and day 5 respectively) in circulation, with a concomitant rise in M2 macrophages on day 5, 
at which time the PLA group had a similar elevation in M1 subtype than was seen 2 days 
earlier in PCO.  Thirdly, neutrophil migration in vitro was blunted as a result of conditioned 
plasma from PCO supplemented rats compared to PLA supplemented rats on the day 1 time 
point specifically. 
Hoechst 
A 
B 
Hoechst and His48 Hoechst, His48 and Trans 
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5.4.1  Neutrophil count and migration study 
White blood cells (leukocytes) are continuously being circulated from the blood into various 
immune compartments, a function essential for the maintenance of an effective immune 
defence system (Sprent and Tough 1994).  The absolute numbers and relative proportions of 
these leukocytes in the blood provide important information regarding the distribution of 
leukocytes in the body and possibly also the activation status of the immune system. 
Numerous studies have investigated the effect of exercise on circulating blood leukocytes 
absolute number, percentage distribution and in vitro function (MacIntyre et al., 1996; Smith 
et al., 1998; MacIntyre et al., 2000; Malm et al., 2000; Quindry et al., 2003).  These studies 
are regarded as important in order to understand the function of the immune system.  
Collectively, these findings also highlight whether there is an inflammatory process and what 
the magnitude of the response is.  The recent history or current use of muscle, and possibly 
injury-specific interactions between muscle and inflammatory cells will influence these 
parameters. 
Inflammation begins at the onset of exercise or damage, when the circulating level of 
neutrophils increases significantly, at a point in time that differs depending on the type of 
injury (MacIntyre et al., 1996; Smith et al., 1998; MacIntyre et al., 2000; Quindry et al., 2003).  
In two different exercise studies, it was evident that neutrophils appear in the blood at 
different time points depending on the type of exercise, but their disappearance from the 
blood coincided (Malm et al., 2000; Starkie et al., 2001).  Neutrophils in the current study in 
the PLA group were significantly increased 12 hr after contusion injury and decreased on day 
1, a time point similar to that seen by Malm and Starkie’s groups (Malm et al., 2000; Starkie 
et al., 2001).  This decrease in circulatory neutrophil numbers could explain the increase 
observed in neutrophils infiltrating the injured and border zone areas on day 1 after injury in 
the PLA group (see Chapter 3).  What this indicates is that in order for damaged muscle to 
repair itself, neutrophils need to migrate into the injured area from circulation, a statement 
supported by the literature (Robertson et al., 1992).  However, many studies only 
179 
 
investigated neutrophils in circulation or in the injured or inflamed tissue, without assessing 
both compartments.  It is therefore a strength of this study that neutrophil infiltration into the 
injured tissue was also assessed using the exact same protocol.   
In the PCO group, although neutrophil numbers were also elevated 12 hr after injury, it 
remained elevated on day 1 and only decreased 3 days after injury.  However, no significant 
elevations in neutrophil number were evident in the PCO group in the muscle on day 3 or any 
other time point (see Chapter 3).  This might suggest that although neutrophil numbers 
decrease in circulation, neutrophils are not able to migrate into the injured area.   
It is well known that in order for neutrophils to enter the tissue from circulation 
(migration/diapedesis), it requires the communication between a whole range of cells and 
tissue itself, which include myocytes, together with mast cells from local connective tissue 
(Fielding et al., 1993).  If the muscle fibre is injured, e.g. as a result of an active stretch, or 
contusion injury, the myocyte interacts with the endothelial wall of the adjacent blood vessel, 
releasing a series of signalling molecules or cytokines, ultimately resulting in the infiltration of 
a cascade of events and neutrophil chemotaxis (Fielding et al., 1993).  It is therefore possible 
that PCO alters the ability of neutrophils to migrate to the injured tissue. 
The neutrophil chemotaxis assay enabled the determination of whether PCO or PLA 
supplementation could influence the magnitude of neutrophil migration.  In this study, a 
transwell assay system was used to test neutrophil migration towards the chemotactic agent,  
fMLP under standard conditions.  Neutrophil migration has been previously studied in vitro 
through 3 µm pores in a transwell system (Smith et al., 1993), but an endothelial cell 
monolayer was necessary to separate the chamber containing the cells from the chamber 
containing the chemoattractant.  Since the goal was to determine the effect of conditioned 
plasma from PCO supplemented rats on neutrophil migration, it was decided to use uncoated 
3 µm pore membranes without an endothelial layer.   
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After migration, equal numbers of neutrophils were evident in suspension in the bottom well, 
irrespective of the addition of plasma from PCO or PLA supplemented rats and irrespective 
of time post-injury, therefore suggesting that gravity might have played a role.  Although it 
may indicate that plasma from PCO supplemented rats had no effect/benefit on neutrophil 
migration, 25 % more neutrophils were evident at the bottom of the migration chamber when 
incubated with conditioned plasma from PLA supplemented rats a day after injury compared 
to all time points in the PCO group.  Similarly, and significantly so, more neutrophils were 
also seen at the bottom of the insert at that specific time point in the PLA group compared to 
the PCO group, verifying the results of blunted neutrophil infiltration after PCO 
supplementation seen in the injured muscle (Chapter 3).  
As highlighted in the introduction, a number of possible mechanisms could explain this 
finding.  It is known that pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) are released as 
a result of injury, and that these cytokines can indirectly cause chemotaxis of granulocytes 
and monocytes, these leukocytes in turn producing further cytokine expression and the 
expression of other pro-inflammatory mediators (Utsunomiya et al., 1996).  TNF-α specifically 
has been shown to be responsible for the release of chemotactic factors such as cytokine-
induced neutrophil chemoattractant (CINC-1, equivalent to rat IL-8), an important mediator 
promoting neutrophil migration and also further exacerbating inflammation (Clozel et al., 
1993).  CINC-1 can increase the expression of LFA-1 integrin on rat neutrophils (Frevert et 
al., 1995) and because expression of leukocyte adhesion molecules such as E-selectin is 
dependent on CINC (Harris et al., 1996), the likely outcome is an increase in neutrophil 
chemotaxis.  In Chapter 3, in the PLA group, both pro-inflammatory cytokines, TNF-α and IL-
6 were elevated locally, on day 1 and 3 after injury in the border zone and injured area 
respectively.  In the PCO group on the other hand, a blunted pro-inflammatory cytokine 
response was evident in both circulation and in the muscle.  Although these results suggest 
that the pro-inflammatory cytokines might be directly responsible for upregulation of integrin 
expression on neutrophils and adhesion molecule expression on endothelial cells, cytokine 
181 
 
release from injured muscle is an effect of injury and may not be a direct cause of a blunted 
neutrophil response, although it might contribute to the effect seen. 
In a study by Garbacki et al. (2004), proanthocyandin from Ribes nigrum leaves was 
harvested and supplemented after carrageenin injection into the plantar region of rat paws.  
Supplementation resulted in the inhibition of TNF-α and CINC-1 levels in pleural exudates of 
the paw membrane indicating that proanthocyanidin might either be directly or indirectly 
responsible for reducing neutrophil migration (Garbacki et al., 2004).  Proanthocyanidin has 
also been shown to reduce the expression of soluble adhesion molecules, ICAM-1, VCAM-1 
and E-selectin in the plasma of systemic sclerosis patients (Kalfin et al., 2002), suggesting 
that PCO might rather have a direct effect on adhesion molecule expression instead.  
A second possibility is a decreased expression of chemotactic factors as a result of 
conditioned plasma from PCO-supplemented rats.  However, since an equally low number of 
neutrophils migrating through the insert filter at all time points in the PCO group was 
observed, as well as all time points in the PLA group, except day 1, the explanation for the 
inhibition of chemotaxis cannot be as a result of a general effect on chemotactic factor 
expression. 
Another possibility to take into account is the potential contribution of G-CSF, which was 
added to all wells.  In a study by Yong (1996), it was demonstrated that G-CSF increases the 
adhesion of neutrophils to both resting and TNF-α-stimulated microvascular endothelial cells.  
Data have also shown that G-CSF upregulates expression of neutrophil adhesion molecules 
in mature neutrophils in vitro (Carulli 1997), as well as increases neutrophil migration (in 
vitro) across a chemotactic gradient in samples from healthy controls and patients with liver 
cirrhosis (Fiuza et al., 2002).  The researchers suggested that this effect of G-CSF is most 
probably due to the direct interaction of G-CSF with neutrophils, as G-CSF failed to enhance 
the secretion of pro-inflammatory cytokines such as TNF-α and GM-CSF or to upregulate the 
expression of adhesion molecules on endothelial cells (Yong 1996; Carulli 1997; Fiuza et al., 
2002).  Although the studies mentioned above suggest that G-CSF can increase the 
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adhesion and migration of neutrophils, the in vivo conditions are more complex to explain.  In 
one specific study, intravenous administration of G-CSF resulted in a decrease in the 
absolute neutrophil count, suggesting that the neutrophils might be bound to the endothelium 
instead, and not migrating (de Haas et al., 1994).  In the current study, G-CSF treatment 
alone, without plasma from PCO- or PLA- supplemented rats, had no effect on neutrophil 
migration, indicating that G-CSF only stimulated neutrophils.   
Thirdly, it is known that neutrophils need to be activated prior to adherence to the 
endothelium and migration.  PCO might have exerted its effect in blunting migration by 
altering neutrophil activation.  However, since treatment of neutrophils with G-CSF in 
combination with plasma from PCO supplemented rats decreased the number of neutrophils 
migrating, but increased the number of neutrophils in the top of the insert, it indicates that 
neutrophils were activated, and therefore they might have been bound too tightly to the insert 
filter itself.  Thus, the possible explanation for PCO’s ability to blunt neutrophil migration at 
the day 1 time point specifically is its ability to alter adhesion molecules on neutrophils and 
possibly endothelium (although not measured here) instead for neutrophil adhesion.  Another 
possibility is that PCO might alter the expression of the adhesion molecule, platelet-
endothelial cell adhesion molecule (PECAM)-1, necessary for neutrophil transmigration.  In 
an in vitro study, it was demonstrated that antibodies against PECAM-1 could significantly 
block neutrophil migration through an endothelial monolayer, without influencing neutrophil 
adhesion (Muller et al., 1993).  This effect has also been confirmed in vivo (Vaporciyan et al., 
1993).  One specific study investigated the effect of resveratrol on PECAM-1 expression 
(Robich et al., 2010).  In this particular study, resveratrol was able to reduce the expression 
of PECAM-1 in blood vessels, which suggests that it can potentially limit subsequent 
neutrophil migration.  This might also be true for PCO in the current study.  The mechanism 
by which PECAM may regulate migration is largely unknown, but it has been thought that it 
involves regulating the expression of the other cellular adhesion molecules (CAMs) on 
neutrophils themselves (Muller et al., 1993).     
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Studies have shown that the CAMs play vital roles in neutrophil migration.  More specifically, 
the interaction between one of the β2 integrins [lymphocyte function associated antigen-1 
(LFA-1, CD11a/18), L-selectin/CD62L or CD11b/Mac-1] and the ligand of immunoglobulin 
intercellular adhesion molecule-1 (ICAM-1) are involved in the process of neutrophil 
migration to an inflammatory lesion (Fiuza et al., 2002).  It has also been shown that after 
neutrophil migration, the expression of surface molecules such as CD29 (β1-integrin) and 
CD18 (β2-integrin) are significantly increased (Kubes et al., 1995; Roussel and Gingras 
1997; Poon et al., 1999), whereas L-selectin is shed (Lewinsohn et al., 1987; Jutila et al., 
1989).     
Antioxidants such as the glutathione (GSH) precursor and radical scavenger N-acetyl-I-
cysteine (NAC) and the antioxidant pyrrolidine dithocarbamate have been shown to inhibit 
adhesion molecule expression (ICAM-1 and VCAM-1 in vitro) induced by cytokines or 
oxidants in different cell types (Marui et al., 1993; Weber et al., 1994; Kawai et al., 1995; Aoki 
et al., 1996).  Other in vitro studies also found that coincubation of resveratrol (another 
grape-derived polyphenol) with different endothelial cell lines (HUVEC, human saphenous 
vein endothelial cells – HSVEC or EA.hu926 cells) and lipopolysaccharide (LPS) or TNF-α 
respectively, resulted in a significant decrease in ICAM-1 and VCAM-1 expression on the 
endothelium (Ferrero et al., 1998).  This therefore suggests that resveratrol may exert its 
beneficial effect by modulating endothelial activation and adhesion rather than neutrophil 
activation (Weber et al., 1995; May et al., 1996; Ferrero et al., 1998).  In studies by Judge et 
al. (2008) and Novelli et al. (1997), it was shown that vitamin E has the ability to attenuate 
neutrophil infiltration following prolonged ischaemia-reperfusion in skeletal muscle, possibly 
due to a decreased expression of VCAM (Zapolska-Downar et al., 2000), ICAM and E-
selectin (Formigli et al., 1997; Wu et al., 1999).  However, not only do antioxidants modulate 
the expression of adhesion molecules on endothelial cells, they also influence the expression 
of the β2 integrins on neutrophils.  In a study regarding the grape seed derivative, 
resveratrol, it was shown that resveratrol has the ability to decrease the expression of Mac-1 
(Rotondo et al., 1998).  These studies therefore suggests that antioxidant supplements might 
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modulate neutrophil migration, either by decreasing adhesion molecule expression on 
endothelial cell, or decrease β2 integrin expression on neutrophils, or both.   
Currently, the specific mediators responsible for the PCO’s ability to blunt neutrophil 
migratory behaviour are unknown.  Expanded efforts making use of cell culture models have 
the potential to clarify these, and could include the incubation of neutrophils either with or 
without an endothelial cell layer with PCO for a period of time, followed by staining for soluble 
receptors or adhesion molecules on neutrophils and endothelial cells specifically.  From the 
literature it is clear that PECAM-1, ICAM-1 and VCAM-1 are worth investigating, as well as 
the Mac-1 integrin on neutrophils.   
     
5.4.2  Macrophage subtypes 
Another goal of the present study was to identify the different subpopulations of monocytes in 
normal rat peripheral blood and in blood harvested at different time points after injury with 
respect to phenotype.  The criteria used to distinguish monocytes were their expression of 
different receptors present on the membrane of monocytes.  Different subpopulations of 
human monocytes can be distinguished according to their expression of CD64 or CD14 and 
CD16.  In mice different markers are used, which include CX3CR1, CCR2, and L-selectin 
(CD62L).  It has been shown in different studies that low expression of CX3CR1 and high 
levels of CCR2 and CD62L are indicative of an M1 phenotype and are recruited to sites of 
inflammation, whereas monocytes expressing high levels of CX3CR1 are predominantly 
recruited to non-inflamed sites (Geissmann and Littman 2003).  This therefore suggests that 
M1 monocytes are the first macrophage to infiltrate the injured area and are involved with 
inflammation, whereas M2 macrophages are only evident when it can be observed that 
inflammation is decreasing.  Another study also identified two very distinct populations of 
F4/80-positive mononuclear cells in peripheral blood of CX3CR1GFP/+ in mice, of which only 
one population expressed CD62L (Palframan et al., 2001), similar to the results seen by 
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Geissmann and Littman (2003).  Together these studies all concur, even though different 
methods were used.   
Results from a study by Sunderkotter et al. (2004) illustrated that distinct subpopulations of 
monocytes can be identified in peripheral blood of normal mice by differential expression of 
various surface markers, in particular, Ly-6C.  Monocytes in circulation are immature and 
predominantly express high levels of Ly-6C (ED1 in rats).  However, monocytes are able to 
mature in circulation under steady state conditions, a process which is reflected by down-
regulation of Ly-6C expression (Sunderkotter et al., 2004).  During inflammation, it has been 
shown that only Ly-6Cmed/high monocytes (still immature) are recruited to the affected sites to 
become inflammatory macrophages.  During inflammation, monocytes also enter the 
bloodstream from bone marrow as immature Ly-6Chigh monocytes, and while some of these 
monocytes migrate to the injured area, the rest gradually down-regulate their Ly-6C 
expression (M2 phenotype) and mature in blood approximately 2 days later (de Bruijn et al., 
1994), and are unable to migrate into the injured area or only to a lesser extent.  What this 
section therefore suggests is that although the M2 macrophage subtypes are found in 
circulation, only M1 macrophage can play a predominant role and can enter the injured area.   
In the current study, CD68 was used to determine M1 monocytes, whereas CD163 was used 
to determine M2c monocytes.  It has been suggested that under normal conditions, human 
and rat macrophages stain brightly for CD163 and play a role in the resolution of 
inflammation as they are found in high numbers in inflamed tissue (Zwadlo et al., 1987), 
whereas CD68 plays a role in phagocytosis and has been shown to release pro-inflammatory 
mediators (Zwadlo-Klarwasser et al., 1995).  In the studies mentioned above, it was shown 
that the anti-inflammatory cytokine, IL-10, but not IL-4 or IL-13, has the ability to increase the 
expression of CD163 on cultured monocytes.  Together these studies suggest that the M1 
monocytes (CD68+) may be able to convert themselves to M2 in the presence of IL-10.  In 
one specific study, circulating monocytes were labelled with both CD163 and CD14 (M2 
phenotype), and it was found that CD163 is expressed on nearly all circulating M2c 
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monocytes (Sulahian et al., 2000).  However, although it has been found that CD163 is 
expressed on circulating M2c monocytes, the presence of this M2 phenotype in circulation 
has not been studied as extensively as the existence of the M1 phenotype. 
The current study indicated that relatively few M1 monocytes/macrophages were evident in 
the PLA group on day 3 after injury, compared to that in the PCO group.  On day 5 on the 
other hand, M1 monocytes/macrophages were significantly elevated in the PLA group, but 
reduced again in the PCO group.  In contrast, more monocytes/macrophages in the PCO 
group (day 5) expressed the chosen marker of the M2c phenotype (CD163), indicating that 
PCO supplementation resulted in, not necessarily a monocyte phenotype switch from M1 to 
M2c, but mobilisation of the majority of the M1 monocytes into the injured tissue, whilst a 
number of the M1 monocytes might mature into M2c macrophages instead in the blood.  
Since the M1 monocytes on day 5 were significantly lower than that observed for the PLA 
group, it could also indicate that PCO might exert its beneficial effect on not only blunting 
neutrophil migration, but also inhibiting M1 monocytes early on.    
In the previous study in Chapter 3, in the muscle tissue, macrophages were significantly 
elevated in the PCO group on day 1 and 3 respectively and only declined on day 5, 
suggesting that the presence of macrophages at this time point in tissue might come from 
circulation and were of the M1 phenotype.  Similarly, macrophages in the PLA group were 
elevated on day 3 but also on day 5, and only decreased in numbers on day 7, suggesting 
the presence of M1 macrophages lasted for several days longer.  However, considering all 
the abovementioned literature, it is still unclear whether macrophages with an M2 phenotype 
are able to infiltrate the injured area from circulation.  Rather, it is thought that M1 monocytes 
infiltrate the injured area from circulation and potentially switch to M2c.  Taking into account 
the results from the current study and previous chapters, since high levels of IL-10 were 
detected in circulation in the PCO group on day 3, at the same time as the high M1 
macrophages, it is possible that PCO mediated IL-10 release in some way, and therefore 
resulted in an increase in M2c macrophages in the circulation which was evident on day 5 
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after injury (Figure 5.6).  Although the M2c macrophages increased significantly in PLA 
between days 1 and 3, this was mainly because they were significantly decreased from 
control at 12 hr and day 1, and returned to normal levels on day 3.  At no time did the M2c 
macrophages in the PLA group exhibit an increase relative to the control.  
 
5.5  Conclusions and limitations 
In this study, it was determined that PCO in Oxiprovin™ do indeed have an anti-inflammatory 
action.  Results from this chapter suggested that chronic PCO supplementation results in a 
macrophage switch from a M1 (pro-inflammatory) to a M2c (anti-inflammatory) phenotype on 
day 5 after injury, a point in time when M1 macrophages were expressed at a high number in 
the PLA group.  Data on the effects of PCO on the relative proportions of M1 and M2 
macrophages within the muscle would be valuable for addressing the relative importance of 
diapedesis and phenotype switching in the changes observed in circulating macrophages 
and should be included for future studies.  Conditioned plasma from PCO-supplemented rats 
also resulted in decreased chemotaxis of control neutrophils towards the chemoattractant 
fMLP.  Because neutrophils have been demonstrated to injure skeletal muscle in vitro and in 
vivo, this specific mechanism of action of PCO provides a potential avenue for alleviating 
neutrophil-mediated secondary muscle injury.  Oxiprovin™ may inhibit the early process of 
neutrophil activation (possibly through inactivating adhesion molecules), and it speeds up the 
mobilisation of M1 macrophages, thus allowing an earlier inflammatory macrophage 
infiltration and phenotype switch. 
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CHAPTER 6 
 
Synthesis 
Both skeletal muscle and immune cells are severely affected by contusion injuries.  Although 
our group have previously shown beneficial effects of a plant-derived polyphenol antioxidant 
(proanthocyanidolic oligomers (PCO) in Oxiprovin™) on muscle recovery, these benefits 
have not been comprehensively investigated.  Therefore, it was the aim of this thesis to 
determine its effect and possible mechanisms of action. 
Initial qualitative comparison of two different treatment regimes revealed that chronic PCO 
supplementation resulted in earlier ultrastuctural recovery than acute post-injury treatment, 
as seen with the H&E sections of the 14 day time point (Figure 6.1).  Muscle from chronically 
supplemented rats illustrated full muscle regeneration, while muscle from acutely 
supplemented rats still displayed some fiber disorganisation – the result of either residual 
oedema or possibly altered adhesion molecule profile – although both supplemented groups 
displayed better ultrastructural recovery when compared to placebo groups.    
 
Figure 6.1:  Histological comparison of muscle recovery after chronic vs. acute PCO 
supplementation. 
Day 14 Day 14 
Chronic Acute 
PLA 
PCO 
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The recovery process involves multiple processes and multiple contributing cells and factors.  
Therefore in order to explain the qualitative results, it is necessary to consider more than one 
potential role player.  A particular strength of this thesis is that a variety of contributors were 
investigated in more than one compartment.   
In the tissue compartment, satellite cells are arguably the most important role player in 
muscle regeneration.  For a treatment to be effective in resulting in quicker muscle 
regeneration, satellite cell activation needs to occur much quicker.  With chronic 
supplementation, the supplement was already available at tissue level at the time of injury, 
which was not the case with acute supplementation, where supplementation only started two 
hours after injury.  Therefore, the difference in recovery can be ascribed at least in part, to 
earlier PCO-induced satellite cell activation.  This was evident in the Pax-7 data, which 
indicated earlier satellite cell activation in the supplementation group. 
However, satellite cells were clearly not the only cell type affected by supplementation.   
The inflammatory process was significantly altered.  Chronic and acute PCO 
supplementation resulted in similarly suppressed neutrophil profiles, indicating that at least 
one possible mechanism of action of PCO is limiting neutrophil-associated secondary 
damage (potential mechanisms investigated will be discussed later).  However, the 
macrophage data is less clear cut.  Both chronic and acute supplementation had a similar 
effect of macrophage infiltration after injury.  Chronic PCO supplementation resulted in a shift 
to the left of time course for macrophage infiltration compared to acute supplementation, 
suggesting that if PCO is taken chronically, it will result in a quicker inflammatory response.  
Interestingly though is the suppression of macrophage infiltration in the border zone after 
acute supplementation, which provides further support for PCO’s proposed mechanism of 
limiting secondary damage.   
The macrophage response in the chronic PCO group also coincided with tissue cytokine and 
satellite cell responses.  This could indicate that PCO, at least as a chronic supplement, was 
able to alter the time course of appearance of macrophages, due to its direct effect on 
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satellite cells and possibly cytokine production.  Since the macrophage response in the acute 
supplementation protocol did not coincide with either the tissue cytokine profile or satellite 
cell response (these two latter responses coincided with one another), it suggests that 
supplementation started 2 hr after injury might not provide adequate timing to affect the early 
responses after injury.  Perhaps starting supplementation at the time of injury might have 
provided a clearer picture or early immune cell infiltration and cytokine responses, closer to 
that seen with chronic supplementation.  However, in this study, this option was not 
available, since oral gavage is not possible with anaesthetised animals.    
Cytokines are not only produced locally (at tissue level) as a result of injury, but also appear 
in circulation later on.  Interestingly, PCO supplementation resulted not only in a blunted pro-
inflammatory cytokine response in the injured muscle, but also a blunted circulatory pro-
inflammatory cytokine response, and an increased circulatory anti-inflammatory cytokine 
response.  Since the response of the muscle pro-inflammatory cytokines, TNF-α and IL-6, 
coincided with the satellite cell response, after both acute and chronic supplementation, the 
direct effect of PCO on satellite cell activation could have accounted for this effect.  Although 
it is also known that macrophages has the ability to influence the pro-inflammatory cytokine 
response, the later appearance of macrophages in the injured area after acute 
supplementation cannot explain the cytokine response.  This suggests that although satellite 
cells and macrophages both produce cytokines, they do not necessarily have to be 
dependent on one another and only one cell type may be influenced by PCO 
supplementation.  
The finding of significantly higher IL-1β content on day 1 after injury in the acute PCO group, 
could indicate an earlier or more potent inflammatory response as a result of PCO 
supplementation.  However, since macrophage and neutrophil numbers (known to be 
responsible for IL-1β release) at that specific time point in the PCO group were relatively low, 
they could not have contributed to an elevation in IL-1β.  PCO could have stimulated 
fibroblasts instead to express IL-1β. 
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Turning attention to circulatory cytokines, no data are available on the effect of contusion 
injury on circulatory inflammatory cytokines, indicating that the findings in this study of an 
altered inflammatory profile in circulation are quite novel.  PCO supplementation resulted in a 
blunted circulatory pro-inflammatory response, which could be explained by PCO’s ability to 
blunt neutrophil infiltration whilst facilitating an earlier increase in macrophage numbers.  
Also, since IL-6 and TNF-α are produced locally as well, these cytokines might have exerted 
their effect locally, rather than “spilling” over in circulation.  The timing of appearance of 
cytokines in the blood was also delayed compared to their appearance in tissue in the 
current model, supporting this option.  Since an increase in tissue cytokines after chronic 
PCO supplementation were observed on day 1 and 3 respectively, it might suggest that time 
points between day 1 and 3, e.g. day 2 or 36 hr, might have been better suited for detection 
of a possible increase in pro-inflammatory cytokines.  Whilst blunting the pro-inflammatory 
cytokine response, PCO was also responsible for a significant increase in circulatory anti-
inflammatory cytokines on day 3 after injury, suggesting an anti-inflammatory action of 
macrophages.  M2 macrophages are known to be responsible for the release of anti-
inflammatory cytokines, one of which includes IL-10, suggesting that the elevations in total 
macrophages seen in the PCO group in the injured muscle on day 3 might potentially contain 
predominantly M2 macrophages.   
To enable a better understanding of the mechanism of chronic PCO in blunting the 
inflammatory response, whilst allowing for an earlier macrophage response, the presence of 
the M1 (classically activated) and M2c (alternatively activated) monocyte/ macrophage 
subtypes were determined in circulation.  We were able to show that PCO supplementation 
resulted in an earlier disappearance of M1 macrophages in circulation, whilst allowing the 
expression of the M2 phenotype.  Various studies in the literature have shown that only the 
M1 phenotype migrates to the injured area and then switch into a M2 phenotype, whereas 
others have not been able to detect the M2 phenotype.  Thus, although our results might 
potentially indicate that PCO supplementation resulted in a switch in macrophage subtypes 
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already in circulation, it does not necessarily imply that M2 macrophages were able to 
infiltrate the injured area. 
From the results regarding contusion injury, it is evident that a decreased neutrophil 
response in circulation coincided with increased neutrophil migration into the injured tissue, 
which suggests that neutrophils migrated to the injured tissue from blood.  The neutrophil 
response as a result of PCO supplementation did not follow the same pattern.  Since PCO 
supplementation resulted in a blunted neutrophil response at tissue level, the finding of 
decreased neutrophil numbers in circulation was somewhat surprising.  These results 
therefore implied that although neutrophil numbers decrease in circulation, PCO might 
function by binding neutrophils too tightly to the vascular endothelium itself, thereby 
suppressing its ability to migrate to the injured area.  Results from the migration study 
indicated that conditioned plasma from PCO-supplemented rats was able to blunt neutrophil 
migration towards a chemotactic factor at all time points after injury.  A couple of 
mechanisms whereby PCO might exert its beneficial effect on blunting neutrophil migration 
have been proposed and include: (a) its potential to influence local cytokine release; (b) its 
involvement in chemotactic factor release, (c) its ability to possibly alter the activation status 
of neutrophils, or (d) a direct effect on adhesion molecule expression either on the 
endothelium or on neutrophils themselves.  Although all of these mechanisms seem 
probable, results from the migration study, as well as support from other studies on PCO and 
antioxidants, suggested that the mechanism of action of PCO most probably involves 
modulating neutrophil migration, by decreasing both adhesion molecule expression on 
endothelial cell as well as β2 integrin expression on neutrophils, thereby limiting diapedesis 
of neutrophils.  However, although its ability to modulate neutrophil adhesion might be the 
likely option, the combined effect of PCO in blunting the circulatory inflammatory cytokine 
response might also be involved in limiting neutrophil chemotaxis. 
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6.3  Conclusions and recommendations for future studies 
This study indicated that PCO does not only have an antioxidant effect, but also anti-
inflammatory properties.  Since it is known that cytokines are important activators or 
suppressors of various inflammatory pathways, including the nuclear factor kappa B (NFκB), 
arachidonic acid or mitogen activating protein kinase (MAPK) pathways, and PCO blunts the 
pro-inflammatory cytokines whilst increasing anti-inflammatory responses, it is worth 
investigating which of the particular upstream and downstream effectors is primarily 
influenced.  Applying western blotting techniques could enable one to test which of the 
various components of the inflammatory pathways are influenced by both acute or chronic 
PCO supplementation.  Also, since we did not determine the different macrophage 
subpopulations at tissue level, immunohistochemical staining of muscle samples at different 
time points after injury will provide valuable insight into a possible phenotype switch after 
injury as a result of PCO supplementation.  In addition, a cell-culture based study can be 
implemented in which either tissue or blood macrophages can be stimulated with various 
inflammatory cytokines, followed by administration of PCO, which will also allow for the 
determination of a possible phenotype switch and the effect of PCO.    
Our results regarding blunting of neutrophil migration at all time points after injury with this 
particular PCO supplement are novel.  Further studies are needed to elucidate the exact 
mechanism(s) of action of PCO resulting in this effect.  Possible adhesion molecules worth 
investigating include CD11b (Mac-1) integrin on neutrophils, although the CD11a/CD18 
integrin might also potentially be involved.  ICAM-1 and VCAM-1 expression on endothelial 
cells should also be measured.  Though our migration study excludes the expression of 
these latter adhesion molecules (we did not add an endothelial cell layer to the culture 
study), the contribution of the endothelial cell adhesion molecules cannot be excluded.  
Finally, although this study provided valuable insight into the various role players involved in 
the recovery process after an injury, more studies are needed in order to answer some of the 
questions that arose during the course of this study.    
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Appendix A:  Automated tissue processing 
Reagents 
1.  Alcohol (70 %, 90 %, 95 %, 100 %) 
2.  Xylene – Sigma-Aldrich 
3.  Paraffin wax – Merck, Histosec melting point 56 °C 
 
Method 
Processing time: 
 A)  Dehydration 
  1)   70 % alcohol    – 1.5 hr 
  2)   70 % alcohol    – 1.5 hr 
  3)   90 % alcohol    – 1.5 hr 
  4)   95 % alcohol    – 1.5 hr 
  5)   95 % alcohol    – 1.5 hr 
  6)   100 % alcohol  – 1.5 hr 
  7)   100 % alcohol  – 1.5 hr 
  8)   100 % alcohol  – 2.0 hr 
 B)  Clearing 
  9)    Xylene                – 1.5 hr 
  10)  Xylene                – 2.0 hr 
C)  Impregnation 
  11)  Paraffin wax   – 2.0 hr 
  12)  Paraffin wax   – 2.0 hr 
 Thus Total processing time = 20 hr 
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Appendix B:  Conventional staining procedure for paraffin-embedded tissue  
Reagents 
1.  Alcohol (50 %, 80 %, 95 %, 100 %) 
2.  Xylene – Sigma-Aldrich 
3.  0.1 % Trypsin – Highveld 
         0.1 g trypsin in 100 ml PBS  
4.  PBS, pH 7.4 
       1 ℓ of 1 M phosphate buffer, 90 g NaCl, 9 ℓ ddH2O  
5.  For antibodies and serum used, see Table 1 (catalogue numbers and supplier provided) 
 
Method 
1. Incubate sections in Xylene: 2 changes, 5 min each. 
2. 100 % absolute alcohol:  2 changes, 3 min each. 
3. 95 % alcohol:  2 changes, 3 min each. 
4. 80 % alcohol:  3 min. 
5. 50 % alcohol:  3 min. 
6. Rinse in distilled water:  2 changes, 3 min each. 
7. Place slides in prewarmed (37 °C) 0.1 % trypsin for 20 min. 
8. Wash slides in PBS after trypsin (step 7, Appendix B). 
9. Encircle samples with a wax pen. 
10. Block for 20 min in 5% serum at room temperature (RT). (Note: Use the same serum in 
which the secondary antibody is raised.) 
11. Shake off serum and incubate sections for 4 hr at RT with the 1st primary antibody.  (Note:  
Do not wash after serum blocking step.) 
12. Wash slides with PBS and add the secondary antibody (1/250) to the sections.  Incubate 
for 40 min at RT.  (Note:  From here on, all steps should be performed in the dark.) 
13. Wash slides with PBS and add the 2nd primary antibody overnight at 4°C. 
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14. Add the 2nd secondary antibody (1/250) for 40 min after washing the sections thoroughly 
with PBS. 
15. Wash sections and add Hoechst (1/200) for 15 min. 
16. Wash slides well and mount with DAKO fluorescent mounting medium. 
 
Notes:  If only use 1 antibody, apply steps 1-12 and then 15 and 16 
 All dilutions and wash steps were done using phosphate buffered saline (PBS) 
If anti-human primary antibodies were used, I made sure that it also cross-reacted  
with rat tissue 
  
Table 1:  Antibodies used to identify satellite cells (Pax-7), pro-inflammatory cytokines (IL-6, 
TNF-α), neutrophils (His48), macrophages (F4/80), and basal lamina (Laminin). 
Antibodies 
 
[Stock]  Dilution Catalogue number  
and supplier  
Primary antibodies: 
 
   
Monoclonal mouse Pax-7 Not stated 1/200 Pax-7, Developmental Studies 
Hybridoma Bank 
Goat polyclonal IL-6 (M-19) 200 µg/ml 1/100 sc-1265, Santa Cruz 
Goat polyclonal TNF-α (L-19) 200 µg/ml 1/100 sc-1351, Santa Cruz 
Mouse monoclonal anti-rat His48 0.5 mg/ml 1/200 554905, BD Biosciences  
Goat polyclonal anti-mouse F4/80  
(A-19) 
200 µg/ml 1/200 sc-26642, Santa Cruz 
Rabbit polyclonal anti-human 
Laminin 
Not stated 1/200 Z 0097, Dako Diagnostec 
    
Fluorescent labelled secondary 
antibodies: 
   
Texas red donkey anti-goat 100 µg/ml 1/250 sc-2783, Santa Cruz  
FITC donkey anti-rabbit 100 µg/ml 1/250 sc-2090, Santa Cruz  
Alexa Fluor 594 goat anti rabbit 2 mg/ml 1/250 A11012, Invitrogen 
Alexa Fluor 488 goat anti-mouse 2 mg/ml 1/250 A11029, Invitrogen  
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Appendix C:  Flow cytometry - measuring cytokines with a CBA kit 
Reagents 
1.  Rat soluble protein master buffer kit – BD558267 
2.  Rat IL-10 – BD558306 
3.  Rat IL-4 – BD558307 
4.  Rat IL-6 – BD558308 
5.  Rat TNF-α – BD558309 
 
Sample preparations 
1. Perform instrument setup procedure. 
2. Dilute serum or plasma samples 1:4 with Sample Diluent and mix thoroughly before 
transferring the samples to the assay wells containing the Capture Beads. 
3. Reconstitute Standards mix and prepare serial dilutions using the Assay Diluent.  
3.1 Pool one lyophilized standard vial from each BD CBA Rat Soluble Flex Set to be 
tested into one tube (Recommended 15 ml Conical Tube, BD Falcon Cat.No.352097) 
and label it Top Standard. 
3.2 Reconstitute the standards with 4.0 ml of Assay Diluent and allow to equilibrate for 15 
min before making serial dilutions.  Do not vortex or mix standards vigorously, use 
only a pipette.  
3.3 Label 10 x 75 mm tubes (BD Falcon Cat.No.352008) and arrange them in the 
following order, according to dilution: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256. 
3.4 Pipette 500 µl of Assay Diluent in each of the labelled tubes. 
3.5 Perform a serial dilution by transferring 500 µl from the Top Standard to the 1:2 
dilution tube and mix thoroughly.  Continue making serial dilutions by transferring 500 
µl from one tube into the next one and continue up to the tube labelled 1:256 (see 
table 2).  Remember to mix by pipette only.  Prepare one tube containing Assay 
Diluent to serve as the 0 pg/ml negative control.  
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3.6 The first ten wells in the experiment should be used for the standards.  Standards 
should be run in order from least concentrated (0 pg/ml) to most concentrated (Top 
Standard). 
Table 2:  BD CBA Rat Flex Set Standard concentrations after dilution 
BD CBA Rat 
Soluble Protein 
Flex Set 
Top 
Standard 
1:2 
Dilution 
Tube 
1:4 
Dilution 
Tube 
1:8 
Dilution 
Tube 
1:16 
Dilution 
Tube 
1:32 
Dilution 
Tube 
1:64 
Dilution 
Tube 
1:128 
Dilution 
Tube 
1:256 
Dilution 
Tube 
Protein (pg/ml) 10000 5000 2500 1250 625 312.5 156 80 40 
 
4. Prepare the diluted BD CBA Rat Soluble Protein Flex Set Capture Beads using Capture 
Bead Diluent.  The Capture Beads provided in each BD CBA Rat Soluble Flex Set are at 
a 50x concentration and must be diluted before adding to a given assay well. 
4.1 Vortex each Capture Bead stock vial for at least 15 seconds to resuspend beads 
thoroughly. 
4.2 Determine the total volume of diluted beads needed for the experiment.  Each well 
requires 50 µl of the diluted beads.  The total volume of diluted beads can be 
calculated by multiplying the number of wells by 50 µl.   
eg, 35 tests × 50 µl = 1750 µl total volume of diluted beads 
4.3 Determine the volume needed for each Capture Bead.  Beads are supplied so that 
1.0 µl = 1 test.  Therefore the required volume (µl) of beads is equal to the number of 
tests.   
eg, 35 tests requires 35 µl of each Capture Bead included in the assay 
4.4 Determine the volume of Capture Bead Diluent needed to dilute the beads.  The 
volume of Capture Bead Diluent can be calculated by subtracting the volume for each 
bead tested from the total volume of diluted beads needed to perform the assay.   
eg, 1750 µl Tot vol dil beads - 35 µl for each bead = vol Capture Bead Diluent    
eg, if testing one analyte: 1750 µl – (35 µl x 1) = 1715 µl diluent 
eg, if testing 5 analytes: 1750 µl – (35 µl x 5) = 1575 µl diluent 
4.5 Pipette the Capture Beads and Capture Bead Diluent into a tube labelled Mixed 
Capture Beads. 
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5. Dilute BD CBA Rat Soluble Protein Flex Set PE Detection Reagents.  The PE Detection 
Reagent is a 50x stock (1 µL/test) and should be mixed with other Flex Set PE Detection 
Reagent (i.e. of different cytokine beads) and diluted to their optimal volume per test (50 
µl/test) before adding to a given assay well.  The calculations are the same as in the 
previous section.   
5.1 Pipette the Detection Reagents and Detection Reagent Diluent into a tube labeled 
Mixed PE Detection Reagents.  (Note: Protect the PE Detection Reagents from exposure 
to direct light because they can become photobleached and will lose fluorescent intensity and 
store at 4°C until ready to use.) 
 
Method 
1. Wet filter plate with 100 µl of Wash Buffer and aspirate using a vacuum manifold. 
2. Transfer 50 µl of capture beads to each assay tube or well. 
3. Add Standard Dilutions and serum/plasma samples to the appropriate wells (50 µl/well).  
Incubate for 1 hr at room temperature and protect from light (tinfoil).  (Note:  Everything 
should be done in duplicate.) 
4. Add mixed PE Detection Reagent to each assay well (50 µl/well).  Incubate for 2 hrs at 
room temperature, protected from light.   
5. Aspirate fluid. 
6. Add Wash Buffer to each assay well (150 µl/well) and analyze samples. 
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Appendix D:  ORAC assay 
Reagents 
Reagents used for the ORAC assay are tabulated below: 
Reagent [Stock]  [Working] Supplier 
AAPH*  153 mM 
0.414 g in 10 ml Phosphate 
buffer, pH 7.4 
Sigma-Aldrich 
44,091-4 
Fluorescein 
 
5x10-3 mM 
(4 °C) 
Light-sensitive 
8.16x10-5 mM (4 °C) 
Made up in phosphate buffer, pH 
7.4 
Sigma-Aldrich 
F6377-1006  
Potassium 
Phosphate buffer 
 75 mM (pH 7.4) (4 °C) 
6.5 g K2HPO4 in 500 ml dist. H2O 
5.1 g KH2PO4 in 500 ml dist. H2O 
Sigma-Aldrich 
60353 (Fluka) 
60218 (Fluka) 
Trolox** 
 
0.02 M 
(-20 °C) 
6.25 µM; 12.5 µM; 25 µM; 50 µM 
in phosphate buffer, pH 7.4 
Sigma-Aldrich 
56510 (Fluka) 
 
*  2,2’-Azobis-(2-methylpropionamidine)-dihydrochloride 
**  6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 
 
Method 
1. Defrost plasma samples at room temp and dilute them 75x with phosphate buffer 
(personal communication:  Dr. Dee Blackhurst, Cape Town University). 
2. Take approximately 10 mg of snap-frozen muscle tissue and add to phosphate buffer 
(1:75 w/v).  Continuously sonicate tissue samples on ice for approximately 1 minute using 
a tissue sonicator (Virsonic 300; The Virtis Company, Inc; Gardiner, N.Y; setting 3) and 
then centrifuge for 10 minutes at 8853xg (12 000 rpm) and 4 °C in a multispeed 
refrigerated centrifuge (PK121R, ACL International SRL, Milano, Italy). 
3. Add 150 µl fluorescein working solution to each well of a black plate. 
4. Add 25 µl TROLOX standards, plasma or tissue extract (supernatant) in triplicate to 
respective wells. 
 BUFFER TROLOX PLASMA/TISSUE 
EXTRACT 
AAPH FLUORESCEIN 
BLANK 25 µl ----- -----  150 µl 
STD ----- 25 µl -----  150 µl 
SAMPLE ----- ----- 25 µl  150 µl 
5. Cover plate with lid and incubate in preheated reader (37oC) for 10 min with 3 min 
shaking. 
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6. Rapidly add 25 µl AAPH to all wells. 
7. Read for 35 min with fluorescence measured every minute. (Excitation wavelength = 485 
± 20 nm; emission wavelength = 530 ± 25 nm). 
8. The net area under the curve (AUC) of all standards and samples are calculated from a 
graph of time (in minutes) against relative fluorescence intensity, as illustrated below:   
 
The AUC was calculated using Microsoft Excel XP as 
0.5 + ƒ1/ƒ0 + … ƒi/ƒ0 + … + ƒ34/ƒ0 + ƒ35/ƒ0                                                     (1)                                                                    
where ƒ0 = initial fluorescence reading at 0 minutes and ƒi = fluorescence reading at time i.   
The net AUC is obtained for all the samples, by subtracting the AUC of the blank from that of 
a sample or a Trolox standard.  
Net AUC = [(AUCsample or Trolox – AUCblank)                                                      (2)                 
9. The standard curve is obtained by plotting the Trolox standard concentrations against the 
average net AUC of these standards:  
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10. The final ORAC values are calculated using the regression equation between Trolox 
concentration and the net AUC.  Results are expressed as µmol Trolox equivalents per 
liter for liquid samples (plasma) and µmol Trolox equivalents per µg protein for solid 
samples (e.g. homogenised muscle).   
 
Note:  The dilution factor (75x in this study) needs to be included for final ORAC value 
calculation.  For the muscle samples, the ORAC values were obtained in the same way as 
that for the plasma samples, but in addition, the ORAC value was divided by the protein 
concentration determined using the Bradford assay (Appendix E).     
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 Appendix E:  Bradford assay 
Reagents 
1. 1 mg/ml bovine serum albumin (BSA) stock solution – Sigma-Aldrich 
     Diluted to 200 µg/ml  
2. Bradford reagent – Sigma-Aldrich, B6916 
 
Method 
1. Prepare phosphate buffer (ORAC) or RIPA (Western blotting, see Appendix G). 
2. Add all of the reagents mentioned in the table below to their respective tubes and 
generate the BSA standard curve: 
[ ] µg/ml BSA stock Distilled water Bradford reagent 
20 100 µl 0 µl 900 µl 
16 80 µl 20 µl 900 µl 
12 60 µl 40 µl 900 µl 
8 40 µl 60 µl 900 µl 
4 20 µl 80 µl 900 µl 
2 10 µl 90 µl 900 µl 
0 0 µl 100 µl 900 µl (BLANK) 
 
3. Vortex and leave on ice for 5 min. 
4. Zero the spectrophotometer with the BLANK and read the absorptions of the standards at 
595 nm. 
5. Add a small piece of snap-frozen tissue samples to either Phosphate buffer (ORAC 
assay) or RIPA buffer (Western blotting) and sonicate on ice for approximately 1 minute 
with a tissue sonicator (Virsonic 300; The Virtis Company, Inc; Gardiner, N.Y; setting 3) 
6. Centrifuge the homogenates for 10 min at 8853xg (12000 rpm) at 4 °C with a multispeed 
refrigerated centrifuge (model: PK121R centrifuge, brand: ALC international SRL, Milano, 
Italy). 
7. Prepare the tissue samples – 5 µl of muscle sample, 95 µl distilled water and 900 µl 
Bradford reagent.  Vortex and read the absorption at 595 nm (UV-visible 
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spectrophotometer, Cary 50) using the computer software Simple Read (version 2, 
WinUV, Cary 50).  (Note:  samples stable for up to 1 hr after preparation.) 
8. Plot the standard curve and calculate the protein concentration in µg:   
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Appendix F:  H&E staining protocol  
Reagents 
1.  10 % Acid alcohol 
       10 ml 1 % HCl dissolved in 1 ℓ 70 % alcohol 
2.  Alcohol (70 %, 95 %, 100 %) 
3.  Eosin 
       Stock solution: 
10 g Eosin dissolved in 1 ℓ distilled water 
       Working solution: 
10 ml Eosin stock solution dissolved in 90 ml distilled water. 
Prepare fresh daily. 
       For staining:   
           Add 2 – 3 drops glacial acetic acid per 100 ml before use. 
4.  Haematoxylin 
       5 g Harris haematoxylin  
       100 g Ammonium Alum 
       50 ml 100 % alcohol 
       1 ℓ distilled water 
       2.5 g Mercuric oxide 
 
       To prepare:  Dissolve haematoxylin in alcohol. 
    Add Ammonium Alum to distilled water and heat to boiling point. 
                          Immediately add mercuric Oxide and shake until solution has   
                         purple-black colour. 
     Cool rapidly in fridge. 
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       For staining:  Filter before use. 
                             Add 4 ml glacial acetic acid per 100 ml of haematoxylin. 
 
5.  Scott’s tap water 
       3.5 g NaHCO3 
       20 g MgSO4 
       10 ml 37 % Formalin 
       1 ℓ tap water 
   
       To prepare:  Dissolve NaHCO3 in tap water first. 
                           Add MgSO4 and formalin. 
6.  Xylene 
 
Method 
1.  Xylene (10 min) 
2.  100 % alcohol (10 dips) 
3.  100 % alcohol (10 dips) 
4.  95 % alcohol (10 dips) 
5.  95 % alcohol (10 dips) 
6.  70 % alcohol (10 dips) 
7.  Rinse in distilled water 
8.  Haematoxylin (3 min) 
9.  Rinse in distilled water 
10.  Rinse in acid alcohol 
11.  Rinse in distilled water 
12.  Blue in Scott’s tap water 
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13.  Rinse distilled water 
14.  2 min in Eosin 
15.  Rinse in distilled water 
16.  70 % alcohol (10 dips) 
17.  95 % alcohol (10 dips) 
18.  95 % alcohol (10 dips)   
19.  100 % alcohol (10 dips) 
20.  100 % alcohol (10 dips) 
21.  Xylene (10 dips) 
22.  Xylene (10 dips) 
23.  Mount with coverslip 
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Appendix G:  Western blotting 
Reagents (Gels and buffers) 
1. RIPA buffer  
      100mM Tris-HCl, 300mM Nacl (stock) 
      To 350 ml distilled water (dH2O), add 7.9 g Tris, 9 g NaCl and pH to 7.4 using HCl.   
      Make up to 500 ml with dH2O and keep at room temperature or in the fridge until needed. 
 
      On the day of extraction: 
Take 25 ml of RIPA stock and add 5 ml of a 10 % NP-40 stock solution, 1.25 ml of 10 % Na-
deoxycholate stock solution (an ionic detergent to extract protein, protect from light), 1 Roche 
complete protease inhibitor tablet, 1 Roche Phostop tablet and 0.25 ml of a 200 mM 
Phenylmethylsulfonyl flouoride (PMSF) stock solution (made up in isopropanol, stored at 
room temperature).   
Make up to 50 ml with dH2O and use immediately. 
 
2. 3x Sample buffer (pre-made, bench) 
      For a 0.5 M Tris solution, add 3.03 g to 50 ml distilled water and adjust the pH to 6.6. 
     Take 33.3 ml and add 8.8 g SDS, 20 g Glycerol and a tiny bit Bromophenol blue.   
      Fill up to 75 ml with dH2O. 
 
For making up samples, take 850 µl of the 3x sample buffer and add 150 µl β-
mercaptoethanol. 
SDS = denature proteins, constant anionic charge-to-mass ration 
Glycerol = give sample a higher density than buffer to “sink” to the bottom of the well 
Mercaptoethanol = reduce disulfide bonds present in protein sample 
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3. Resolving gel (2 gels)    12 %   10 % 
      Millipore H2O     3.35 ml  3.850 ml 
      1.5 M Tris-HCl, pH 8.8 (store in fridge)  2.5 ml   2.5 ml 
      (68.1 g Tris base dissolved in 1 liter dH2O) 
      10 % SDS stock (recipe below)   100 µl   100 µl 
      (10 g APS dissolved in 100 ml dH2O) 
      Acrylamide (carcinogenic)   3 ml   2.5 ml 
      10 % APS (fresh every day)   50 µl   50 µl 
      (0.1 g APS dissolved in 1 ml dH2O) 
      Temed (add at very end in fume hood)  20 µl   5 µl 
 
4. Stacking gel (2 gels)    4 %   5 % 
      Millipore H2O     3.05 ml  1.875 ml 
      0.5 M Tris-HCl, pH 6.8 (store in fridge)  1.25 ml  0.75 ml 
      (6.06 g Tris base dissolved in 1 liter dH2O) 
      10 % SDS-stock     50 µl   30 µl 
      Acrylamide     500 µl   375 µl 
      10 % APS (0.1 g/ml)    50 µl   20 µl 
      Temed (add at very end in fume hood)  10 µl   10 µl 
 
5. 10X running buffer (STOCK – store in fridge) 
Tris base 60.6 g 
Glycine 288 g 
10 % SDS 20 g 
Dissolve in 2 liter distilled water. 
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6. 10 x TBS (STOCK – store in fridge) 
      48.4 g Tris 
      160 g NaCl 
Dissolve in 500 ml distilled water, set pH to 7.6 with concentrated HCl and then make up       
to 2 liters. 
 
7. Coomassie 
Stain:  40 % methanol; 10 % acetic acid; 50 % water; 0.1 (w/v) Coomassie Brilliant Blue 
R250 (27816, Sigma-Adrich) 
De-stain:  40 % methanol; 10 % acetic acid; 50 % water    
 
Method 
Setting up and casting the gels: 
1. Clean glass plates with 70 % ethanol and assemble the plates into the casting frame and 
casting stand.  (Note:  The grey gaskets must be present underneath the glass plates to allow 
proper sealing of the system.) 
2. Place a comb between the gel plates and mark 1 cm below the bottom of the comb and 
then remove the comb. 
3. Pour freshly prepared resolving gel up to the marked level using a pasteur pipet.  (NB:  
The size of the gel will depend on the size of the protein.  If the protein of interest is smaller than 
40 kDa, use a 12 % gel; if the protein is bigger than 40 kDa, but smaller than 100 kDa, use a 10 % 
gel; and if it is bigger than 100 kDa, use a 8 % or 6 % gel.) 
4. Pour few ml isobutanol on top of the gel to straighten it out.  Let gel polymerise for 30 min 
to 1 hr.  (Note: Watch progress by observing spare gel solution left in your tube.) 
5. Pour off the top isobutanol layer by tilting the apparatus and wash a couple of times with 
distilled water.  Use filter paper strips or paper towels to dry the space.  (Note:  Be careful 
at this stage not to touch the gel, as it will cause the gel to stick to the paper strips) 
6. Pour in stacking gel till it overflows.  Immediately put in the comb and let gel polymerise 
for 30 min.   
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7. After gels have set, remove the comb prior to disassembling the glass plates from the 
casting apparatus. 
 
Electrophoresis: 
8. Assemble glass plates in the gel chamber with the thin plate facing inward, and pour 200-
300 ml 1x running buffer into the middle of the gel chamber.  (Note:  Put paper towels 
underneath to see if buffer leaks out.  If it leaks, reclamp plates, otherwise the level of the buffer 
will be too low and the electrical circuit will be broken, therefore no electrophoresis will occur.)   
9. Boil samples for 5 min at 95 °C and spin them down quickly with a benchtop centrifuge.  
(Note:  Do not boil the protein marker (ladder) – just take it out of the freezer and allow to reach 
room temperature.)    
10. Load 5 µl of the protein marker (27-2110, PeqGOLD protein marker IV, Peqlab) into the 
first well of each gel, followed by the samples.  (Note:  Do not let one sample overflow into the 
next well.) 
11. Place the gel chamber into the electrophoresis mini tank and pour the rest of the running 
buffer into the tank, making sure to fill up the gel chamber properly.  (Note:  Be careful not 
to pour too close to the gel wells, because the samples might spill out of the wells and thus protein 
concentration will not be equal.)  
12. Connect the electrical leads to a power source and run the gels in two individual 
sessions.  The first run set at 100 V, 400 mA for 10 minutes will allow the proteins to 
reach the stacking gel, and the second set to run at 200 V, 400 mA for 50 minutes.  (Note:  
The time of the second run will depend on the size of the protein that you’re looking for.)  
13. Just before the run is over, soak 2 pieces (per gel) of thick blotting paper into transfer 
buffer.  Soak PVDF membranes in methanol for 15 sec and then in transfer buffer.  
14. When the run is complete, remove the spacers and separate the glass plates from one 
another.  Cut off the stacking gel with the glass plate and put in transfer buffer. 
15. Put one blotting paper, the gel, the membrane and then the other blotting paper on the 
semi-dry apparatus,  Press out all the bubbles by using a wet test tube. 
16. Transfer the proteins to the membrane by using the following settings for 1-2 hours: 0.5 
A, and 15 V. 
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17. Make up the blocking solution by adding 10 g milk powder to 200 ml of a 1x TBS-Tween 
solution (1 ml Tween-20 per 100 ml of 1x TBS).  (Note:  Use 50 ml blocking buffer per 
membrane.) 
18. After transfer, remove the membrane and place in methanol for couple of seconds, 
followed by 10 min airdry. 
19. Add the membranes to the blocking solution for 2 hr in plastic tub. 
20. Place the gel in a plastic container with lid containing enough Coomassie stain to cover 
the gel.  Put lid on and microwave on high for 1 min, and then stain while shaking for 2 
min to detect proteins.  Pour out the stain, add a large amount of de-stain and de-stain on 
rocker at room temperature for a few minutes.  If no proteins are detected on the gel, 
then all proteins have transferred to the membranes.   
21. Make up primary antibody in TBS-T in 50 ml falcon tube according to recommended 
dilution on antibody data sheet just prior to taking the membranes off the milk.  (Note:  The 
usual recommendation is 1:1000, thus 5 µl antibody in 5 ml TBS-T.)  Antibodies used are 
tabulated below (Note:  Store made up primary antibodies in the fridge.): 
 
Antibodies 
 
[Stock]  Dilution Catalogue number  
and supplier  
Primary antibodies: 
 
   
Mouse monoclonal IL-1β 200 µg/ml 1/1000 sc-7884, Santa Cruz 
Goat polyclonal IL-6 (M-19) 200 µg/ml 1/1000 sc-1265, Santa Cruz 
Goat polyclonal TNF-α (L-19) 200 µg/ml 1/1000 sc-1351, Santa Cruz 
Rabbit polyclonal β-actin  1/1000 sc-81178, Santa Cruz 
Human anti-mouse MHCf  1/1000 F1.652, Developmental Studies 
Hybridoma Bank (DSHB) 
    
Horseradish peroxidase 
conjugated secondary antibodies: 
   
Donkey anti-rabbit  1/4000 sc-2313, Santa Cruz 
Donkey anti-mouse  1/4000 sc-2318, Santa Cruz 
Donkey anti-goat  1/4000 sc-2768, Santa Cruz 
   
22. After blocking is complete, rinse the membranes in TBS-T and place the membrane 
inside the falcon tube containing the primary antibody. 
23. Allow to rotate overnight at 4 °C in the cold room. 
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Developing: 
24. Take out the membrane from the falcon tube and wash the membranes (3x 5 min each) 
with TBS-T. 
25. Make up the horseradish peroxidase-conjugated secondary antibody in TBS-T 
(Amersham Life Science; 1/4000) in a 50 ml falcon tube.  
26. Incubate the membranes for 1 hr at room temperature in the secondary antibody. 
27. After incubation with the secondary antibody, warm up the ECL kit (Amersham Life 
Science Inc., Arlignton Heights, IL, USA) containing solution A and solution B to room 
temperature. 
28. Wash membrane 3x 5 min each with TBS-T. 
29. Whilst washing, prepare dark room cassettes by cleaning them with alcohol first and 
allowing to air dry.  Now cut a transparency in half and stick to cassette. 
30. Make up the ECL (500 µl of solution A + 500 µl of solution B per membrane) in 15 ml 
falcon tube.  (Note:  Protect from light.) 
31. Pour 1 ml of ECL on top of each membrane in the specific area where the protein of 
interest is located and leave on for 1 min. 
32. Blot excess ECL, place between transparencies and close the cassette. 
33. In the dark room, cut a piece of hyperfilm (RPN-2103K, Amersham BioSciences), place 
on top of the transparencies, and allow to expose for 5 min or longer depending on the 
clarity of the bands. 
34. Develop and fix the film (Fixing and Developing Solutions from Axim, 9x23013 and 
9x23018, respectively) and analyse with the program, UNSCANIT (Silk Scientific 
Corporation (SilkScience), USA, version 5.1) 
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Appendix H:  Labelling immune cells in whole blood for flow cytometry 
Reagents 
1. Fc Block/CD32 (550271, BD) 
2. BD FACS™ Lysing Buffer (349202, BD) 
3. FITC-conjugated mouse anti-rat granulocyte marker (anti-His48, BD Pharmingen, 
554907) 
4. PE-conjugated mouse anti-rat macrophage subset marker (anti-F4/80, BD Pharmingen, 
554901) 
5. Alexa Fluoro mouse anti-rat CD68 (anti-M1, Serotec, MCA647)  
6. FITC-conjugated mouse anti-rat CD163 (anti-M2c, Serotec, MCA341)   
 
Method 
1. Label two 15 ml falcon tubes (c and d) per sample (four tubes when setting up the 
method). 
a. Unstained (only needed for optimisation). 
b. Stained with neutrophil marker, His48 (determine neutrophil population – used as 
gate to enable counting of other immune cells). 
c. Stained with total macrophage marker, F4/80. 
d. Stained with M1 macrophage marker, CD68 and M2c macrophage marker, 
CD163. 
2. Add 500 µl of whole blood to the respective tubes. 
3. Block by incubating the cell suspension with  Fc block (CD32) for 10 min at 4°C (≤ 1 
µg/million cells in 100 µl).  Do not rinse.  Proceed with staining.  (Note:  It is very important 
to block Fc receptors for certain cell types, including, but not limited to, mouse and rat blood, 
mouse spleen, mouse bone marrow, etc.) 
Thus, for 1 million cells, add 2 µl Fc block/100 µl RPMI medium or add to whole blood 
as is. 
4. Add primary antibodies (≤ 1 µg/million cells) to the respective tubes and incubate for 20-
30 min at 4 °C in dark on ice. 
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Primary antibody Concentration For staining   
Anti-F4/80     200 µg/ml  5 µl 
Anti-His48  500 µg/ml  2 µl 
Anti-CD68  500 µg/ml  2 µl 
Anti-CD163  500 µg/ml  2 µl 
5. For each 500 µl of blood, add 5 ml of BD Lysing solution (1:10 in distilled water) to lyse 
the red blood cells.  Blood needs to be lysed for 5 min at room temperature.  (Note:  If cells 
are lysed beyond 5 min, then the white blood cells might also be lysed.   Also, if the lysing solution 
is cold, the cells will not lyse correctly.) 
6. Centrifuge for 5 min at 2000 rpm. 
7. To wash off excess antibody following staining, add 1.5-2 ml of PBS to each tube.  
Centrifuge in tabletop microfuge for 5 min at 2000 rpm.  Repeat 1-2x.   
8. Resuspend in 2 ml PBS. 
9. Acquire results. 
 
Notes on determining macrophage subpopulation distribution: 
A pilot study was done to optimise the method for macrophage identification.  Firstly, a 
scatter plot was generated without using a cellular marker antibody according to forward 
scatter (x-axis) and side scatter (y-axis) to determine different populations of white blood 
cells according to size and granularity.  A gate is set around the neutrophil population (the 
easiest to identify in non-human samples), and this population is then used as reference cell 
population.  Secondly, a similar scatter plot was generated, but in the presence of a 
fluorescence-labelled antibody directed against His48, a neutrophil marker.  This neutrophil 
population identified by the fluorescent marker was identical to the population indicated by 
the arrow, and it was decided that a neutrophil marker is not necessary in this particular 
study. 
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a) Using scatter characteristics or fluorescently labelled antibodies 
 
 
Macrophages within whole blood were either labelled with a PE-conjugated total macrophage 
marker (anti-F4/80) or with markers specifically identifying the APC-labelled M1 (anti-CD68) 
and FITC-labelled M2c (anti-CD163) population of macrophages.  M1 and M2c macrophages 
were counted relative to 5000 neutrophils.  Since the starting blood volume (used for 
staining) and the total number of neutrophils were known, the volume used to count 5000 
neutrophils could be calculated.  This volume was used and cells were expressed as the 
number of M1 and M2c macrophages per 1 µl of blood. 
A representative image of the cell scatter for each of these markers are indicated in the 
images below. 
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Flow settings for the FACSAria: 
All flow cytometric analysis were performed on a FACSAria Cell sorter flow cytometer 
(Becton Dickinson Biosciences, San Jose, CA) equipped with a 488 nm Coherent Sapphire 
solid state laser (13-20 mW), 633 nm JDS Uniphase HeNe air-cooled laser (10-20 mW) and 
407 nm Point Source Violet solid state laser (10-25 mW).  For each sample, population 
information from a minimum of 5000 events (gated around the neutrophil population to 
identify M1 and M2c macrophages) or 1000 events (gated around the beads in the 
TruCOUNT tubes to identify migrated and non-migrated neutrophils – see Appendix I) was 
acquired using a 70 µM nozzle.  Instrument setup and calibration were performed prior to 
each data acquisition.  FACSDiva Version 6.1 was used to display data acquired from each 
population. 
 
 
 
Q1: M1 macrophages 
Q2: M1 and M2c co-
expressing macrophages 
Q4: M2c macrophages 
M1 macrophages M2c macrophages 
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Appendix I:  Migration study 
Reagents 
1. Ficoll-Histopaque (10771, Sigma) 
2. BD FACS™ Lysing Buffer (349202, BD) 
3. FITC-conjugated mouse anti-rat granulocyte marker (anti-His48, BD Pharmingen, 
554907) 
4. fMLP (F3506, Sigma) 
5. G-CSF (G8160, Sigma) 
6. RPMI 1640 media (GIBCO, 21875) 
7. Plasma from control and injured rats, PLA and PCO supplemented 
8. Cell culture inserts for 24-well plates (3 µm pores, BD, 353492) 
9. Cell culture plates (24-well) 
 
Method 
1. Pipette 3 ml of Ficoll-Histopaque into a 15 ml Falcon tube. 
2. Layer 4 ml of whole blood slowly on top of the Ficoll by holding the tube at a 30° angle. 
3. Spin the tube for 25 min at 4 °C at a speed of 1500 rpm using a low brake. 
4. Discard the supernatant and add Lysis buffer to the red blood cell containing solution 
according to manufacturer’s instructions.  (Note:  Add 10 parts of 1x Lysis buffer and 1 part 
red blood cell solution, thus 10 ml 1x Lysis buffer and 1 ml red blood cell solution.) 
5. Allow to stand for 5 min at room temperature. 
6. Spin down at 1500 rpm for 5 min at 4 °C. 
7. Discard supernatant and resuspend pellet in 2 ml RPMI medium. 
8. Perform a cell count using a haemocytometer.  
9. Resuspend 200 000 neutrophils per tube in pre-warmed RPMI media and add to 
separate sterile eppendorff tubes to a total volume of ± 156.8 µl. 
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10. To this, add 3.2 µl G-CSF of a 5 µg/ml stock solution (final G-CSF concentration of 100 
ng/ml) and 40 µl plasma from rats supplemented with either placebo or PCO from control 
and rats at different time points after injury to respective eppendorff tubes containing 
neutrophils. 
11. Add the abovementioned cocktail to the insert, and 800 µl media containing fMLP at a 
concentration of 1x10-7 M to the bottom well of the migration chamber and allow to 
incubate separately for 15 min prior to the actual migration assay.  (Note: Do not add 
the inserts to the wells right away, but allow to incubate separately in order for the G-CSF to 
stimulate the neutrophils prior to migration.) 
12. Following the pre-incubation period, place the inserts over the media containing fMLP 
and allow migration to take place for 2 hr.  (Note:  Carefully place the inserts over the 
wells containing medium, as bubbles trapped underneath the insert will prevent migration in 
that specific area to take place.)  
13. After migration, take off the media containing cells from the insert and the bottom well 
respectively and place into separate eppendorff tubes. 
14. Label 2 TruCOUNT tubes per sample either as “top” or “bottom”. 
15. Add 400 µl of cell suspension (from either the inserts and the culture wells) to the 
respective TruCOUNT tube and allow the pellet to dissolve. 
16. Vortex the tubes and read using a flow cytometer.   
17. Neutrophils are expressed relative to 1000 beads, whereafter, taking total beads and 
volume into account, the results were expressed as the total number of cells per “top” 
and “bottom” of the insert.  (Note:  This method also resulted in an accurate counting of 
neutrophils and was decided to be the best possible method.) 
18. Add ice cold acetone:methanol (50:50 v/v) to all inserts and wells and incubate for 10 
min at 4 °C. 
19. Aspirate acetone:methanol off and allow samples to airdry for 20 min. 
20. Add 1 ml hoechst (1/200) to all inserts and wells for 15 min at room temperature. 
21. Remove hoechst and wash twice with PBS. 
22. Incubate plates in the fridge overnight, covered with PBS. 
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23. Aspirate PBS off and add FITC-conjugated His48 (1/1000) to all respective inserts 
and wells for 1 hr at room temperature. 
24. Wash inserts and wells twice with PBS and visualise using a fluorescence 
microscope. 
25. Express cells as the number of migrated/non-migrated neutrophils per area. 
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Appendix J:  Methods tested but not used for migration study 
For neutrophil isolation:  Dextran sedimentation method 
Assay principle:  This method is based on firstly separating neutrophils from other white 
blood cells and red blood cells by means of sedimentation, and then lysing any further red 
blood cells that might contaminate the separation procedure. 
 
Analytical procedure: 
Reagents 
1. ACD:   
To 250ml ddH2O, add: 
 7.36 g  Citric Acid 
 14.71 g  Sodium Citrate 
 9.91 g Dextrose 
Store at 4°C 
 
2. 6% Dextran: 
To 250ml ddH2O, add: 
 15.00 g Dextran (at least 100 000 MW) 
 2.25 g NaCl 
Store at 4°C 
 
3. 0.6M KCl: 
To 250ml ddH2O add: 
 11.18 g KCl 
Store at 4°C 
4. Ficoll-Histopaque 1077 (Sigma-Aldrich, 10771) 
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Method 
1. Pipette 4 ml of ACD into a 50 ml falcon tube and pipette 20 ml of whole blood down the 
side of the tube.  Gently invert the tube several times to mix (or 1 ml for each 5 ml).  
2. Pipette 12 ml (50% of blood volume in 1) of 6 % Dextran / 0.9 % NaCl solution into the 
ACD/blood mixture and invert 18-20 times to ensure adequate mixing. Pipette the mixture 
into 4, 15 ml tubes (10 ml/tube).  Let the four tubes stand at RT for 45 min – 1 hr, or until 
separation is complete. 
3. After separation, pipette the yellowish supernatant into a 50 ml tube.  Spin at 1150 rpm 
for 12 min at 4°C using a low brake. 
4. Discard the supernatant and resuspend in 12 ml of ice-cold dH2O to break the pellet.  
After 20 sec, add 4 ml of 0.6 M KCl and mix several times.  Dilute the solution to 50 ml 
with PBS and spin at 1300 rpm for 6 min at 4°C using a high brake. 
5. Repeat Step 4, 1-2 times, until no RBC's remain. 
6. Discard supernatant and resuspend the pellet in 2.5 ml of PBS. 
7. Layer the cell suspension over 3 ml of Ficoll-Histopaque in a 15 ml tube.  Spin at 1500 
rpm for 30 min at 4°C using a low brake.  
8. When the cells have finished spinning suck off the supernatant, using a pasteur pipette.   
9. Resuspend the pellet in 2 ml RPMI at 4°C.  Determine the cell concentration using a 
haemocytometer, or other device. 
 
Results:  Although the neutrophils isolated with this method were relatively pure, with limited 
or no red blood cells, it resulted in a relatively low yield.  This method is also very long (2-3 
hrs) and involves multiple steps, making it difficult to determine whether some of the 
neutrophils might have become activated as a result. 
 
Quantifying migrated vs non-migrated neutrophils 
In solution 
A) Haemocytometer counting 
Method: 
1. Two eppendorff tubes per sample were labelled either as “top” or “bottom”. 
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2. Cells in solution from the top or bottom of the inserts were added to their 
respective 1.5 ml eppendorff tube. 
1. Cells were resuspended and 20 µl from each tube were added to a 
haemocytometer and cells counted. 
 
Results:  Since some of the bottom wells after migration, only had a limited number 
of neutrophils, it resulted in a relatively low number of neutrophils to count and thus 
potentially resulting in an inaccurate cell count.  This method was therefore not 
considered to be a good method to count cells after migration.   
 
B) Grid counting on a slide 
Method: 
1. Two tubes per sample were labelled either as “top” or “bottom”. 
2. Cells in solution from the top or bottom of the inserts were added to the 
eppendorff tubes. 
3. Cells were spun down at 3000 rpm for 5 min. 
4. The supernatant were aspirated off and the cells resuspended in 30 µl of PBS. 
5. Cells were pipetted on a slide and a smear was mad. 
6. Cells were then stained with either Rapidiff, which consists of a fixing solution, 
Stain A and stain B, or Haematoxylin and Eosin (H&E) (steps 6-20, Appendix F). 
7. Slides were then left to dry and viewed with a light microscope. 
 
 
 
Results:  Cells stained with Rapidiff, as well as with H&E appear very light with 
intense background staining with H&E.  Since the whole slide mostly contains cells, 
and possibly not equally distributed, it is not easy to randomly select different fields of 
A) Rapidiff staining B)  Haematoxylin and Eosin staining 
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view to acquire images.   It is also not known whether some of the cells washed away 
with H&E staining, since cells are not properly adhered to the slide prior to staining.  
This method was not considered to be a good method for counting cells.  A indicates 
a picture of neutrophils stained with Rapidiff, whilst B is an H&E stained image. 
 
Adherent 
A) Scraping cells from bottom of the insert after staining and fixing to slides 
Method: 
1. After cells in solution were placed into eppendorff tubes, ice cold 
acetone:methanol were added to all inserts and wells and left for 10 min at 4 °C. 
2. Acetone:methanol were aspirated off and left to airdry for 20 min. 
3. Hoechst (1/200) were added to all inserts and wells for 15 min at room 
temperature. 
4. Hoechst were aspirated off and inserts and wells washed twice with PBS. 
5. Plates were placed in the fridge overnight. 
6. PBS were aspirated off and FITC-conjugated His48 (1/1000) were added to all 
respective inserts and wells for 1 hour at room temperature. 
7.  Inserts and wells were washed twice with PBS. 
8. Cells from the bottom of the inserts were scraped to remove all cells that have 
possibly migrated and the inserts were adhered to slides with fluorescent 
mounting medium. 
  
Results:  After scraping, all pores were stained blue (i.e. cells most probably pushed 
back into pores) and no clear identification of migrated vs. non-migrated neutrophils 
could be made.  Scraping of cells were therefore not considered to be the best 
possible method of identifying migrated vs. non-migrated neutrophils.   
 
B) Paraformaldehyde fixing after staining of intact insert  
Method: 
1. After cells in solution were placed into eppendorff tubes, inserts and wells were 
stained with FITC-conjugated His48 (1/1000) for 1 hr at room temperature. 
2. Inserts and wells were washed twice with PBS and Hoechst (1/200) added for 15 
min. 
3. After washing inserts and wells with PBS again, 2 % paraformaldehyde were 
added to the cells and left overnight in the fridge. 
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4. Inserts and wells were washed twice and visualised. 
  
Results:  Due to the fact that cells were only fixed after staining with 
paraformaldehyde, it resulted in a lower number of intact neutrophils.  This method 
was therefore not considered to be the best possible option for counting adhered 
neutrophils. 
 
 
 
 
 
 
 
 
 
